FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Moirongo, RM
   Lorenz, E
   Ntinginya, NE
   Dekker, D
   Fernandes, J
   Held, J
   Lamshoft, M
   Schaumburg, F
   Mangu, C
   Sudi, L
   Sie, A
   Souares, A
   Heinrich, N
   Wieser, A
   Mordmuller, B
   Owusu-Dabo, E
   Adegnika, AA
   Coulibaly, B
   May, J
   Eibach, D
AF Moirongo, Rehema Moraa
   Lorenz, Eva
   Ntinginya, Nyanda E.
   Dekker, Denise
   Fernandes, Jose
   Held, Jana
   Lamshoeft, Maike
   Schaumburg, Frieder
   Mangu, Chacha
   Sudi, Lwitiho
   Sie, Ali
   Souares, Aurelia
   Heinrich, Norbert
   Wieser, Andreas
   Mordmueller, Benjamin
   Owusu-Dabo, Ellis
   Adegnika, Akim Ayola
   Coulibaly, Boubacar
   May, Juergen
   Eibach, Daniel
TI Regional Variation of Extended-Spectrum Beta-Lactamase (ESBL)-Producing
   Enterobacterales, Fluoroquinolone-ResistantSalmonella entericaand
   Methicillin-ResistantStaphylococcus aureusAmong Febrile Patients in
   Sub-Saharan Africa
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE antimicrobial resistance; sub-Saharan Africa; fever; Salmonella
   enterica; methicillin-resistantStaphylococcus aureus; Enterobacterales;
   extended-spectrum beta-lactamase-(ESBL)
ID BLOOD-STREAM INFECTIONS; SEROVAR TYPHI; REDUCED SUSCEPTIBILITY;
   ESCHERICHIA-COLI; RESISTANCE; CIPROFLOXACIN; GHANA
AB Background Antimicrobial resistance (AMR) thwarts the curative power of drugs and is a present-time global problem. We present data on antimicrobial susceptibility and resistance determinants of bacteria the WHO has highlighted as being key antimicrobial resistance concerns in Africa, to strengthen knowledge of AMR patterns in the region. Methods Blood, stool, and urine specimens of febrile patients, aged between >= 30 days and <= 15 years and hospitalized in Burkina Faso, Gabon, Ghana, and Tanzania were cultured from November 2013 to March 2017 (Patients > 15 years were included in Tanzania). Antimicrobial susceptibility testing was performed for all Enterobacterales andStaphylococcus aureusisolates using disk diffusion method. Extended-spectrum beta-lactamase (ESBL) production was confirmed by double-disk diffusion test and the detection ofbla(CTX-M),bla(TEM)andbla(SHV). Multilocus sequence typing was conducted for ESBL-producingEscherichia coliandKlebsiella pneumoniae, ciprofloxacin-resistantSalmonella entericaandS. aureus. Ciprofloxacin-resistantSalmonella entericawere screened for plasmid-mediated resistance genes and mutations ingyrA, gyrB, parC, and parE.S. aureusisolates were tested for the presence ofmecAand Panton-Valentine Leukocidin(PVL)and further genotyped byspatyping. Results Among 4,052 specimens from 3,012 patients, 219 cultures were positive of which 88.1% (n= 193) were Enterobacterales and 7.3% (n= 16)S. aureus. The prevalence of ESBL-producing Enterobacterales (all CTX-M15 genotype) was 45.2% (14/31; 95% CI: 27.3, 64.0) in Burkina Faso, 25.8% (8/31; 95% CI: 11.9, 44.6) in Gabon, 15.1% (18/119; 95% CI: 9.2, 22.8) in Ghana and 0.0% (0/12; 95% CI: 0.0, 26.5) in Tanzania. ESBL positive non-typhoidSalmonella(n= 3) were detected in Burkina Faso only and methicillin-resistantS. aureus(n= 2) were detected in Ghana only. While sequence type (ST)131 predominated among ESBLE. coli(39.1%;9/23), STs among ESBLK. pneumoniaewere highly heterogenous. Ciprofloxacin resistant ntSalmonellawere commonest in Burkina Faso (50.0%; 6/12) and all harboredqnrBgenes.PVLwere found in 81.3%S. aureus. Conclusion Our findings reveal a distinct susceptibility pattern across the various study regions in Africa, with notably high rates of ESBL-producing Enterobacterales and ciprofloxacin-resistant ntSalmonellain Burkina Faso. This highlights the need for local AMR surveillance and reporting of resistances to support appropriate action.
C1 [Moirongo, Rehema Moraa; Lorenz, Eva; Dekker, Denise; Lamshoeft, Maike; May, Juergen; Eibach, Daniel] Bernhard Nocht Inst Trop Med, Infect Dis Epidemiol, Hamburg, Germany.
   [Lorenz, Eva; Dekker, Denise; Held, Jana; Lamshoeft, Maike; Souares, Aurelia; Heinrich, Norbert; Wieser, Andreas; Mordmueller, Benjamin; May, Juergen; Eibach, Daniel] Hamburg Lubeck Borstel Riems, German Ctr Infect Res DZIF, Tubingen, Germany.
   [Lorenz, Eva] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, Mainz, Germany.
   [Ntinginya, Nyanda E.; Mangu, Chacha; Sudi, Lwitiho] Mbeya Med Res Ctr, Natl Inst Med Res, Mbeya, Tanzania.
   [Fernandes, Jose; Held, Jana; Schaumburg, Frieder; Mordmueller, Benjamin; Adegnika, Akim Ayola] Ctr Rech Med Lambarene CERMEL, Lambarene, Gabon.
   [Fernandes, Jose; Held, Jana; Mordmueller, Benjamin; Adegnika, Akim Ayola] Univ Klinikum Tubingen, Inst Tropenmed, Tubingen, Germany.
   [Schaumburg, Frieder] Univ Hosp Munster, Inst Med Microbiol, Munster, Germany.
   [Sie, Ali; Coulibaly, Boubacar] Ctr Rech Sante Nouna, Nouna, Burkina Faso.
   [Souares, Aurelia] Heidelberg Univ Hosp, Heidelberg Inst Global Hlth HIGH, Heidelberg, Germany.
   [Heinrich, Norbert; Wieser, Andreas] Ludwig Maximilians Univ Munchen, Dept Infect Dis & Trop Med, Munich, Germany.
   [Wieser, Andreas] Ludwig Maximilians Univ Munchen, Max Von Pettenkofer Inst, Fac Med, Munich, Germany.
   [Mordmueller, Benjamin; Adegnika, Akim Ayola] German Ctr Infect Res DZIF, African Partner Inst, Lambarene, Gabon.
   [Owusu-Dabo, Ellis] Kumasi Ctr Collaborat Res Trop Med KCCR, Kumasi, Ghana.
RP Eibach, D (corresponding author), Bernhard Nocht Inst Trop Med, Infect Dis Epidemiol, Hamburg, Germany.; Eibach, D (corresponding author), Hamburg Lubeck Borstel Riems, German Ctr Infect Res DZIF, Tubingen, Germany.
EM eibach@bnitm.de
FU German Center for Infection Research (DZIF) [TI03.001, 8000 201-3];
   Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SCHA
   1994/5-1]; German Federal Foreign Office, through the German Partnership
   Program for Excellence in Biological and Health Security
FX This study was made possible through grants from the German Center for
   Infection Research (DZIF) (Grant Nos: TI03.001 and 8000 201-3), the
   Deutsche Forschungsgemeinschaft (SCHA 1994/5-1, granted to FS), and the
   German Federal Foreign Office, through the German Partnership Program
   for Excellence in Biological and Health Security.
CR Aber C, 2007, PEDIATR ANN, V36, P30, DOI 10.3928/0090-4481-20070101-09
   Al-Emran HM, 2016, CLIN INFECT DIS, V62, pS42, DOI 10.1093/cid/civ788
   Alabi AS, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-455
   Auta A, 2019, J INFECTION, V78, P8, DOI 10.1016/j.jinf.2018.07.001
   Campos CB, 2014, INT J MED MICROBIOL, V304, P678, DOI 10.1016/j.ijmm.2014.04.012
   Chau TT, 2007, ANTIMICROB AGENTS CH, V51, P4315, DOI 10.1128/AAC.00294-07
   Diancourt L, 2005, J CLIN MICROBIOL, V43, P4178, DOI 10.1128/JCM.43.8.4178-4182.2005
   Dr. Schweitzer's Hospital Fund, 2016, SCHWEITZ HOSP LAMB
   Eibach D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170320
   Eibach D, 2016, INT J MED MICROBIOL, V306, P249, DOI 10.1016/j.ijmm.2016.05.006
   Eibach D, 2016, CLIN INFECT DIS, V62, pS32, DOI 10.1093/cid/civ757
   Elbireer AM, 2011, LABMEDICINE, V42, P719, DOI 10.1309/LM2OBNYY9D0UXZJO
   Elias C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016264
   EUCAST, 2020, RES MECH
   Feikin DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016085
   Hendriksen RS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08853-3
   Hogan B, 2018, CLIN INFECT DIS, V66, P1838, DOI 10.1093/cid/cix1120
   Kapasi AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160278
   Kariuki S, 2014, ANN NY ACAD SCI, V1323, P43, DOI 10.1111/nyas.12380
   Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115
   Kpoda D. S., 2017, African Journal of Microbiology Research, V11, P1120, DOI 10.5897/ajmr2017.8598
   Maltha J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089103
   Nicolas-Chanoine MH, 2014, CLIN MICROBIOL REV, V27, P543, DOI 10.1128/CMR.00125-13
   Obeng-Nkrumah N, 2013, AM J TROP MED HYG, V89, P960, DOI 10.4269/ajtmh.12-0642
   Okeke IN, 2007, EMERG INFECT DIS, V13, P1640, DOI 10.3201/eid1311.070674
   ONeill J., 2014, ANTIMICROBIAL RESIST
   Ouedraogo AS, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1655-3
   Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363
   Pfeifer Y, 2009, EMERG INFECT DIS, V15, P1533, DOI 10.3201/eid1509.090567
   Pietsch F, 2017, J ANTIMICROB CHEMOTH, V72, P75, DOI 10.1093/jac/dkw364
   Seale Anna C, 2017, Wellcome Open Res, V2, P92, DOI 10.12688/wellcomeopenres.12527.1
   UNDP, 2019, 2019 HUM DEV IND RAN
   WHO, 2015, GLASS GLOB ANT RES S
   WHO, 2019, WHO COUNTR PROGR IMP
   WHO, 2017, GLASS GLOB ANT RES S
   Williams PCM, 2018, LANCET INFECT DIS, V18, pE33, DOI 10.1016/S1473-3099(17)30467-X
   Wirth T, 2006, MOL MICROBIOL, V60, P1136, DOI 10.1111/j.1365-2958.2006.05172.x
   World Health Organization, 2013, WHO INF CONS FEV MAN
   Yala J.-F., 2016, CURRENT RES MICROBIO, V4, P944
NR 39
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD SEP 25
PY 2020
VL 11
AR 567235
DI 10.3389/fmicb.2020.567235
PG 10
WC Microbiology
SC Microbiology
GA NY2CH
UT WOS:000576203700001
PM 33101240
OA DOAJ Gold
DA 2020-10-30
ER

PT J
AU de Azevedo, JWV
   Fernandes, TAAD
   Fernandes, JV
   de Azevedo, JCV
   Lanza, DCF
   Bezerra, CM
   Andrade, VS
   de Araujo, JMG
   Fernandes, JV
AF de Azevedo, Judson Welber Verissimo
   de Medeiros Fernandes, Thales Allyrio Araujo
   Fernandes, Jose Verissimo, Jr.
   de Azevedo, Jenner Chrystian Verissimo
   Lanza, Daniel Carlos Ferreira
   Bezerra, Christiane Medeiros
   Andrade, Vania Sousa
   de Araujo, Joselio Maria Galvao
   Fernandes, Jose Verissimo
TI Biology and pathogenesis of human osteosarcoma
SO ONCOLOGY LETTERS
LA English
DT Review
DE bone tumor; osteosarcoma; osteosarcoma biology; osteosarcoma
   pathogenesis
ID MESENCHYMAL STEM-CELLS; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; CIRCULAR
   RNA; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; INHIBITS
   PROLIFERATION; EPIGENETIC ALTERATIONS; HISTONE MODIFICATIONS;
   DOWN-REGULATION
AB Osteosarcoma (OS) is a bone tumor of mesenchymal origin, most frequently occurring during the rapid growth phase of long bones, and usually located in the epiphyseal growth plates of the femur or the tibia. Its most common feature is genome disorganization, aneuploidy with chromosomal alterations, deregulation of tumor suppressor genes and of the cell cycle, and an absence of DNA repair. This suggests the involvement of surveillance failures, DNA repair or apoptosis control during osteogenesis, allowing the survival of cells which have undergone alterations during differentiation. Epigenetic events, including DNA methylation, histone modifications, nucleosome remodeling and expression of non-coding RNAs have been identified as possible risk factors for the tumor. It has been reported that p53 target genes or those genes that have their activity modulated by p53, in addition to other tumor suppressor genes, are silenced in OS-derived cell lines by hypermethylation of their promoters. In osteogenesis, osteoblasts are formed from pluripotent mesenchymal cells, with potential for self-renewal, proliferation and differentiation into various cell types. This involves complex signaling pathways and multiple factors. Any disturbance in this process can cause deregulation of the differentiation and proliferation of these cells, leading to the malignant phenotype. Therefore, the origin of OS seems to be multifactorial, involving the deregulation of differentiation of mesenchymal cells and tumor suppressor genes, activation of oncogenes, epigenetic events and the production of cytokines.
C1 [de Azevedo, Judson Welber Verissimo] Deoclecio Marques Hosp, Orthoped Trauma Clin Serv, BR-59141085 Parnamirim, RN, Brazil.
   [de Medeiros Fernandes, Thales Allyrio Araujo] Univ Rio Grande do Norte State, Dept Biomed Sci, Rua Miguel Antonio da Silva Neto S-N, BR-59607360 Mossoro, RN, Brazil.
   [Fernandes, Jose Verissimo, Jr.] Getulio Vargas Hosp, Orthoped Trauma Clin Serv, BR-50630060 Recife, PE, Brazil.
   [de Azevedo, Jenner Chrystian Verissimo] Univ Fed Rio Grande do Norte, Dept Pediat, Univ Hosp Onofre Lopes, BR-59012300 Natal, RN, Brazil.
   [Lanza, Daniel Carlos Ferreira] Univ Fed Rio Grande do Norte, Dept Biochem, BR-59072970 Natal, RN, Brazil.
   [Bezerra, Christiane Medeiros; Andrade, Vania Sousa; de Araujo, Joselio Maria Galvao; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
RP Fernandes, TAAD (corresponding author), Univ Rio Grande do Norte State, Dept Biomed Sci, Rua Miguel Antonio da Silva Neto S-N, BR-59607360 Mossoro, RN, Brazil.
EM thalesallyrio@uern.br
RI Andrade, Vania Sousa/AAR-3922-2020
CR Al-Romaih K, 2008, NEOPLASIA, V10, P471, DOI 10.1593/neo.08174
   Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018-015-1918-y
   Ali A, 2018, J STEM CELL RES THER, V8, P3, DOI [10.4172/2157-7633.1000418, DOI 10.4172/2157-7633.1000418]
   Amente S, 2011, NUCLEIC ACIDS RES, V39, P9498, DOI 10.1093/nar/gkr638
   Baglio SR, 2017, CLIN CANCER RES, V23, P3721, DOI 10.1158/1078-0432.CCR-16-2726
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Calin GA, 2019, MOL ONCOL, V13, P3, DOI 10.1002/1878-0261.12418
   Cantelli G, 2017, SEMIN CANCER BIOL, V42, P60, DOI 10.1016/j.semcancer.2016.08.009
   Chen DM, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0009-8
   Chen KS, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a000992
   Chen Y, 2018, CELL PHYSIOL BIOCHEM, V51, P1313, DOI 10.1159/000495550
   Chen Z, 2016, DIS MARKERS, DOI 10.1155/2016/4639575
   Del Mare S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12959
   Del Mare S, 2011, AM J CANCER RES, V1, P585
   Denduluri SK, 2016, J BIOMED RES, V30, P5, DOI 10.7555/JBR.30.20150075
   Deng R, 2019, INT J MOL MED, V43, P1157, DOI 10.3892/ijmm.2018.4039
   Deng ZL, 2008, FRONT BIOSCI-LANDMRK, V13, P2001, DOI 10.2741/2819
   Fernandes Juliane C. R., 2019, Non-Coding RNA, V5, P17, DOI 10.3390/ncrna5010017
   Foucher ED, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056045
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Goldszmid RS, 2012, NAT IMMUNOL, V13, P932, DOI 10.1038/ni.2422
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Gross AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99791
   Gu WF, 2018, BIOMED PHARMACOTHER, V106, P890, DOI 10.1016/j.biopha.2018.06.173
   Guo W, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819841438
   Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143
   Hamidi T, 2015, EPIGENOMICS-UK, V7, P247, DOI [10.2217/EPI.14.80, 10.2217/epi.14.80]
   Han G, 2012, ONCOL RES, V20, P149, DOI 10.3727/096504012X13522227232237
   Han Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06304-x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He C, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0605-x
   Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10
   Honorati MC, 2007, J CANCER RES CLIN, V133, P1017, DOI 10.1007/s00432-007-0296-8
   Huang GX, 2012, CANCER RES, V72, P908, DOI 10.1158/0008-5472.CAN-11-1460
   Ishikawa T, 2013, CANCER SCI, V104, P880, DOI 10.1111/cas.12163
   Jeziorska DM, 2017, P NATL ACAD SCI USA, V114, pE7526, DOI 10.1073/pnas.1703087114
   Jiang R, 2017, AM J CANCER RES, V7, P88
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663
   Kanherkar Riya R, 2014, Front Cell Dev Biol, V2, P49, DOI 10.3389/fcell.2014.00049
   Kato H, 2015, ONCOLOGY-BASEL, V88, P139, DOI 10.1159/000368414
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kim H, 2018, P NATL ACAD SCI USA, V115, pE11128, DOI 10.1073/pnas.1814044115
   Klein MJ, 2006, AM J CLIN PATHOL, V125, P555, DOI 10.1309/UC6KQHLD9LV2KENN
   Klimczak A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4285215
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418-018-1640-6
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   Lamora A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5110096
   Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921
   Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428
   Li BH, 2014, MOL BIOL REP, V41, P3303, DOI 10.1007/s11033-014-3193-7
   Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133
   Li FF, 2014, CELL PHYSIOL BIOCHEM, V34, P2169, DOI 10.1159/000369660
   Li Q, 2017, INT J BIOL SCI, V13, P1038, DOI 10.7150/ijbs.19476
   Li SS, 2012, INT J MOL SCI, V13, P12461, DOI 10.3390/ijms131012461
   Li XG, 2017, J CANCER RES CLIN, V143, P2189, DOI 10.1007/s00432-017-2478-3
   Li Y, 2009, HUM PATHOL, V40, P1441, DOI 10.1016/j.humpath.2009.03.003
   Li YS, 2016, ONCOTARGETS THER, V9, P3101, DOI 10.2147/OTT.S96561
   Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370
   Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180
   Liu WH, 2017, CELL PHYSIOL BIOCHEM, V43, P969, DOI 10.1159/000481650
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lopes-Junior LC, 2016, ONCOLOGY COMMUNICATI, V2, pe1167
   Lu JC, 2015, ONCOTARGET, V6, P16802, DOI 10.18632/oncotarget.4696
   Luo ZQ, 2016, J BONE ONCOL, V5, P167, DOI 10.1016/j.jbo.2016.06.002
   Mannerstrom B, 2019, EPIGENETICS-US, V14, P352, DOI 10.1080/15592294.2019.1585177
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Martin Jeff W., 2012, Sarcoma, V2012, P627254, DOI 10.1155/2012/627254
   Mens MMJ, 2018, STEM CELL REV REP, V14, P309, DOI 10.1007/s12015-018-9808-y
   Min EY, 2014, INT J ONCOL, V45, P47, DOI 10.3892/ijo.2014.2426
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707
   Mori T, 2014, ONCOGENE, V33, P4236, DOI 10.1038/onc.2013.545
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Nie JH, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5020036
   Nie ZG, 2018, ONCOL LETT, V16, P6502, DOI 10.3892/ol.2018.9453
   Nowacka-Zawisza M, 2017, ONCOL REP, V38, P2587, DOI 10.3892/or.2017.5972
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1
   Patil VS, 2014, CRIT REV BIOCHEM MOL, V49, P16, DOI 10.3109/10409238.2013.844092
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Pfeifer GP, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041166
   Qu Y, 2016, TUMOR BIOL, V37, P5275, DOI 10.1007/s13277-015-4389-8
   Rao-Bindal Krithi, 2011, Sarcoma, V2011, P679457, DOI 10.1155/2011/679457
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Rosenblum JM, 2015, EPIGENETICS-US, V10, P31, DOI 10.4161/15592294.2014.989084
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sachdeva M, 2015, CANCER LETT, V369, P202, DOI 10.1016/j.canlet.2015.08.016
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Segaliny AI, 2015, INT J CANCER, V137, P73, DOI 10.1002/ijc.29376
   Shanmugam M. K, 2017, ONCOTARGET, V9, P11414
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199
   Shin MH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005884
   Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115
   Stiller CA, 2006, EUR J CANCER, V42, P2115, DOI 10.1016/j.ejca.2006.05.011
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z
   Techavichit P, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2909-6
   Tian W, 2018, GENE, V650, P7, DOI 10.1016/j.gene.2018.01.093
   Tu B, 2014, EXP CELL RES, V320, P164, DOI 10.1016/j.yexcr.2013.10.013
   Tu B, 2012, CANCER LETT, V325, P80, DOI 10.1016/j.canlet.2012.06.006
   Tung PY, 2015, ONCOGENE, V34, P2288, DOI 10.1038/onc.2014.172
   Turtle CJ, 2012, CURR OPIN IMMUNOL, V24, P633, DOI 10.1016/j.coi.2012.06.004
   Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021
   Vaidya H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151392
   Varshney Jyotika, 2016, Vet Sci, V3, DOI 10.3390/vetsci3010003
   Velez AMA, 2015, N AM J MED SCI, V7, P176, DOI 10.4103/1947-2714.157476
   Velletri T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.367
   Verrecchia F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00133
   Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021
   Wang CY, 2018, MED SCI MONITOR, V24, P7043, DOI 10.12659/MSM.912092
   Wang D, 2019, CANCER RES, V79, P7, DOI 10.1158/0008-5472.CAN-18-1086
   Wang MM, 2013, CANCER BIOL THER, V14, P155, DOI 10.4161/cbt.22955
   Wang Q, 2017, MOL MED REP, V16, P901, DOI 10.3892/mmr.2017.6635
   Wang QZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180558
   Wang T, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1195-y
   Wang YM, 2012, NAT IMMUNOL, V13, P753, DOI 10.1038/ni.2360
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Wu Stephanie C, 2018, Oncotarget, V9, P32580, DOI 10.18632/oncotarget.25953
   Wu X, 2012, CANCER EPIDEMIOL, V36, P212, DOI 10.1016/j.canep.2011.08.002
   Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1007-1
   Wu Z, 2017, ONCOTARGETS THER, V10, P5329, DOI 10.2147/OTT.S149905
   Xiao QR, 2017, ONCOL RES, V25, P267, DOI 10.3727/096504016X14732510786564
   Xu GX, 2017, SCI REP-UK, V7, DOI 10.1038/srep42411
   Xu HD, 2016, ONCOL LETT, V12, P5247, DOI 10.3892/ol.2016.5355
   Xu HD, 2014, CELL PHYSIOL BIOCHEM, V33, P1547, DOI 10.1159/000358718
   Xu J, 2017, J BONE ONCOL, V9, P34, DOI 10.1016/j.jbo.2017.05.001
   Yang Yi, 2017, Genes Cancer, V8, P484, DOI 10.18632/genesandcancer.133
   Yu Q, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-71
   Yu X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1509-1
   Zhang DY, 2017, J BUON, V22, P258
   Zhang HL, 2013, FASEB J, V27, P232, DOI 10.1096/fj.12-215491
   Zhang HX, 2013, STEM CELLS, V31, P433, DOI 10.1002/stem.1298
   Zhang HH, 2019, MED SCI MONITOR, V25, P1307, DOI 10.12659/MSM.915001
   Zhao YH, 2014, ACTA BIOCH BIOPH SIN, V46, P180, DOI 10.1093/abbs/gmt147
   Zheng Y, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0780-x
   Zhou Y, 2019, CANCER BIOL THER, V20, P1141, DOI 10.1080/15384047.2019.1598766
   Zhu KP, 2018, INT J BIOL SCI, V14, P321, DOI 10.7150/ijbs.24360
NR 142
TC 4
Z9 4
U1 1
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD FEB
PY 2020
VL 19
IS 2
BP 1099
EP 1116
DI 10.3892/ol.2019.11229
PG 18
WC Oncology
SC Oncology
GA KE9UD
UT WOS:000508895000001
PM 31966039
OA Green Published, Other Gold
DA 2020-10-30
ER

PT J
AU da Silva, MHM
   Moises, RNC
   Alves, BEB
   Pereira, HWB
   de Paiva, AAP
   Morais, IC
   Nascimento, YM
   Monteiro, JD
   de Souto, JT
   Nascimento, MSL
   de Araujo, JMG
   da Guedes, PMM
   Fernandes, JV
AF Matias da Silva, Marcelo Henrique
   Cunha Moises, Raiza Nara
   Bizerra Alves, Brenda Elen
   Bezerra Pereira, Hannaly Wana
   Pereira de Paiva, Anne Aline
   Morais, Ingryd Camara
   Nascimento, Yasmim Mesquita
   Monteiro, Joelma Dantas
   de Souto, Janeusa Trindade
   Lima Nascimento, Manuela Sales
   Galvao de Araujo, Joselio Maria
   Matta da Guedes, Paulo Marcos
   Fernandes, Jose Verissimo
TI Innate immune response in patients with acute Zika virus infection
SO MEDICAL MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
DE Zika virus; Patient; Innate immune receptors; Toll-like receptors
   (TLRs); RIG-like receptors (RLRs); Cytokines
ID DENGUE VIRUS; BARRE-SYNDROME; TRANSMISSION; ENHANCEMENT; RECEPTORS;
   OUTBREAK; GUILLAIN; AMERICA
AB Innate immunity receptors (Toll-like receptors/TLRs and RIG-like receptors/RLRs) are important for the initial recognition of Zika virus (ZIKV), modulation of protective immune response, and IFN-alpha and IFN-beta production. Immunological mechanisms involved in protection or pathology during ZIKV infection have not yet been determined. In this study, we evaluated the mRNA expression of innate immune receptors (TLR3, TLR7, TLR8, TLR9, melanoma differentiation-associated protein 5/MDA-5, and retinoic acid inducible gene/RIG-1), its adapter molecules (Myeloid Differentiation Primary Response Gene 88/Myd88, Toll/IL-1 Receptor Domain-Containing Adaptor-Inducing IFN-beta/TRIF), and cytokines (IL-6, IL-12, TNF-alpha, IFN-alpha, IFN-beta, and IFN-gamma) in the acute phase of patients infected by ZIKV using real-time PCR in peripheral blood. Patients with acute ZIKV infection had high expression of TLR3, IFN-alpha, IFN-beta, and IFN-gamma when compared to healthy controls. In addition, there was a positive correlation between TLR3 expression compared to IFN-alpha and IFN-beta. Moreover, viral load is positively correlated with TLR8, RIG-1, MDA-5, IFN-alpha, and IFN-beta. On the other hand, patients infected by ZIKV showed reduced expression of RIG-1, TLR8, Myd88, and TNF-alpha molecules, which are also involved in antiviral immunity. Similar expressions of TLR7, TLR9, MDA-5, TRIF, IL-6, and IL-12 were observed between the group of patients infected with ZIKV and control subjects. Our results indicate that acute infection (up to 5 days after the onset of symptoms) by ZIKV in patients induces the high mRNA expression of TLR3 correlated to high expression of IFN-gamma, IFN-alpha, and IFN-beta, even though the high viral load is correlated to high expression of TLR8, RIG-1, MDA-5, IFN-alpha, and IFN-beta in ZIKV patients.
C1 [Matias da Silva, Marcelo Henrique; Bizerra Alves, Brenda Elen; Bezerra Pereira, Hannaly Wana; de Souto, Janeusa Trindade; Galvao de Araujo, Joselio Maria; Matta da Guedes, Paulo Marcos; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Grad Program Parasitary Biol, Natal, RN, Brazil.
   [Cunha Moises, Raiza Nara; Bizerra Alves, Brenda Elen; Bezerra Pereira, Hannaly Wana; Pereira de Paiva, Anne Aline; Nascimento, Yasmim Mesquita; Monteiro, Joelma Dantas; de Souto, Janeusa Trindade; Galvao de Araujo, Joselio Maria; Matta da Guedes, Paulo Marcos; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Natal, RN, Brazil.
   [Bizerra Alves, Brenda Elen; Bezerra Pereira, Hannaly Wana; Pereira de Paiva, Anne Aline; Morais, Ingryd Camara; Nascimento, Yasmim Mesquita; Monteiro, Joelma Dantas; Galvao de Araujo, Joselio Maria] Univ Fed Rio Grande do Norte, Virol Lab, Inst Trop Med, Natal, RN, Brazil.
   [Lima Nascimento, Manuela Sales] Santos Dumont Inst, Edmond & Lily Safra Int Inst Neurosci ELS IIN, Macaiba, RN, Brazil.
RP da Guedes, PMM; Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Grad Program Parasitary Biol, Natal, RN, Brazil.; da Guedes, PMM; Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Natal, RN, Brazil.
EM pauloguedes@cb.ufrn.br; veris@cb.ufrn.br
OI Matta Guedes, Paulo Marcos/0000-0002-4564-6791; Fernandes, Jose
   Verissimo/0000-0002-5169-6496; nascimento, manuela/0000-0002-6887-8931
FU National Council for Scientific and Technological Development
   (MEC/MCTI/CAPES/CNPq/FAPS-PVE Grant) [400328/2014-3]; National Council
   for Scientific and Technological Development (MCTI/CNPq/Universal Grant)
   [404904/2016-5]; University Faculty Advanced Studies Coordination Unit
   (CAPES); CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by the National Council for Scientific and
   Technological Development (MEC/MCTI/CAPES/CNPq/FAPS-PVE Grant no.
   400328/2014-3 and MCTI/CNPq/Universal Grant no. 404904/2016-5).
   Post-graduation research fellows are supported by University Faculty
   Advanced Studies Coordination Unit (CAPES). The author PMMG acknowledges
   the CNPq for the research productivity fellowship.
CR Abdalla LF, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0938-2
   Araujo LM, 2016, ARQ NEURO-PSIQUIAT, V74, P253, DOI 10.1590/0004-282X20160035
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164
   Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Chaudhary V, 2017, J VIROL, V91, DOI 10.1128/JVI.00163-17
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Garcez P, 2005, AM J HUM GENET, V76, P717, DOI [10.1086/429930, DOI 10.1086/429930]
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Ikejezie J, 2017, AM J TRANSPLANT, V17, P1681, DOI 10.1111/ajt.14333
   Kam Y-W, 2017, J INFECT DIS, DOI [10.1093/neuonc/nox188/4265638, DOI 10.1093/NEUONC/NOX188/4265638]
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Kucharski AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004726
   Kumar A, 2016, EMBO REP, V17, P1766, DOI 10.15252/embr.201642627
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Laurent-Rolle M, 2010, J VIROL, V84, P3503, DOI 10.1128/JVI.01161-09
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lubick KJ, 2015, CELL HOST MICROBE, V18, P61, DOI 10.1016/j.chom.2015.06.007
   Luo HL, 2018, ANTIVIR RES, V151, P55, DOI 10.1016/j.antiviral.2018.01.003
   Malkki H, 2016, NAT REV NEUROL, V12, DOI [10.1038/nrneurol.2016.117, 10.1038/nrneurol.2016.78, 10.1038/nrneurol.2016.52, 10.1038/nrneurol.2016.151, 10.1038/nrneurol.2016.139, 10.1038/nrneurol.2016.30, 10.1038/nrneurol.2016.58, 10.1038/nrneurol.2016.175, 10.1038/nrneurol.2016.79, 10.1038/nrneurol.2016.22]
   Morris G, 2018, MOL NEUROBIOL, V55, P4160, DOI 10.1007/s12035-017-0635-y
   Nascimento OJM, 2017, CURR OPIN NEUROL, V30, P500, DOI 10.1097/WCO.0000000000000471
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Ornelas AMM, 2017, ANN NEUROL, V81, P152, DOI 10.1002/ana.24839
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Pierson T, 2013, CELL HOST MICROBE, V17, P148, DOI [10.1007/s10461-012-0143-z.Provider-patient, DOI 10.1007/S10461-012-0143-Z.PROVIDER-PATIENT]
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004
   Silasi M, 2015, AM J REPROD IMMUNOL, V73, P199, DOI 10.1111/aji.12355
   Simoni MK, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12613
   Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Welte T, 2009, J GEN VIROL, V90, P2660, DOI 10.1099/vir.0.011783-0
   Xia HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02816-2
   Ye J, 2013, VACCINE, V31, P461, DOI 10.1016/j.vaccine.2012.11.015
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 46
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0300-8584
EI 1432-1831
J9 MED MICROBIOL IMMUN
JI Med. Microbiol. Immunol.
PD DEC
PY 2019
VL 208
IS 6
BP 703
EP 714
DI 10.1007/s00430-019-00588-8
PG 12
WC Immunology; Microbiology
SC Immunology; Microbiology
GA KH8MA
UT WOS:000510903600001
PM 30879197
DA 2020-10-30
ER

PT J
AU de Brito-Neto, JG
   de Andrade, MF
   de Almeida, VD
   Paiva, DCC
   de Morais, NM
   Bezerra, CM
   Fernandes, JV
   do Nascimento, EGC
   Fonseca, IAT
   Fernandes, TAAD
AF de Brito-Neto, Jose Garcia
   de Andrade, Micassio Fernandes
   de Almeida, Valeria Duarte
   Costa Paiva, Dayane Carla
   de Morais, Nickson Melo
   Bezerra, Christiane Medeiros
   Fernandes, Jose Verissimo
   Cosme do Nascimento, Ellany Gurgel
   Teixeira Fonseca, Ivana Alice
   Araujo de Medeiros Fernandes, Thales Allyrio
TI Strength training improves body composition, muscle strength and
   increases CD4(+) T lymphocyte levels in people living with HIV/AIDS
SO INFECTIOUS DISEASE REPORTS
LA English
DT Article
DE AIDS; body composition; immunity; muscle strength; resistance training
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PHYSICAL-ACTIVITY; EXERCISE; MODERATE
AB The establishment of physical training programs for people living with HIV/AIDS (PLWHA) has several benefits. The study aimed to analyze the effect of resistance training using prediction of intensity by subjective perception of effort (SPE) on body composition, muscle strength, and TCD4(+) lymphocyte levels in PLWHA. This a randomized controlled trial study. Participants (11 men and 8 women), were divided in two groups: exercise group (EG) and control group (CG). The EG was submitted to 12 weeks of a resistance-training program based in the prediction of intensity by SPE. Body mass percentages were evaluated using tetrapolar bioelectrical impedance and skinfold methods. We used Flow Cytometry to quantify CD4 + T lymphocytes. Patients showed significant changes in Body Fat Percentage (Delta%=-6.23%), Lean Body Mass (Delta%=2.45%), and CD4T lymphocytes levels (Delta(%)=15.77%). They also showed significant increase in muscular strength presented in the test for one repetition maximum in all the evaluated exercises. Our data suggest that exercising program prescribed by SPE is capable of improving immune function, body composition, and muscular strength in PLWHA.
C1 [de Brito-Neto, Jose Garcia; de Andrade, Micassio Fernandes; de Almeida, Valeria Duarte; Costa Paiva, Dayane Carla; de Morais, Nickson Melo; Cosme do Nascimento, Ellany Gurgel; Araujo de Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, Mossoro, Brazil.
   [Bezerra, Christiane Medeiros; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Natal, RN, Brazil.
   [Teixeira Fonseca, Ivana Alice] Univ Rio Grande Norte State, Dept Phys Educ, Mossoro, Brazil.
RP de Andrade, MF (corresponding author), Univ Rio Grande Norte State, Fac Hlth Sci, Dept Biomed Sci, Rua Miguel Antonio da Silva Neto S-N, BR-59607360 Mossoro, RN, Brazil.
EM micassiofernandes@gmail.com
RI Fernandes, Thales/F-4813-2010
OI Fernandes, Thales/0000-0003-4559-8918
FU Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES; National Council for Scientific and Technological
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX The Coordination for the Improvement of Higher Education Personnel
   (CAPES) and the National Council for Scientific and Technological
   Development (CNPq) funded this study.
CR Ahtiainen JP, 2010, EUR J APPL PHYSIOL, V108, P273, DOI 10.1007/s00421-009-1211-6
   Alves R. C, 2014, J EXERCISE PHYSL ONL, V17, P66
   Bessa A, 2017, J SPORT MED PHYS FIT, V57, P1051, DOI 10.23736/S0022-4707.16.06357-X
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Burd NA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012033
   Cannon J, 2010, J SPORT SCI, V28, P1505, DOI 10.1080/02640414.2010.517544
   Dolan SE, 2006, ARCH INTERN MED, V166, P1225, DOI 10.1001/archinte.166.11.1225
   Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012
   Ferrari R, 2013, EXP GERONTOL, V48, P1236, DOI 10.1016/j.exger.2013.07.016
   Florindo AA, 2008, REV BRAS ATIV FIS SA, V13, P75
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Gentil P, 2017, PHYSIOL BEHAV, V179, P148, DOI 10.1016/j.physbeh.2017.06.004
   Gomes RD, 2010, BRAZ J PHYS THER, V14, P390, DOI 10.1590/S1413-35552010000500007
   Haddad M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00612
   Kamitani E, 2017, AIDS EDUC PREV, V29, P347, DOI 10.1521/aeap.2017.29.4.347
   Kraemer W. J., 1995, PHYSL ASSESSMENT HUM
   Kruger K, 2014, EXERC IMMUNOL REV, V20, P117
   Lancaster GI, 2016, IMMUNOL CELL BIOL, V94, P115, DOI 10.1038/icb.2015.103
   Matthews CE, 2002, MED SCI SPORT EXER, V34, P1242, DOI 10.1097/00005768-200208000-00003
   Neves I, 2000, MEM I OSWALDO CRUZ, V95, P393, DOI 10.1590/S0074-02762000000300016
   Noakes TD, 2011, APPL PHYSIOL NUTR ME, V36, P23, DOI 10.1139/H10-082
   O'Brien KK, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2342-8
   Paes Lorena da Silva, 2015, Open AIDS J, V9, P80, DOI 10.2174/1874613601509010080
   Pedro RE, 2017, J SPORT MED PHYS FIT, V57, P685, DOI 10.23736/S0022-4707.16.06234-4
   Portugal EMM, 2015, PERCEPT MOTOR SKILL, V121, P465, DOI 10.2466/29.PMS.121c17x3
   Robertson RJ, 2003, MED SCI SPORT EXER, V35, P333, DOI 10.1249/01.MSS.0000048831.15016.2A
   Roubenoff R, 2001, MED SCI SPORT EXER, V33, P1811, DOI 10.1097/00005768-200111000-00003
   Sweet TW, 2004, J STRENGTH COND RES, V18, P796
   Valente Angélica M.M., 2005, Arq Bras Endocrinol Metab, V49, P871, DOI 10.1590/S0004-27302005000600004
   Williams DM, 2008, PSYCHOL SPORT EXERC, V9, P231, DOI 10.1016/j.psychsport.2007.04.002
NR 30
TC 3
Z9 3
U1 0
U2 0
PU PAGEPRESS PUBL
PI PAVIA
PA MEDITGROUP, VIA G BELLI, 4, PAVIA, 27100, ITALY
SN 2036-7430
EI 2036-7449
J9 INFECT DIS REP
JI Infect. Dis. Rep.
PY 2019
VL 11
IS 1
BP 10
EP 15
DI 10.4081/idr.2019.7925
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA IY5LX
UT WOS:000486434700003
PM 31205641
OA DOAJ Gold, Green Published
DA 2020-10-30
ER

PT J
AU Alves, JJP
   Fernandes, TAAD
   De Araujo, JMG
   Cobucci, RNO
   Lanza, DCF
   Bezerra, FL
   Andrade, VS
   Fernandes, JV
AF Paiva Alves, Jayra Juliana
   Araujo De Medeiros Fernandes, Thales Allyrio
   Galvao De Araujo, Joselio Maria
   Oliveira Cobucci, Ricardo Ney
   Ferreira Lanza, Daniel Carlos
   Bezerra, Fabiana Lima
   Andrade, Vania Sousa
   Fernandes, Jose Verissimo
TI Th17 response in patients with cervical cancer
SO ONCOLOGY LETTERS
LA English
DT Review
DE Th17 cells; uterine cervical cancer; carcinogenesis; immune system
ID HUMAN-PAPILLOMAVIRUS INFECTION; IL-17-PRODUCING T-CELLS;
   TUMOR-INFILTRATING LYMPHOCYTES; INFLAMMATORY-DISEASES; IMMUNE-RESPONSES;
   HOST-DEFENSE; ASSOCIATION ANALYSIS; EFFECTOR FUNCTIONS; INTERLEUKIN 17;
   MESSENGER-RNA
AB Persistent infection by high-risk human papillomavirus (HR-HPV) is the main risk factor for uterine cervical cancer (UCC). However, viral infection alone is not sufficient for the development and progression of premalignant cervical lesions for cancer. In previous years it has been suggested that the adaptive immune response triggered by the differentiation of naive helper T cells in Th17 cells may serve an important role in disease development. It has been hypothesized that Th17 cells may be involved in the promotion of UCC, as high levels of interleukin 17 (IL17) expression have been detected in the mucosa of the uterine cervix of patients affected by the disease. However, the role of Th17 cells in the tumor development and progression remains unclear. It is believed that the immune response of the Th17 type during persistent infection of the genital tract with HR-HPV triggers chronic inflammation with a long duration with the production of IL17 and other pro-inflammatory cytokines, creating a favorable environment for tumor development. These cytokines are produced by immune system cells in addition to tumor cells and appear to function by modulating the host immune system, resulting in an immunosuppressive response as opposed to inducing an effective protective immune response, thus contributing to the growth and progression of the tumor. In the present review, the latest advances are presented about the function of Th17 cells and the cytokines produced by them in the development and progression of UCC.
C1 [Paiva Alves, Jayra Juliana; Galvao De Araujo, Joselio Maria; Bezerra, Fabiana Lima; Andrade, Vania Sousa; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Araujo De Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, Rua Miguel Antonio da Silva Neto S-N, BR-59607360 Mossoro, RN, Brazil.
   [Oliveira Cobucci, Ricardo Ney] Univ Potiguar, Dept Gynecol & Obstet, BR-5905600 Natal, RN, Brazil.
   [Ferreira Lanza, Daniel Carlos] Univ Fed Rio Grande do Norte, Dept Biochem, BR-59072970 Natal, RN, Brazil.
RP Fernandes, TAAD (corresponding author), Univ Rio Grande Norte State, Dept Biomed Sci, Rua Miguel Antonio da Silva Neto S-N, BR-59607360 Mossoro, RN, Brazil.
EM thalesallyrio@yahoo.com.br
RI Fernandes, Thales/F-4813-2010; Cobucci, Ricardo Ney
   Oliveira/E-2907-2015; Andrade, Vania Sousa/AAR-3922-2020; Araujo,
   Joselio M G/B-5502-2013
OI Fernandes, Thales/0000-0003-4559-8918; Cobucci, Ricardo Ney
   Oliveira/0000-0002-0184-2061; Araujo, Joselio M G/0000-0003-3548-2786;
   Fernandes, Jose Verissimo/0000-0002-5169-6496
CR Annunziato F, 2015, IMMUNOLOGY, V144, P343, DOI 10.1111/imm.12399
   Arnold CE, 2015, IMMUNOBIOLOGY, V220, P10, DOI 10.1016/j.imbio.2014.09.022
   Asadzadeh Z, 2017, CELL IMMUNOL, V322, P15, DOI 10.1016/j.cellimm.2017.10.015
   Backert I, 2014, J IMMUNOL, V193, P3779, DOI 10.4049/jimmunol.1303076
   Barnes MJ, 2009, IMMUNITY, V31, P401, DOI 10.1016/j.immuni.2009.08.011
   Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036
   Bie QL, 2017, MOL IMMUNOL, V90, P50, DOI 10.1016/j.molimm.2017.07.004
   Blaskewicz CD, 2011, BIOL REPROD, V85, P97, DOI 10.1095/biolreprod.110.090423
   Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002
   Bosch FX, 2007, DIS MARKERS, V23, P213, DOI 10.1155/2007/914823
   Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045
   Catarino R, 2015, WORLD J CLIN ONCOL, V6, P281, DOI 10.5306/wjco.v6.i6.281
   Chen ZF, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-61
   Cong JL, 2015, INT J CLIN EXP PATHO, V8, P9567
   Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800
   Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749-6632.2009.05133.x
   Daud II, 2011, INT J CANCER, V128, P879, DOI 10.1002/ijc.25400
   Davidson MG, 2013, J IMMUNOL, V191, P1175, DOI 10.4049/jimmunol.1203201
   Dong C, 2014, CELL RES, V24, P901, DOI 10.1038/cr.2014.92
   Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004
   Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202
   Feng MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108502
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Fu BQ, 2014, CELL MOL IMMUNOL, V11, P564, DOI 10.1038/cmi.2014.54
   Gaffen SL, 2009, NAT REV IMMUNOL, V9, DOI 10.1038/nri2625
   Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017
   Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452
   Gagliani N, 2014, CELL, V157, P776, DOI 10.1016/j.cell.2014.03.006
   Galvez J, 2014, ISRN INFLAMM, V2014, DOI DOI 10.1155/2014/928461
   Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543
   Goldszmid RS, 2014, CELL HOST MICROBE, V15, P295, DOI 10.1016/j.chom.2014.02.003
   Gosmann C, 2014, J IMMUNOL, V193, P2248, DOI 10.4049/jimmunol.1400216
   Guery L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/314620
   Hardikar S, 2015, GYNECOL ONCOL, V139, P90, DOI 10.1016/j.ygyno.2015.07.110
   Hartupee J, 2009, J IMMUNOL, V182, P1660, DOI 10.4049/jimmunol.182.3.1660
   Hervouet C, 2010, J IMMUNOL, V184, P4842, DOI 10.4049/jimmunol.0901695
   Hou F, 2013, CLIN CHIM ACTA, V415, P337, DOI 10.1016/j.cca.2012.11.004
   Hou F, 2012, CLIN CHIM ACTA, V413, P1848, DOI 10.1016/j.cca.2012.07.012
   Hu Y, 2011, ANN NY ACAD SCI, V1217, P60, DOI 10.1111/j.1749-6632.2010.05825.x
   Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504
   Huang Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep36551
   Huber M, 2009, EUR J IMMUNOL, V39, P1716, DOI 10.1002/eji.200939412
   Iwasaki A, 2010, NAT REV IMMUNOL, V10, P699, DOI 10.1038/nri2836
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Kaplan MH, 2013, IMMUNOL REV, V252, P104, DOI 10.1111/imr.12028
   Karczmarczyk A, 2014, ACTA HAEMATOL POL, V45, P155
   Kemp TJ, 2010, CANCER EPIDEM BIOMAR, V19, P1954, DOI 10.1158/1055-9965.EPI-10-0184
   Kim HS, 2017, J EXP MED, V214, P3381, DOI 10.1084/jem.20170523
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Li L, 2015, GENET MOL RES, V14, P12178, DOI 10.4238/2015.October.9.6
   Li YX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118391
   Liang SC, 2007, J IMMUNOL, V179, P7791, DOI 10.4049/jimmunol.179.11.7791
   Liang W, 2016, CANCER IMMUNOL RES, V4, P83, DOI 10.1158/2326-6066.CIR-15-0313
   Lima Erika Galvao, 2013, ISRN Obstet Gynecol, V2013, P930479, DOI 10.1155/2013/930479
   Lin Y, 2014, SOUTH MED J, V107, P281, DOI 10.1097/SMJ.0000000000000100
   Lv QY, 2015, TUMOR BIOL, V36, P3979, DOI 10.1007/s13277-015-3041-y
   Maddur MS, 2012, AM J PATHOL, V181, P8, DOI 10.1016/j.ajpath.2012.03.044
   Mandic A, 2014, J BUON, V19, P958
   Mellett M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2127
   Mills KHG, 2008, EUR J IMMUNOL, V38, P2636, DOI 10.1002/eji.200838535
   Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105
   Mora-Garcia Maria Lourdes, 2015, Rev Med Inst Mex Seguro Soc, V53 Suppl 2, pS206
   Morrison PJ, 2011, IMMUNOLOGY, V133, P397, DOI 10.1111/j.1365-2567.2011.03454.x
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954
   Nalbant Ayten, 2016, Front Biosci (Elite Ed), V8, P427
   Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x
   Paradkar PH, 2014, ASIAN PAC J CANCER P, V15, P3851, DOI 10.7314/APJCP.2014.15.9.3851
   Peters A, 2011, CURR OPIN IMMUNOL, V23, P702, DOI 10.1016/j.coi.2011.08.007
   Punt S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.984539
   Quan Y, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/258293
   Ron D, 2008, INT J BIOCHEM CELL B, V40, P2040, DOI 10.1016/j.biocel.2008.03.013
   Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200
   Saavedra K, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-13
   Saleh A, 2009, J IMMUNOL, V182, P3357, DOI 10.4049/jimmunol.0801882
   Sasagawa T, 2012, J INFECT CHEMOTHER, V18, P807, DOI 10.1007/s10156-012-0485-5
   Schmitt E, 2014, TRENDS IMMUNOL, V35, P61, DOI 10.1016/j.it.2013.10.004
   Shabgah AG, 2014, POSTEP DERM ALERGOL, V31, P256, DOI 10.5114/pdia.2014.40954
   Shukla S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067849
   Song D, 2015, ONCOL LETT, V10, P600, DOI 10.3892/ol.2015.3295
   Stanley MA, 2009, INDIAN J MED RES, V130, P266
   Stanley M, 2008, GYNECOL ONCOL, V109, pS15, DOI 10.1016/j.ygyno.2008.02.003
   Sun DX, 2011, NAT IMMUNOL, V12, P853, DOI 10.1038/ni.2081
   Sun LX, 2015, GENET MOL RES, V14, P13612, DOI 10.4238/2015.October.28.22
   Tajima M, 2011, INT IMMUNOL, V23, P751, DOI 10.1093/intimm/dxr086
   Tartour E, 1999, CANCER RES, V59, P3698
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Trajkovic V, 2001, J NEUROIMMUNOL, V119, P183, DOI 10.1016/S0165-5728(01)00391-5
   Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024
   van Hamburg JP, 2009, ARTHRITIS RHEUM-US, V60, P750, DOI 10.1002/art.24329
   Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659
   Vidal AC, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0005-1
   Walch-Ruckheim B, 2015, CANCER RES, V75, P5248, DOI 10.1158/0008-5472.CAN-15-0732
   Wei L, 2016, MOL MED REP, V13, P1673, DOI 10.3892/mmr.2015.4694
   Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
   Wright JF, 2007, J BIOL CHEM, V282, P13447, DOI 10.1074/jbc.M700499200
   Wu MY, 2011, J FORMOS MED ASSOC, V110, P580, DOI 10.1016/j.jfma.2011.07.005
   Xue JS, 2018, CANCER MED-US, V7, P297, DOI 10.1002/cam4.1279
   Ye J, 2013, AM J PATHOL, V182, P10, DOI 10.1016/j.ajpath.2012.08.041
   Young MRI, 2016, INT J CANCER, V138, P2487, DOI 10.1002/ijc.29989
   Yu Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120855
   Zhang J, 2017, ONCOTARGET, V8, P24797, DOI 10.18632/oncotarget.15044
   Zhang S, 2017, NATURE, V551, P105, DOI 10.1038/nature24283
   Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086812
   Zhang Y, 2011, CLIN CHIM ACTA, V412, P894, DOI 10.1016/j.cca.2011.01.015
   Zhao M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02890-0
   Zhu S, 2012, CLIN SCI, V122, P487, DOI 10.1042/CS20110496
   Ziegler SF, 2009, MICROBES INFECT, V11, P594, DOI 10.1016/j.micinf.2009.04.002
NR 110
TC 7
Z9 8
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2018
VL 16
IS 5
BP 6215
EP 6227
DI 10.3892/ol.2018.9481
PG 13
WC Oncology
SC Oncology
GA GY3FG
UT WOS:000448433500092
PM 30405758
OA Other Gold, Green Published
DA 2020-10-30
ER

PT J
AU Santos, MCD
   Nascimento, YM
   Monteiro, JD
   Alves, BEB
   Melo, MF
   Paiva, AAP
   Pereira, HWB
   Medeiros, LG
   Morais, IC
   Neto, JCF
   Fernandes, JV
   Araujo, JMG
   Lima, KMG
AF Santos, Marfran C. D.
   Nascimento, Yasmin M.
   Monteiro, Joelma D.
   Alves, Brenda E. B.
   Melo, Marilia F.
   Paiva, Anne A. P.
   Pereira, Hannaly W. B.
   Medeiros, Leandro G.
   Morais, Ingryd C.
   Fagundes Neto, Joao Ciro
   Fernandes, Jose V.
   Araujo, Joselio M. G.
   Lima, Kassio M. G.
TI ATR-FTIR spectroscopy with chemometric algorithms of multivariate
   classification in the discrimination between healthy vs. dengue vs.
   chikungunya vs. zika clinical samples (vol 10, pg 1280, 2018)
SO ANALYTICAL METHODS
LA English
DT Correction
C1 [Santos, Marfran C. D.; Lima, Kassio M. G.] Univ Fed Rio Grande do Norte, Biol Chem & Chemometr, Inst Chem, BR-59072970 Natal, RN, Brazil.
   [Nascimento, Yasmin M.; Monteiro, Joelma D.; Alves, Brenda E. B.; Melo, Marilia F.; Paiva, Anne A. P.; Pereira, Hannaly W. B.; Medeiros, Leandro G.; Fagundes Neto, Joao Ciro; Fernandes, Jose V.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Nascimento, Yasmin M.; Monteiro, Joelma D.; Alves, Brenda E. B.; Melo, Marilia F.; Paiva, Anne A. P.; Pereira, Hannaly W. B.; Medeiros, Leandro G.; Morais, Ingryd C.; Fagundes Neto, Joao Ciro; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Virol Lab, Inst Trop Med, BR-59072970 Natal, RN, Brazil.
RP Lima, KMG (corresponding author), Univ Fed Rio Grande do Norte, Biol Chem & Chemometr, Inst Chem, BR-59072970 Natal, RN, Brazil.
EM kassiolima@gmail.com
OI Fernandes, Jose Verissimo/0000-0002-5169-6496
CR Santos MCD, 2018, ANAL METHODS-UK, V10, P1280, DOI 10.1039/c7ay02784b
NR 1
TC 0
Z9 0
U1 0
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9660
EI 1759-9679
J9 ANAL METHODS-UK
JI Anal. Methods
PD SEP 28
PY 2018
VL 10
IS 36
BP 4472
EP 4473
DI 10.1039/c8ay90116c
PG 2
WC Chemistry, Analytical; Food Science & Technology; Spectroscopy
SC Chemistry; Food Science & Technology; Spectroscopy
GA GY2VF
UT WOS:000448401300013
OA Other Gold
DA 2020-10-30
ER

PT J
AU Brandao, LDS
   Boniek, D
   Stoianoff, MAR
   da Mata, FMR
   de Azevedo, PRM
   Fernandes, JV
   Andrade, VS
AF Brandao, L. D. S.
   Boniek, D.
   Resende Stoianoff, M. A.
   da Mata, F. M. R.
   de Azevedo, P. R. M.
   Fernandes, J. V.
   Andrade, V. S.
TI Prevalence and antifungal susceptibility of Candida species among
   pregnant women attending a school maternity at Natal, Brazil
SO LETTERS IN APPLIED MICROBIOLOGY
LA English
DT Article
DE antifungal susceptibility; Candida species; diagnosis; pregnant women;
   vulvovaginal candidiasis
ID VULVO-VAGINAL CANDIDIASIS; BACTERIAL VAGINOSIS; IDENTIFICATION;
   HORMONES; CULTURE; CARE
AB Vulvovaginal candidiasis (VVC) is an inflammatory disease of the vulva and vagina caused by different yeasts of the genus Candida which is responsible for infection in pregnant patients who attended Maternidade Escola Januario Cicco, Rio Grande do Norte, Brazil. From 41 samples, 19 yeasts were identified phenotypically as Candida albicans and one as Candida glabrata which is reported as the non-albicans species most frequently isolated from vulvovaginitis. The susceptibility to selected antifungal agents (flucytosine, fluconazole, voriconazole, amphotericin B, caspofungin and micafungin) was determined, and the association between patient-related signs and symptoms aided the construction of an epidemiological profile. Antifungal susceptibility testing performed by automated method showed that all strains were sensitive to the drugs tested, including the C. glabrata specimen despite its known resistance or dose-dependent susceptibility to azole derivatives. Regarding patient signs and symptoms, no statistically significant association between these and the establishment of VVC was found. It can be concluded that the laboratorial diagnosis of VVC is necessary prior to the administration of treatment, since only 4878% of the patients had VVC but for all of them antifungal therapy were prescribed.
C1 [Brandao, L. D. S.; Fernandes, J. V.; Andrade, V. S.] Univ Fed Rio Grande do Norte, UFRN, Ctr Biociencias, Dept Microbiol & Parasitol, Natal, RN, Brazil.
   [Boniek, D.; Resende Stoianoff, M. A.; da Mata, F. M. R.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [de Azevedo, P. R. M.] Univ Fed Rio Grande do Norte, UFRN, Ctr Ciencias Exatas Terra, Dept Estat, Natal, RN, Brazil.
RP Stoianoff, MAR (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM maresend@icb.ufmg.br
RI Andrade, Vania Sousa/AAR-3922-2020; Boniek, Douglas/B-1674-2018
OI Resende Stoianoff, Maria Aparecida/0000-0002-6220-1321; Boniek,
   Douglas/0000-0001-6923-7143; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
FU Post-Graduation Program of Parasitic Biology
FX The authors thank Dr Ubiraci Gomes de Paula Lana for supervising the
   sequencing and the staff of Maternity School Januario Cicco (MSJC) for
   the help provided during the samples collection. This work was
   financially supported by the Post-Graduation Program of Parasitic
   Biology.
CR Achkar JM, 2010, CLIN MICROBIOL REV, V23, P253, DOI 10.1128/CMR.00076-09
   Ahmad A, 2009, EUR J OBSTET GYN R B, V144, P68, DOI 10.1016/j.ejogrb.2008.12.020
   Ahmad S, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-230
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   BERGMAN JJ, 1984, J FAM PRACTICE, V18, P549
   Carrara MA, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.011
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   Dias LB, 2011, BRAZ J MICROBIOL, V42, P1300, DOI 10.1590/S1517-83822011000400009
   Dota KFD, 2011, LABMEDICINE, V42, P87, DOI 10.1309/LMDFCA8YEZ0MQULA
   ElFeky DS, 2016, ALEX J MED, V52, P269, DOI 10.1016/j.ajme.2015.10.001
   Eraso E, 2006, J CLIN MICROBIOL, V44, P3340, DOI 10.1128/JCM.00213-06
   Fernandez Limia Octavio, 2004, MedGenMed, V6, P50
   Fidel PL, 2000, INFECT IMMUN, V68, P651, DOI 10.1128/IAI.68.2.651-657.2000
   Godinho VM, 2013, ISME J, V7, P1434, DOI 10.1038/ismej.2013.77
   Guzel AB, 2011, MYCOPATHOLOGIA, V172, P25, DOI 10.1007/s11046-011-9392-z
   Looke M, 2011, BIOTECHNIQUES, V50, P325, DOI 10.2144/000113672
   Lu FX, 2002, CLIN EXP IMMUNOL, V128, P10, DOI 10.1046/j.1365-2249.2002.01780.x
   Masri SN, 2015, PAK J MED SCI, V31, P658, DOI 10.12669/pjms.313.7072
   McClelland RS, 2009, J INFECT DIS, V199, P1883, DOI 10.1086/599213
   Mendling W, 2015, MYCOSES, V58, P1, DOI 10.1111/myc.12292
   Mulu A, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-82
   Olowe OA, 2014, EUR J MICROBIOL IMMU, V4, P193, DOI 10.1556/EUJMI-D-14-00027
   Rahman T, 1991, Indian J Med Sci, V45, P212
   Rodrigues MT, 2013, REV BRAS GINECOL OBS, V35, P554, DOI 10.1590/S0100-72032013001200005
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114
   Spinillo A, 1999, AM J OBSTET GYNECOL, V180, P14, DOI 10.1016/S0002-9378(99)70141-9
   Taylor BD, 2013, SEX TRANSM DIS, V40, P117, DOI 10.1097/OLQ.0b013e31827c5a5b
   White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1
   Workowski KA, 2015, MMWR RECOMM REP, V64, P1
   Zhou X, 2009, INFECT IMMUN, V77, P4130, DOI 10.1128/IAI.00436-09
   Ziarrusta B. G., 2002, REV IBEROAM MICOL, V19, P22
NR 32
TC 0
Z9 0
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0266-8254
EI 1472-765X
J9 LETT APPL MICROBIOL
JI Lett. Appl. Microbiol.
PD SEP
PY 2018
VL 67
IS 3
BP 285
EP 291
DI 10.1111/lam.13034
PG 7
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA GP5QM
UT WOS:000440928000010
PM 29908032
DA 2020-10-30
ER

PT J
AU Cavalcante, GHO
   de Araujo, JMG
   Fernandes, JV
   Lanza, DCF
AF Cavalcante, Gustavo Henrique O.
   de Araujo, Joselio M. G.
   Fernandes, Jose Verissimo
   Lanza, Daniel C. F.
TI A seminested PCR assay for detection and typing of human papillomavirus
   based on E1 gene sequences
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE HPV; Cervical cancer; Genotyping; Molecular diagnosis; E1 protein
ID DNA-BINDING; REPLICATION PROTEIN; PHOSPHORYLATION; LOCALIZATION;
   DIMERIZATION; ALIGNMENT; HELICASE; DOMAIN; WOMEN
AB HPV infection is considered one of the leading causes of cervical cancer in the world. To date, more than 180 types of HPV have been described and viral typing is critical for defining the prognosis of cancer. In this work, a seminested PCR which allow fast and inexpensively detection and typing of HPV is presented. The system is based on the amplification of a variable length region within the viral gene E1, using three primers that potentially anneal in all HPV genomes. The amplicons produced in the first step can be identified by high resolution electrophoresis or direct sequencing. The seminested step includes nine specific primers which can be used in multiplex or individual reactions to discriminate the main types of HPV by amplicon size differentiation using agarose electrophoresis, reducing the time spent and cost per analysis. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Cavalcante, Gustavo Henrique O.; Lanza, Daniel C. F.] Univ Fed Rio Grande do Norte, Dept Biochem, Appl Mol Biol Lab LAPLIC, Natal, RN, Brazil.
   [de Araujo, Joselio M. G.; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Lab Mol Biol Infect Dis & Canc LADIC, Natal, RN, Brazil.
   [Cavalcante, Gustavo Henrique O.] Univ Fed Rio Grande do Norte, Postgrad Program Biochem, Natal, RN, Brazil.
RP Lanza, DCF (corresponding author), Univ Fed Rio Grande do Norte, Dept Biochem, Appl Mol Biol Lab LAPLIC, Natal, RN, Brazil.
EM danielclanza@gmail.com
RI Araujo, Joselio M G/B-5502-2013
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES,
   BrazilCAPES
FX This work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - CAPES, Brazil.
CR Auster AS, 2004, J BIOL CHEM, V279, P3733, DOI 10.1074/jbc.M311681200
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Castle PE, 2008, J CLIN MICROBIOL, V46, P2595, DOI 10.1128/JCM.00824-08
   Costa MESM, 2016, ACTA TROP, V159, P120, DOI 10.1016/j.actatropica.2016.03.035
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Deng WT, 2004, J VIROL, V78, P13954, DOI 10.1128/JVI.78.24.13954-13965.2004
   Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Forslund O, 1999, J GEN VIROL, V80, P2437, DOI 10.1099/0022-1317-80-9-2437
   Fradet-Turcotte A, 2010, J VIROL, V84, P11747, DOI 10.1128/JVI.01445-10
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057
   IARC, 2007, IARC MON EV CARC RIS, P90, DOI 10.1094/PDIS-91-4-0467B
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kitchener HC, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13510
   Kleter B, 1998, AM J PATHOL, V153, P1731, DOI 10.1016/S0002-9440(10)65688-X
   Kurian EM, 2011, AM J CLIN PATHOL, V136, P808, DOI 10.1309/AJCPCQD7B7DPVHLH
   LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993
   MANOS MM, 1989, CANCER CEL, V7, P209
   MINCHEVA A, 1987, MED MICROBIOL IMMUN, V176, P245, DOI 10.1007/bf00190531
   Naryshkin S, 2012, DRUG HEALTHC PATIENT, V4, P167, DOI 10.2147/DHPS.S37273
   SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Smith L, 2015, UROL CLIN N AM, V42, P507, DOI 10.1016/j.ucl.2015.06.004
   Thomer LK, 1993, J VIROL, V67, P6000
   Titolo S, 2003, J VIROL, V77, P5178, DOI 10.1128/JVI.77.9.5178-5191.2003
   Vallone PM, 2004, BIOTECHNIQUES, V37, P226, DOI 10.2144/04372ST03
   Van Doorslaer K, 2013, NUCLEIC ACIDS RES, V41, pD571, DOI 10.1093/nar/gks984
   VANDENBRULE AJC, 1990, J CLIN MICROBIOL, V28, P2739, DOI 10.1128/JCM.28.12.2739-2743.1990
   Veldhuijzen NJ, 2010, LANCET INFECT DIS, V10, P862, DOI 10.1016/S1473-3099(10)70190-0
   Walboomers JMM, 1992, DIAGNOSTIC MOL PATHO, VII, P153
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
NR 35
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD MAY
PY 2018
VL 91
IS 1
BP 20
EP 26
DI 10.1016/j.diagmicrobio.2017.12.016
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA GE3CK
UT WOS:000431091000004
PM 29370952
DA 2020-10-30
ER

PT J
AU Santos, MCD
   Nascimento, YM
   Monteiro, JD
   Alves, BEB
   Melo, MF
   Paiva, AAP
   Pereira, HWB
   Medeiros, LG
   Morais, IC
   Neto, JCF
   Fernandes, JV
   Araujo, JMG
   Lima, KMG
AF Santos, Marfran C. D.
   Nascimento, Yasmin M.
   Monteiro, Joelma D.
   Alves, Brenda E. B.
   Melo, Marilia F.
   Paiva, Anne A. P.
   Pereira, Hannaly W. B.
   Medeiros, Leandro G.
   Morais, Ingryd C.
   Fagundes Neto, Joao Ciro
   Fernandes, Jose V.
   Araujo, Joselio M. G.
   Lima, Kassio M. G.
TI ATR-FTIR spectroscopy with chemometric algorithms of multivariate
   classification in the discrimination between healthy vs. dengue vs.
   chikungunya vs. zika clinical samples
SO ANALYTICAL METHODS
LA English
DT Article
ID ENHANCED RAMAN-SPECTROSCOPY; COMPUTATIONAL ANALYSIS;
   INFRARED-SPECTROSCOPY; VARIABLE SELECTION; IR SPECTROSCOPY; VIRUS;
   IDENTIFICATION; BLOOD
AB Dengue, zika and chikungunya are arboviruses transmitted by mosquitoes of genus Aedes. In clinical diagnostic routines, cross reactions between dengue and zika may occur because they are viruses of the same family (Flaviviridae); on the other hand, chikungunya is an alphavirus. In this study we suggest the use of FTIR spectroscopy in conjunction with PCA-LDA, SPA-LDA and GA-LDA multivariate classification algorithms as a tool sensitive to biochemical variations caused by the presence of different viruses in the blood. We used 45 blood samples from patients diagnosed with dengue, 30 blood samples from patients diagnosed with zika, 10 samples from patients diagnosed with chikungunya and 45 blood samples from people without these viruses. The objective of the study was to evaluate, mainly, the specificity of the technique in discriminating the blood samples based only on the presence or absence of different viruses and to compare it with some standard diagnostic methods. The results showed sensitivity and specificity values of 100% for the healthy, dengue and chikungunya classes and values close to 90% for zika, suggesting that spectroscopic techniques have great potential for detecting the biochemical variations that the presence of the virus causes in the blood, through a fast methodology.
C1 [Santos, Marfran C. D.; Lima, Kassio M. G.] Univ Fed Rio Grande do Norte, Biol Chem & Chemometr, Inst Chem, BR-59072970 Natal, RN, Brazil.
   [Nascimento, Yasmin M.; Monteiro, Joelma D.; Alves, Brenda E. B.; Melo, Marilia F.; Paiva, Anne A. P.; Pereira, Hannaly W. B.; Medeiros, Leandro G.; Fagundes Neto, Joao Ciro; Fernandes, Jose V.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Nascimento, Yasmin M.; Monteiro, Joelma D.; Alves, Brenda E. B.; Melo, Marilia F.; Paiva, Anne A. P.; Pereira, Hannaly W. B.; Medeiros, Leandro G.; Morais, Ingryd C.; Fagundes Neto, Joao Ciro; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Lab Virol, Inst Trop Med, BR-59072970 Natal, RN, Brazil.
RP Lima, KMG (corresponding author), Univ Fed Rio Grande do Norte, Biol Chem & Chemometr, Inst Chem, BR-59072970 Natal, RN, Brazil.
EM kassiolima@gmail.com
RI Lima, kassio M G/Q-7042-2019; Araujo, Joselio M G/B-5502-2013
OI Lima, kassio M G/0000-0002-3827-3800; Araujo, Joselio M
   G/0000-0003-3548-2786; Fernandes, Jose Verissimo/0000-0002-5169-6496
FU CAPESCAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq) [305962/2014-0, 400328/2014-3]
FX Marfran C. D. Santos would like to thank CAPES for its financial support
   and the PPGQ-UFRN for its scientific support. The authors thank the
   Unidade de Pronto Atendimento - UPA - Pajucara (Natal-RN) in the person
   of Samara B. S. Silveira for the supply of samples from healthy people.
   This work was supported by grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq (grant no. 305962/2014-0
   and 400328/2014-3).
CR Baia TC, 2016, ANAL METHODS-UK, V8, P968, DOI 10.1039/c5ay02342d
   Baker MJ, 2014, NAT PROTOC, V9, P1771, DOI 10.1038/nprot.2014.110
   Byrne HJ, 2016, CHEM SOC REV, V45, P1865, DOI 10.1039/c5cs00440c
   Cialla D, 2009, J RAMAN SPECTROSC, V40, P240, DOI 10.1002/jrs.2123
   Costa FSL, 2016, ANAL METHODS-UK, V8, P7107, DOI [10.1039/c6ay01893a, 10.1039/C6AY01893A]
   Cui L, 2016, ANAL METHODS-UK, V8, P481, DOI 10.1039/c5ay02638e
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Economopoulou A, 2009, EPIDEMIOL INFECT, V137, P534, DOI 10.1017/S0950268808001167
   Fan C, 2010, J FOOD SCI, V75, pM302, DOI 10.1111/j.1750-3841.2010.01619.x
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Hermann P, 2011, ANALYST, V136, P1148, DOI 10.1039/c0an00531b
   Kawiecki AB, 2016, J INFECT DIS, V214, P1357, DOI 10.1093/infdis/jiw377
   Kazarian SG, 2006, BBA-BIOMEMBRANES, V1758, P858, DOI 10.1016/j.bbamem.2006.02.011
   Kelly JG, 2011, J PROTEOME RES, V10, P1437, DOI 10.1021/pr101067u
   KENNARD RW, 1969, TECHNOMETRICS, V11, P137, DOI 10.2307/1266770
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lim JY, 2015, ANAL CHEM, V87, P11652, DOI 10.1021/acs.analchem.5b02661
   Marques AD, 2014, J MICROBIOL METH, V98, P26, DOI 10.1016/j.mimet.2013.12.015
   Marques AS, 2015, TALANTA, V134, P126, DOI 10.1016/j.talanta.2014.11.006
   Martin FL, 2010, NAT PROTOC, V5, P1748, DOI 10.1038/nprot.2010.133
   Misra A. K., 2011, P SOC PHOTO-OPT INS, V8025
   Nikiforov VN, 2016, B EXP BIOL MED+, V161, P88, DOI 10.1007/s10517-016-3352-z
   Peeling RW, 2010, NAT REV MICROBIOL, pS30, DOI 10.1038/nrmicro2459
   Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
   Sakudo A, 2012, CLIN CHIM ACTA, V414, P130, DOI 10.1016/j.cca.2012.08.022
   Santos MCD, 2017, RSC ADV, V7, P25640, DOI 10.1039/c7ra03361c
   Taylor SE, 2011, BRIT J CANCER, V104, P790, DOI 10.1038/sj.bjc.6606094
   Trevisan J, 2012, ANALYST, V137, P3202, DOI 10.1039/c2an16300d
   Vargis E, 2012, TRANSL ONCOL, V5, P172, DOI 10.1593/tlo.12106
NR 31
TC 6
Z9 6
U1 1
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9660
EI 1759-9679
J9 ANAL METHODS-UK
JI Anal. Methods
PD MAR 14
PY 2018
VL 10
IS 10
BP 1280
EP 1285
DI 10.1039/c7ay02784b
PG 6
WC Chemistry, Analytical; Food Science & Technology; Spectroscopy
SC Chemistry; Food Science & Technology; Spectroscopy
GA GE1ES
UT WOS:000430960200019
DA 2020-10-30
ER

PT J
AU Medeiros, AS
   Costa, DMP
   Branco, MSD
   Sousa, DMC
   Monteiro, JD
   Galvao, SPM
   Azevedo, PRM
   Fernandes, JAV
   Jeronimo, SMB
   Araujo, JMG
AF Medeiros, Arlinete S.
   Costa, Diego M. P.
   Branco, Mario S. D.
   Sousa, Daise M. C.
   Monteiro, Joelma D.
   Galvao, Silvio P. M.
   Azevedo, Paulo Roberto M.
   Fernandes, Jose A. V.
   Jeronimo, Selma M. B.
   Araujo, Joselio M. G.
TI Dengue virus in Aedes aegypti and Aedes albopictus in urban areas in the
   state of Rio Grande do Norte, Brazil: Importance of virological and
   entomological surveillance
SO PLOS ONE
LA English
DT Article
ID TRANS-OVARIAL TRANSMISSION; CHIKUNGUNYA VIRUS; POPULATIONS; MOSQUITOS;
   OUTBREAK
AB Background
   Vector control remains the sole effective method to prevent dengue virus (DENV) transmission, although a vaccine for dengue has recently become available and testing of its efficacy and coverage is being performed in multiple places. Entomological surveillance is a key factor in alerting authorities to possible outbreaks, but until now natural DENV infection of mosquito populations has been scarcely used as an early warning system to monitor fluctuating prevalence of infected mosquitoes. The purpose of this study was to determine the burden of adult and larval/pupae of Aedes aegypti and Aedes albopictus with DENV in urban areas in the state of Rio Grande do Norte, Brazil.
   Methodology/Principal findings
   Immature insect forms (larvae and pupae) were collected from April 2011 to March 2012, whereas the collection of adults was conducted along 3 years: May 2011 to April 2014. Total RNAs of the samples were extracted and the nested reverse transcriptase PCR assay for detecting and typing DENV was performed. Of the 1333 immature insects collected during the study period, 1186 (89%) were A. aegypti and 147 (11%) A. albopictus. DENV-4 was identified in pools of A. aegypti larvae. The rate of DENV infection in immature A. aegypti was expressed as MIR = 3.37. DENV wasnot detected in immature A. albopictus. A total of 1360 adult female mosquitoes of the Aedes genus were captured from May 2011 to April 2014. Of this total, 1293 were A. aegypti (95%) and 67 were A. albopictus (5%). From the 130 pools studied, 27 (20.7%) were positive for DENV. DENV-1 was identified in 2/27 (7.4%) pools; 1of A. albopictus and 1 of A. aegypti. DENV-2 was identified in only 1/27 (3.7%) A. aegypti pools. DENV-4 was the most prevalent, identified in 24/27 (88.8%) of the positive pools, with 19 being of A. aegypti and 5 of A. albopictus pools. The minimum infection rate for adults of the Aedes genus was 19.8, considering both A. aegypti and A. albopictus.
   Conclusions/Significance
   This work represents the most complete study to date on the interaction between dengue viruses and Aedes mosquitoes in the State of Rio Grande do Norte, and raises important questions about a possible role of A. albopictus in the transmission of dengue virus in Brazil.
C1 [Medeiros, Arlinete S.; Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, PostGraduateHlth Program, Hlth Sci Ctr, Natal, RN, Brazil.
   [Medeiros, Arlinete S.; Costa, Diego M. P.; Branco, Mario S. D.; Sousa, Daise M. C.; Monteiro, Joelma D.; Galvao, Silvio P. M.; Fernandes, Jose A. V.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Biosci Ctr, Lab Mol Biol Infect Dis & Canc, Natal, RN, Brazil.
   [Medeiros, Arlinete S.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Inst Trop Med, Lab Virol, Natal, RN, Brazil.
   [Azevedo, Paulo Roberto M.] Univ Fed Rio Grande do Norte, Dept Stat, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Immunogenet Lab, Dept Biochem, Biosci Ctr, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Lab Complex Dis, Inst Trop Med, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Inst Sci & Technol Trop Dis, Brasilia, DF, Brazil.
RP Araujo, JMG (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Biosci Ctr, Lab Mol Biol Infect Dis & Canc, Natal, RN, Brazil.; Araujo, JMG (corresponding author), Univ Fed Rio Grande do Norte, Inst Trop Med, Lab Virol, Natal, RN, Brazil.
EM joselio@cb.ufrn.br
RI Araujo, Joselio M G/B-5502-2013; Jeronimo, Selma/AAY-4033-2020
OI Araujo, Joselio M G/0000-0003-3548-2786; Jeronimo,
   Selma/0000-0002-4784-9904; Fernandes, Jose Verissimo/0000-0002-5169-6496
FU Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [479828/2013-0, PVE 400328/2014-3]
FX This investigation received financial support from the Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico-CNPq (grants Universal
   479828/2013-0 and PVE 400328/2014-3). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bonilauri P, 2008, EMERG INFECT DIS, V14, P852, DOI 10.3201/eid1405.071144
   Branco MSD, 2015, TROP MED INT HEALTH, V20, P1707, DOI 10.1111/tmi.12612
   Chao DY, 2007, J CLIN MICROBIOL, V45, P584, DOI 10.1128/JCM.00842-06
   Chow VTK, 1998, AM J TROP MED HYG, V58, P578, DOI 10.4269/ajtmh.1998.58.578
   da Costa CF, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2194-5
   Dalla Bona AC, 2011, B MALARIOL SALUD AMB, V51, P107
   Delatte H, 2008, VECTOR-BORNE ZOONOT, V8, P25, DOI 10.1089/vbz.2007.0649
   Freire M.S.B., 1990, ACTA BOT BRAS, V4, P41, DOI DOI 10.1590/S0102-33061990000300006
   Garcia-Rejon J, 2008, AM J TROP MED HYG, V79, P940, DOI 10.4269/ajtmh.2008.79.940
   Guedes DRD, 2010, J VECTOR DIS, V47, P67
   Gunther J, 2007, INTERVIROLOGY, V50, P347, DOI 10.1159/000107272
   Gutierrez-Bugallo G, 2017, ACTA TROP, V174, P146, DOI 10.1016/j.actatropica.2017.07.012
   Instituto Brasileiro de Geografia e Estatistica (IBGE), 2017, NAT
   Joshi V, 2002, AM J TROP MED HYG, V67, P158, DOI 10.4269/ajtmh.2002.67.158
   KHIN MM, 1983, AM J TROP MED HYG, V32, P590, DOI 10.4269/ajtmh.1983.32.590
   Kumar NP, 2012, VECTOR-BORNE ZOONOT, V12, P907, DOI 10.1089/vbz.2012.0969
   Kumari R, 2011, TROP MED INT HEALTH, V16, P949, DOI 10.1111/j.1365-3156.2011.02789.x
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lequime S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005548
   Pages F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004691
   Paupy C, 2012, VECTOR-BORNE ZOONOT, V12, P167, DOI 10.1089/vbz.2011.0736
   Pierson TC, 2013, FIELDSVIROLOGY
   Ramos-Castaneda J, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005224
   Rodriguez-Barraquer I, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000935
   Rohani A., 2007, Dengue Bulletin, V31, P47
   ROSEN L, 1983, AM J TROP MED HYG, V32, P1108, DOI 10.4269/ajtmh.1983.32.1108
   Sivan A, 2016, ACTA TROP, V156, P122, DOI 10.1016/j.actatropica.2016.01.015
   Sousa DM, 2015, THESIS
   Thongrungkiat S, 2011, J VECTOR ECOL, V36, P147, DOI 10.1111/j.1948-7134.2011.00151.x
   Urdaneta Ludmel, 2005, Infection Genetics and Evolution, V5, P177, DOI 10.1016/j.meegid.2004.09.004
   World Health Organization, 2009, DENG GUID DIAGN TREA
   World Health Organization, 2012, GLOB STRAT DENG PREV
NR 32
TC 14
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 13
PY 2018
VL 13
IS 3
AR e0194108
DI 10.1371/journal.pone.0194108
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ0JA
UT WOS:000427253500025
PM 29534105
OA DOAJ Gold, Green Published
DA 2020-10-30
ER

PT J
AU Nunes, ARD
   Alves, BEB
   Pereira, HWB
   Nascimento, YM
   Morais, IC
   Fernandes, JV
   Araujo, JMG
   Lanza, DCF
AF Nunes, Allan R. D.
   Alves, Brenda Elen B.
   Pereira, Hannaly W. B.
   Nascimento, Yasmin M.
   Morais, Ingryd C.
   Fernandes, Jose Verissimo
   Araujo, Joselio M. G.
   Lanza, Daniel C. F.
TI Improved reverse transcription-polymerase chain reaction assay for the
   detection of flaviviruses with semi-nested primers for discrimination
   between dengue virus serotypes and Zika virus
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE arbovirus; Flaviviridae; West Nile virus; yellow fever virus
ID RIO-DE-JANEIRO; RAPID IDENTIFICATION; PCR; TRANSMISSION; COINFECTION
AB BACKGROUND The genus Flavivirus includes a variety of medically important viruses, including dengue virus (DENV) and Zika virus (ZIKV), which are most prevalent in Brazil. Because the clinical profile of patients affected by different DENV serotypes or ZIKV may be similar, the development of new methods that facilitate a rapid and accurate diagnosis is crucial.
   OBJECTIVES The current study aimed to develop an improved reverse transcription-polymerase chain reaction (RT-PCR) protocol for universal detection of flaviviruses by using semi-nested primers that discriminate between DENV serotypes and ZIKV.
   METHODS The bioinformatics workflow adopted for primer design included: (1) alignment of 1,442 flavivirus genome sequences, (2) characterisation of 27 conserved regions, (3) generation of a primer set comprising 77 universal primers, and (4) selection of primer pairs with greatest coverage and specificity. Following primer design, the reaction was validated in vitro. The same approach was applied to the design of primers specific for DENV and ZIKV, using a species-specific sequence database.
   FINDINGS The new assay amplified an 800-806 nt variable region of the NS5 gene and allowed discrimination of virtually all flavivirus species using reference-sequence comparison. The 800-806 nt fragment was validated as a template for a semi-nested multiplex PCR using five additional primers for the detection of DENV and ZIKV. These primers were designed to generate amplicons of different sizes, allowing differentiation of the four serotypes of DENV, and ZIKV using agarose gel electrophoresis.
   MAIN CONCLUSIONS The bioinformatics pipeline allowed efficient primer design, making it possible to identify the best targets within the coding region of the NS5 protein. The multiplex system proved effective in differentiation of DENV1-4 and ZIKV on a 2% agarose gel. The possibility of discriminating DENV serotypes and ZIKV in the same reaction provided a faster result consuming less sample. In addition, this simplified approach ensured the reduction of the cost per analysis.
C1 [Nunes, Allan R. D.; Lanza, Daniel C. F.] Univ Fed Rio Grande do Norte, Dept Bioquim, Lab Biol Mol Aplicada, Natal, RN, Brazil.
   [Alves, Brenda Elen B.; Pereira, Hannaly W. B.; Nascimento, Yasmin M.; Morais, Ingryd C.; Fernandes, Jose Verissimo; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Lab Biol Mol Doencas Infecciosas & Canc, Natal, RN, Brazil.
   [Nunes, Allan R. D.; Morais, Ingryd C.; Lanza, Daniel C. F.] Univ Fed Rio Grande do Norte, Programa Posgrad Bioquim, Natal, RN, Brazil.
   [Alves, Brenda Elen B.; Pereira, Hannaly W. B.; Fernandes, Jose Verissimo; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Programa Posgrad Biol Parasitaria, Natal, RN, Brazil.
   [Alves, Brenda Elen B.; Pereira, Hannaly W. B.; Nascimento, Yasmin M.; Morais, Ingryd C.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Inst Med Trop, Lab Virol, Natal, RN, Brazil.
RP Lanza, DCF (corresponding author), Univ Fed Rio Grande do Norte, Dept Bioquim, Lab Biol Mol Aplicada, Natal, RN, Brazil.; Lanza, DCF (corresponding author), Univ Fed Rio Grande do Norte, Programa Posgrad Bioquim, Natal, RN, Brazil.
EM danielclanza@gmail.com
RI Araujo, Joselio M G/B-5502-2013
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX CAPES, CNPq.
CR Calvet GA, 2016, J CLIN VIROL, V74, P1, DOI 10.1016/j.jcv.2015.11.014
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Chao DY, 2007, J CLIN MICROBIOL, V45, P584, DOI 10.1128/JCM.00842-06
   CHOW VTK, 1993, ARCH VIROL, V133, P157, DOI 10.1007/BF01309751
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Dyer J, 2007, J VIROL METHODS, V145, P9, DOI 10.1016/j.jviromet.2007.05.001
   ELDADAH ZA, 1991, J MED VIROL, V33, P260, DOI 10.1002/jmv.1890330410
   Figueiredo LTM, 1998, AM J TROP MED HYG, V59, P357, DOI 10.4269/ajtmh.1998.59.357
   FULOP L, 1993, J VIROL METHODS, V44, P179, DOI 10.1016/0166-0934(93)90053-T
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Kuno G, 1998, J VIROL METHODS, V72, P27, DOI 10.1016/S0166-0934(98)00003-2
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Maher-Sturgess SL, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-16
   Nogueira RMR, 2011, MEM I OSWALDO CRUZ, V106, P255, DOI 10.1590/S0074-02762011000300001
   PIERRE V, 1994, RES VIROLOGY, V145, P93, DOI 10.1016/S0923-2516(07)80011-2
   PURI B, 1994, ARCH VIROL, V134, P29, DOI 10.1007/BF01379104
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Sanchez-Seco MP, 2005, J VIROL METHODS, V126, P101, DOI 10.1016/j.jviromet.2005.01.025
   Scaramozzino N, 2001, J CLIN MICROBIOL, V39, P1922, DOI 10.1128/JCM.39.5.1922-1927.2001
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   Simmonds P, 2017, J GEN VIROL, V98, P2, DOI 10.1099/jgv.0.000672
   TAJIMA F, 1984, MOL BIOL EVOL, V1, P269
   TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R
   Villamil-Gomez WE, 2016, INT J INFECT DIS, V51, P135, DOI 10.1016/j.ijid.2016.07.017
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 28
TC 2
Z9 2
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2018
VL 113
IS 5
AR e170393
DI 10.1590/0074-02760170393
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA GA9WT
UT WOS:000428693000003
PM 29513820
OA DOAJ Gold, Green Published
DA 2020-10-30
ER

PT J
AU Moizeis, RNC
   Fernandes, TAAD
   Guedes, PMD
   Pereira, HWB
   Lanza, DCF
   de Azevedo, JWV
   Galvao, JMD
   Fernandes, JV
AF Cunha Moizeis, Raiza Nara
   Araujo de Medeiros Fernandes, Thales Allyrio
   da Matta Guedes, Paulo Marcos
   Bezerra Pereira, Hannaly Wana
   Ferreira Lanza, Daniel Carlos
   Verissimo de Azevedo, Judson Welber
   de Araujo Galvao, Joselio Maria
   Fernandes, Jose Verissimo
TI Chikungunya fever: a threat to global public health
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Review
DE Chikungunya virus; chikungunya virus infection; chikungunya virus
   pathogenesis; chikungunya fever; arboviruses
ID VIRUS NONSTRUCTURAL PROTEIN-2; VERTICAL TRANSMISSION; REUNION ISLAND;
   INFECTION; ARTHRITIS; PATHOGENESIS; REPLICATION; DOMAINS;
   MANIFESTATIONS; COMPLICATIONS
AB Chikungunya fever is an emerging arbovirus infection, representing a serious public health problem. Its etiological agent is the Chikungunya virus (CHIKV). Transmission of this virus is mainly vector by mosquitoes of the genus Aedes, although transmission by blood transfusions and vertical transmission has also been reported. The disease presents high morbidity caused mainly by the arthralgia and arthritis generated. Cardiovascular and neurological manifestations have also been reported. The severity of the infection seems to be directly associated with the action of the virus, but also with the decompensation of preexisting comorbidities. Currently, there are no therapeutic products neither vaccines licensed to the infection CHIKV control, although several vaccine candidates are being evaluated and human polyvalent immunoglobulins anti-CHIKV had been tested. Antibodies can protect against the infection, but in sub-neutralizing concentrations can augment virus infection and exacerbate disease severity. So, the prevention still depends on the use of personal protection measures and vector control, which are only minimally effective.
C1 [Cunha Moizeis, Raiza Nara; da Matta Guedes, Paulo Marcos; Bezerra Pereira, Hannaly Wana; de Araujo Galvao, Joselio Maria; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Programa Posgrad Biol Parasitaria, Natal, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Estado Rio Grande do Norte, Dept Ciencias Biomed, Mossoro, Brazil.
   [da Matta Guedes, Paulo Marcos; de Araujo Galvao, Joselio Maria; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Natal, RN, Brazil.
   [Ferreira Lanza, Daniel Carlos] Univ Fed Rio Grande do Norte, Dept Bioquim, Natal, RN, Brazil.
   [Verissimo de Azevedo, Judson Welber] Univ Fed Triangulo Mineiro, Dept Ortopedia, Uberaba, Brazil.
RP Fernandes, TAAD (corresponding author), Univ Estado Rio Grande do Norte, Dept Ciencias Biomed, Mossoro, Brazil.
EM thalesallyrio@yahoo.com.br
RI Araujo, Joselio M G/B-5502-2013; Guedes, Paulo/Y-2546-2018; Fernandes,
   Thales/F-4813-2010
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes,
   Thales/0000-0003-4559-8918; Fernandes, Jose
   Verissimo/0000-0002-5169-6496; Matta Guedes, Paulo
   Marcos/0000-0002-4564-6791
CR Abdelnabi R, 2018, ANTIVIR RES, V149, P113, DOI 10.1016/j.antiviral.2017.09.016
   Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Akhrymuk I, 2012, J VIROL, V86, P7180, DOI 10.1128/JVI.00541-12
   Alvarez Maria Fernanda, 2017, F1000Res, V6, P390, DOI 10.12688/f1000research.11078.1
   [Anonymous], 2015, B EPIDEMIOLOGICO, V46, P1
   [Anonymous], 2017, GUI VIG SAUD
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P668, DOI 10.1590/0037-8682-0279-2016
   Bandeira AC, 2016, IDCases, V5, P57, DOI 10.1016/j.idcr.2016.07.008
   Brandler S, 2008, COMP IMMUNOL MICROB, V31, P271, DOI 10.1016/j.cimid.2007.07.012
   Brizzi K, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0561-1
   Broeckel R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005637
   Brouard C, 2008, TRANSFUSION, V48, P1333, DOI 10.1111/j.1537-2995.2008.01646.x
   Burt FJ, 2017, LANCET INFECT DIS, V17, pE107, DOI 10.1016/S1473-3099(16)30385-1
   Burt FJ, 2012, LANCET, V379, P662, DOI 10.1016/S0140-6736(11)60281-X
   Cardona-Correa SE, 2017, REV CHIL PEDIATR-CHI, V88, P285, DOI 10.4067/S0370-41062017000200015
   Cassadou S, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.13.20752
   Cerny T, 2017, NEUROCRIT CARE, V27, P447, DOI 10.1007/s12028-017-0413-8
   Chaaithanya IK, 2014, INDIAN J MED RES, V140, P142
   Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5
   Chen MW, 2017, ANTIVIR RES, V143, P38, DOI 10.1016/j.antiviral.2017.04.001
   Chen RB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003591
   Chen WQ, 2015, TRENDS MICROBIOL, V23, P35, DOI 10.1016/j.tim.2014.09.005
   Chiam CW, 2015, J GEN VIROL, V96, P3243, DOI 10.1099/jgv.0.000263
   Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042
   Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029
   Couderc T, 2012, J INFECT DIS, V206, P851, DOI 10.1093/infdis/jis296
   Couderc T, 2009, J INFECT DIS, V200, P516, DOI 10.1086/600381
   da Cunha RV, 2017, MEM I OSWALDO CRUZ, V112, P523, DOI 10.1590/0074-02760170044
   Das PK, 2014, J BIOL CHEM, V289, P5635, DOI 10.1074/jbc.M113.503433
   Das T, 2010, PROG NEUROBIOL, V91, P121, DOI 10.1016/j.pneurobio.2009.12.006
   Sa PKD, 2017, REV SOC BRAS MED TRO, V50, P265, DOI 10.1590/0037-8682-0375-2016
   Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873
   Fros JJ, 2013, J VIROL, V87, P10394, DOI 10.1128/JVI.00884-13
   Fros JJ, 2010, J VIROL, V84, P10877, DOI 10.1128/JVI.00949-10
   Gasque P, 2015, VECTOR-BORNE ZOONOT, V15, P241, DOI 10.1089/vbz.2014.1710
   Gerardin P, 2016, NEUROLOGY, V86, P94, DOI 10.1212/WNL.0000000000002234
   Gerardin P, 2008, PLOS MED, V5, P413, DOI 10.1371/journal.pmed.0050060
   Goo L, 2016, J INFECT DIS, V214, P1487, DOI 10.1093/infdis/jiw431
   Goupil Brad A, 2016, Open Rheumatol J, V10, P129, DOI 10.2174/1874312901610010129
   Halstead SB, 2015, EMERG INFECT DIS, V21, P557, DOI 10.3201/eid2104.141723
   Hawman DW, 2013, J VIROL, V87, P13878, DOI 10.1128/JVI.02666-13
   Her ZS, 2010, J IMMUNOL, V184, P5903, DOI 10.4049/jimmunol.0904181
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   Hochedez P, 2006, EMERG INFECT DIS, V12, P1565, DOI 10.3201/eid1210.060495
   Honorio NA, 2015, CAD SAUDE PUBLICA, V31, P906, DOI 10.1590/0102-311XPE020515
   Inglis FM, 2016, J NEUROVIROL, V22, P140, DOI 10.1007/s13365-015-0378-3
   Johnson BW, 2016, J INFECT DIS, V214, pS471, DOI 10.1093/infdis/jiw274
   Joob B, 2017, ARQ NEURO-PSIQUIAT, V75, P326, DOI 10.1590/0004-282X20170029
   Judith D, 2013, EMBO REP, V14, P534, DOI 10.1038/embor.2013.51
   Kam YW, 2009, MICROBES INFECT, V11, P1186, DOI 10.1016/j.micinf.2009.09.003
   Karpe YA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022336
   Kelvin AA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001279
   Kosasih H, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002483
   Lemant J, 2008, CRIT CARE MED, V36, P2536, DOI 10.1097/CCM.0b013e318183f2d2
   Leung JYS, 2011, ADV VIROL, V2011, DOI 10.1155/2011/249640
   Lo Presti A, 2014, ASIAN PAC J TROP MED, V7, P925, DOI 10.1016/S1995-7645(14)60164-4
   Lourenco-de-Oliveira R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005698
   Lum FM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20305-4
   Lum FM, 2015, ANTIVIR RES, V120, P165, DOI 10.1016/j.antiviral.2015.06.009
   Mahendradas P, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-35
   Malet H, 2009, J VIROL, V83, P6534, DOI 10.1128/JVI.00189-09
   Marimoutou C, 2012, MEDICINE, V91, P212, DOI 10.1097/MD.0b013e318260b604
   Marques CDL, 2017, REV BRAS REUMATOL, V57, P421, DOI DOI 10.1016/J.RBR.2017.05.004
   Martinez-Pulgarin DF, 2016, TRAVEL MED INFECT DI, V14, P451, DOI 10.1016/j.tmaid.2016.05.008
   Miner JJ, 2015, ARTHRITIS RHEUMATOL, V67, P1214, DOI 10.1002/art.39027
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   Mohan Alladi, 2010, Indian J Dermatol, V55, P54, DOI 10.4103/0019-5154.60355
   Neuvonen M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002383
   Ng LFP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004261
   Nhan T-X, 2016, J CLIN CASE REP, V6
   Pakran J, 2011, INT J DERMATOL, V50, P61, DOI 10.1111/j.1365-4632.2010.04644.x
   Panas MD, 2014, J VIROL, V88, P5888, DOI 10.1128/JVI.00439-14
   Parashar D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/631642
   PEIRIS JSM, 1979, NATURE, V282, P509, DOI 10.1038/282509a0
   Petersen LR, 2010, VOX SANG, V98, P495, DOI 10.1111/j.1423-0410.2009.01286.x
   Phuklia W, 2013, VIRUS RES, V177, P179, DOI 10.1016/j.virusres.2013.08.011
   Rodrigues NCP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165945
   Plante K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002142
   Powers AM, 2000, J GEN VIROL, V81, P471, DOI 10.1099/0022-1317-81-2-471
   Powers AM, 2007, J GEN VIROL, V88, P2363, DOI 10.1099/vir.0.82858-0
   Powers AM, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00104-16
   Prashant Soma, 2009, Indian J Dermatol, V54, P128, DOI 10.4103/0019-5154.53186
   Puiprom O, 2013, INFECT GENET EVOL, V17, P210, DOI 10.1016/j.meegid.2013.04.005
   Rajapakse S, 2010, T ROY SOC TROP MED H, V104, P89, DOI 10.1016/j.trstmh.2009.07.031
   Ramful D, 2007, PEDIATR INFECT DIS J, V26, P811, DOI 10.1097/INF.0b013e3180616d4f
   Reddy V, 2014, J MED VIROL, V86, P1393, DOI 10.1002/jmv.23875
   Robillard PY, 2006, PRESSE MED, V35, P785, DOI 10.1016/S0755-4982(06)74690-5
   ROSS R. W., 1956, JOUR HYG, V54, P177
   Rothan HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126360
   Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137
   Schilte C, 2010, J EXP MED, V207, P429, DOI 10.1084/jem.20090851
   Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263
   Schwartz O, 2010, NAT REV MICROBIOL, V8, P491, DOI 10.1038/nrmicro2368
   Simon Fabrice, 2011, Curr Infect Dis Rep, V13, P218, DOI 10.1007/s11908-011-0180-1
   Singh SK, 2011, REV MED VIROL, V21, P78, DOI 10.1002/rmv.681
   Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089
   Staples JE, 2009, CLIN INFECT DIS, V49, P942, DOI 10.1086/605496
   Sudeep AB, 2015, TRENDS MICROBIOL, V23, P35
   Tandale BV, 2009, J CLIN VIROL, V46, P145, DOI 10.1016/j.jcv.2009.06.027
   Tang BL, 2012, CELL MICROBIOL, V14, P1354, DOI 10.1111/j.1462-5822.2012.01825.x
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Teng TS, 2015, J INFECT DIS, V211, P1925, DOI 10.1093/infdis/jiv049
   Teng TS, 2011, FUTURE VIROL, V6, P975, DOI 10.2217/FVL.11.67
   Teo TH, 2013, J IMMUNOL, V190, P259, DOI 10.4049/jimmunol.1202177
   Thangamani S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012137
   Thiberville SD, 2013, ANTIVIR RES, V99, P345, DOI 10.1016/j.antiviral.2013.06.009
   Thiboutot MM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000623
   Thon-Hon VG, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-213
   Torres JR, 2016, INT J INFECT DIS, V51, P85, DOI 10.1016/j.ijid.2016.09.009
   Torres JR, 2015, IDCases, V2, P6, DOI 10.1016/j.idcr.2014.12.002
   Utt A, 2015, J VIROL, V89, P3145, DOI 10.1128/JVI.03213-14
   van Duijl-Richter MKS, 2015, VIRUSES-BASEL, V7, P3647, DOI 10.3390/v7072792
   van Genderen FT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004625
   Vega-Rua A, 2015, VIRUSES-BASEL, V7, P5902, DOI 10.3390/v7112917
   Vega-Rua A, 2014, J VIROL, V88, P6294, DOI 10.1128/JVI.00370-14
   Versteeg L, 2016, CURR TROP MED REP, V3, P60, DOI [10.1007/s40475-016-0074-2, DOI 10.1007/S40475-016-0074-2]
   Volk SM, 2010, J VIROL, V84, P6497, DOI 10.1128/JVI.01603-09
   Wahid B, 2017, INT J INFECT DIS, V58, P69, DOI 10.1016/j.ijid.2017.03.006
   Wauquier N, 2011, J INFECT DIS, V204, P115, DOI 10.1093/infdis/jiq006
   Waymouth HE, 2013, SEMIN ARTHRITIS RHEU, V43, P273, DOI 10.1016/j.semarthrit.2013.03.003
   Weaver SC, 2015, ANTIVIR RES, V120, P32, DOI 10.1016/j.antiviral.2015.04.016
   World Health Organization, CHIK
NR 122
TC 5
Z9 6
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PY 2018
VL 112
IS 4
BP 182
EP 194
DI 10.1080/20477724.2018.1478777
PG 13
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA GT5TC
UT WOS:000444571800003
PM 29806537
OA Green Published
DA 2020-10-30
ER

PT J
AU de Araujo, IDR
   de Aquino, NC
   Guerra, ACVD
   de Almeida, RF
   Araujo, RM
   de Araujo, RF
   Farias, KJS
   Fernandes, JV
   Andrade, VS
AF Reboucas de Araujo, Italo Diego
   de Aquino, Nayara Coriolano
   Veras de Aguiar Guerra, Andreza Conceicao
   de Almeida Junior, Renato Ferreira
   Araujo, Renata Mendonca
   de Araujo Junior, Raimundo Fernandes
   Silva Farias, Kleber Juvenal
   Fernandes, Jose Verissimo
   Andrade, Vania Sousa
TI Chemical composition and evaluation of the antibacterial and Cytotoxic
   activities of the essential oil from the leaves of Myracrodruon
   urundeuva
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Myracrodruon urundeuva; Bactericidal activity; Minimum inhibitory
   concentration; Chemical characterization; Essential oil; Cytotoxicity
ID BRAZILIAN MEDICINAL-PLANTS; LEAF ESSENTIAL OIL; L. ESSENTIAL OIL;
   ANTIMICROBIAL ACTIVITY; ANTICANCER ACTIVITY; ANTIOXIDANT ACTIVITIES;
   BIOLOGICAL-ACTIVITIES; AROMATIC PLANTS; ALPHA-PINENE; BETA-PINENE
AB Background: This study evaluated the in vitro activity of essential oil extracted from the leaves of Myracrodruon urundeuva.
   Methods: The oil was obtained by hydro-distillation and characterized by Gas Chromatography coupled to Mass Spectrometry (GC-MS) and Gas Chromatography with Flame Ionization Detector (GC-FID). The antibacterial activity was evaluated by the broth microdilution technique and the MIF was determined by using growth indicator CTT (2,3,5triphenyl-tetrazolium) and CBM in BHI agar. The oil's cytotoxicity was evaluated in HeLa, HEK-293, and Vero E6 cells using MTT, 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium.
   Results: The oil showed chemical markers, including alpha-pinene (87.85%), trans-caryophyllene (1.57%), limonene (1.49%) and beta-pinene (1.42%), and activity against all strains: Staphylococcus aureus (MIC = MBC = 0.22 mg/mL), Staphylococcus epidermidis (MIC = 0.11 mg/mL and MBC = 0.22 mg/mL), Escherichia coli (MIC = 0.88mg/mL and MBC = 1.75 mg/mL), Pseudomonas aeruginosa (MIC = MBC = 7 mg/mL) and Salmonella Enteritidis (MIC = MBC = 0.44 mg/mL). In vitro cytotoxicity tests showed that the oil is not toxic and has slight antitumor activity.
   Conclusions: We conclude that the M. urundeuva oil results are promising, with prospects of being pharmacologically viable.
C1 [Reboucas de Araujo, Italo Diego; Fernandes, Jose Verissimo; Andrade, Vania Sousa] Univ Fed Rio Grande do Norte UFRN, CB, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [de Aquino, Nayara Coriolano] Univ Fed Ceara, Ctr Ciencias, Dept Quim Organ & Inorgan, BR-60021940 Fortaleza, Ceara, Brazil.
   [Veras de Aguiar Guerra, Andreza Conceicao; de Araujo Junior, Raimundo Fernandes] Univ Fed Rio Grande do Norte UFRN, Dept Morfol, CB, BR-59072970 Natal, RN, Brazil.
   [de Almeida Junior, Renato Ferreira] Univ Fed Rio Grande do Norte UFRN, CCS, Dept Anal Clin & Toxicol, BR-59072970 Natal, RN, Brazil.
   [Araujo, Renata Mendonca] Univ Fed Rio Grande do Norte UFRN, CCET, Inst Quim, BR-59072970 Natal, RN, Brazil.
   [Silva Farias, Kleber Juvenal] Univ Fed Rio Grande do Norte UFRN, IMT, BR-59072970 Natal, RN, Brazil.
RP de Araujo, IDR (corresponding author), Univ Fed Rio Grande do Norte UFRN, CB, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
EM italo_diego1989@hotmail.com
RI Araujo, Renata/K-6550-2018; FARIAS, KLEBER/AAC-9815-2019; Andrade, Vania
   Sousa/AAR-3922-2020
OI Araujo, Renata/0000-0001-5514-5192; Fernandes, Jose
   Verissimo/0000-0002-5169-6496; Coriolano de Aquino,
   Nayara/0000-0003-1997-8474
FU FAPERN (Fundacao de Apoio a Pesquisa do RN); CAPES (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior)CAPES
FX FAPERN (Fundacao de Apoio a Pesquisa do RN) provided funding for the
   study design and CAPES (Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior) funded the work during its development.
CR Abdel-Reheem M. A. T., 2015, Annals of Agricultural Science (Cairo), V60, P335, DOI 10.1016/j.aoas.2015.10.001
   Adams RP, 2007, IDENTIFICATION ESSEN
   Alanis AD, 2005, J ETHNOPHARMACOL, V100, P153, DOI 10.1016/j.jep.2005.02.022
   Alves PM, 2009, REV SOC BRAS MED TRO, V42, P222, DOI 10.1590/S0037-86822009000200028
   Alves TMD, 2000, MEM I OSWALDO CRUZ, V95, P367
   [Anonymous], 2016, M100S26 CLIN LAB STA
   Apel MA, 2006, BRAZILIAN J PHARMACO, V16, P402
   Asekun OT, 2007, FOOD CHEM, V101, P995, DOI 10.1016/j.foodchem.2006.02.052
   Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106
   Ben Hsouna A, 2011, INT J FOOD MICROBIOL, V148, P66, DOI 10.1016/j.ijfoodmicro.2011.04.028
   Betoni JEC, 2006, MEM I OSWALDO CRUZ, V101, P387, DOI 10.1590/S0074-02762006000400007
   Carvalho CES, 2017, EXP PARASITOL, V175, P59, DOI 10.1016/j.exppara.2017.02.012
   Chiang P, 2003, J BACTERIOL, V185, P2374, DOI 10.1128/JB.185.7.2374-2378.2003
   Costa OB, 2014, INT J FOR RES, V2014, P1, DOI [DOI 10.1155/2014/982576, 10.1155/2014/982576]
   COSTERTON JW, 1974, BACTERIOL REV, V38, P87, DOI 10.1128/MMBR.38.1.87-110.1974
   de Menezes TEC, 2010, PHARM BIOL, V48, P300, DOI 10.3109/13880200903122202
   D'Costa VM, 2011, NATURE, V477, P457, DOI 10.1038/nature10388
   Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007
   de Pinho L, 2012, CIENC RURAL, V42, P326, DOI 10.1590/S0103-84782012005000003
   DUARTE AE, 2016, MOLECULES, V21
   Edris AE, 2007, PHYTOTHER RES, V21, P308, DOI 10.1002/ptr.2072
   El Bouzidi L, 2013, IND CROP PROD, V43, P450, DOI 10.1016/j.indcrop.2012.07.063
   Ferreira PMP, 2011, AN ACAD BRAS CIENC, V83, P1045, DOI 10.1590/S0001-37652011005000017
   Figueredo FG, 2014, PHARM BIOL, V52, P560, DOI 10.3109/13880209.2013.853810
   Fitsiou E, 2016, MOLECULES, V21, DOI 10.3390/molecules21081069
   Gachkar L, 2007, FOOD CHEM, V102, P898, DOI 10.1016/j.foodchem.2006.06.035
   Gottlieb O, 1960, CHEM ANAL, V49, P114
   Hajlaoui H, 2016, MICROB PATHOGENESIS, V95, P86, DOI 10.1016/j.micpath.2016.03.003
   Hu HB, 2012, ENVIRON TOXICOL PHAR, V34, P618, DOI 10.1016/j.etap.2012.07.005
   Imelouane B, 2009, INT J AGRIC BIOL, V11, P205
   Jalan R, 2014, J HEPATOL, V60, P1310, DOI 10.1016/j.jhep.2014.01.024
   Jandu J. J. B., 2015, Journal of Medicinal Plants Research, V9, P641
   Jeong-Ho L, 2008, J MICROBIOL BIOTECHN, V18, P497
   Kazemi M, 2015, J HERB MED, V5, P217, DOI 10.1016/j.hermed.2015.09.001
   Kumar A.S., 2008, BANGL J PHARMACOL, V4, P13
   Lang GR, 2012, FLAVOUR FRAG J, V27, P13, DOI 10.1002/ffj.2082
   Leite Aristides Medeiros, 2007, Rev. Bras. Cienc. Farm., V43, P121, DOI 10.1590/S1516-93322007000100015
   Montanari RM, 2012, MOLECULES, V17, P9728, DOI 10.3390/molecules17089728
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nissen L, 2010, FITOTERAPIA, V81, P413, DOI 10.1016/j.fitote.2009.11.010
   Nunes YRF, 2008, REV ARVORE, V32, P233, DOI 10.1590/S0100-67622008000200006
   Petrelli R, 2016, MOLECULES, V21, DOI 10.3390/molecules21081065
   Potzernheim Miriam Cristina Leone, 2006, Rev. bras. farmacogn., V16, P246, DOI 10.1590/S0102-695X2006000200019
   Qi XL, 2014, IND CROP PROD, V58, P322, DOI 10.1016/j.indcrop.2014.04.038
   Rashid S, 2013, FOOD CHEM, V138, P693, DOI 10.1016/j.foodchem.2012.10.102
   Rattanachaikunsopon P, 2010, BIOSCI BIOTECH BIOCH, V74, P1200, DOI 10.1271/bbb.90939
   Reichling J, 2009, FORSCH KOMPLEMENTMED, V16, P79, DOI 10.1159/000207196
   da Silva ACR, 2012, MOLECULES, V17, P6305, DOI 10.3390/molecules17066305
   Sa RA, 2009, WOOD SCI TECHNOL, V43, P85, DOI 10.1007/s00226-008-0220-7
   Santos A, 2009, REV BRAS FARMACOGN, V19, P436, DOI 10.1590/S0102-695X2009000300017
   Sartoratto A, 2004, BRAZ J MICROBIOL, V35, P275, DOI 10.1590/S1517-83822004000300001
   Sefidkon F, 2007, FOOD CHEM, V100, P1054, DOI 10.1016/j.foodchem.2005.11.016
   Shakeri A, 2014, IND CROP PROD, V58, P315, DOI 10.1016/j.indcrop.2014.04.009
   Sharifi-Rad J, 2015, 3 BIOTECH, V5, P677, DOI 10.1007/s13205-014-0266-1
   Si W, 2006, J APPL MICROBIOL, V100, P296, DOI 10.1111/j.1365-2672.2005.02789.x
   Silva CM, 2013, J MED PLANTS RES, V7, P2407
   Sousa OV, 2012, MOLECULES, V17, P11056, DOI 10.3390/molecules170911056
   Sylvestre M, 2006, J ETHNOPHARMACOL, V103, P99, DOI 10.1016/j.jep.2005.07.011
   Sylvestre M, 2005, PHYTOMEDICINE, V12, P299, DOI 10.1016/j.phymed.2003.12.004
   Tacconelli E, 2014, CLIN MICROBIOL INFEC, V20, P1, DOI 10.1111/1469-0691.12427
   Unlu M, 2010, FOOD CHEM TOXICOL, V48, P3274, DOI 10.1016/j.fct.2010.09.001
   Valgas C, 2007, BRAZ J MICROBIOL, V38, P369, DOI 10.1590/S1517-83822007000200034
   Veiga VF, 2005, QUIM NOVA, V28, P519, DOI 10.1590/S0100-40422005000300026
   Veras HNH, 2012, FITOTERAPIA, V83, P508, DOI 10.1016/j.fitote.2011.12.024
   Viana GSB, 2003, PHYTOMEDICINE, V10, P189, DOI 10.1078/094471103321659924
   Wang W, 2012, MOLECULES, V17, P2704, DOI 10.3390/molecules17032704
   Xiong L, 2013, MOLECULES, V18, P963, DOI 10.3390/molecules18010963
   Ye CL, 2013, FOOD CONTROL, V30, P48, DOI 10.1016/j.foodcont.2012.07.033
   Yu JQ, 2011, FOOD CHEM, V126, P1593, DOI 10.1016/j.foodchem.2010.12.027
NR 69
TC 6
Z9 6
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 22
PY 2017
VL 17
AR 419
DI 10.1186/s12906-017-1918-6
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FE8KV
UT WOS:000408454900006
PM 28830478
OA DOAJ Gold, Green Published
DA 2020-10-30
ER

PT J
AU Nobre, CCG
   de Araujo, JMG
   Fernandes, TAAD
   Cobucci, RNO
   Lanza, DCF
   Andrade, VS
   Fernandes, JV
AF Guimaraes Nobre, Camila Cristina
   Galvao de Araujo, Joselio Maria
   Araujo de Medeiros Fernandes, Thales Allyrio
   Oliveira Cobucci, Ricardo Ney
   Ferreira Lanza, Daniel Carlos
   Andrade, Vania Sousa
   Fernandes, Jose Verissimo
TI Macrophage Migration Inhibitory Factor (MIF): Biological Activities and
   Relation with Cancer
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Review
DE Macrophage migration inhibitory factor; Neoplasms; Tumorigenesis;
   Inflammation
ID HUMAN BREAST-CANCER; SQUAMOUS-CELL CARCINOMA; SUPPRESSOR-CELLS;
   TUMOR-GROWTH; PROMOTER POLYMORPHISMS; THERAPEUTIC TARGET; ANGIOGENIC
   FACTORS; FACTOR EXPRESSION; RECEPTOR COMPLEX; IMMUNE-RESPONSE
AB Macrophage migration inhibitory factor (MIF) emerged in recent years as an important inflammation mediator, playing a prominent role in the pathogenesis of various types of malignant neoplasm. MIF is a glycoprotein that presents a wide spectrum of biological activities and exerts a complex interaction with various cellular signaling pathways, causing imbalance of homeostasis. Experimental and clinical studies show that high levels of MIF are found in almost all types of human cancers and are implicated in seemingly all stages of development of the tumors. The production of MIF is triggered through an autocrine signal emitted by tumor cells, and stimulates the production of cytokines, chemokines, and growth as well as angiogenic factors that lead to growth of the tumor, increasing its aggressiveness and metastatic potential. MIF is produced by virtually all types of human body cells, in response to stress caused by different factors, leading to pathological conditions such as chronic inflammation and immunomodulation with suppression of immune surveillance and of immune response against tumors, angiogenesis, and carcinogenesis. In this review, we present recent advances on the biological activity of MIF, the signaling pathways with which it is involved and their role in tumorigenesis.
C1 [Guimaraes Nobre, Camila Cristina; Galvao de Araujo, Joselio Maria; Oliveira Cobucci, Ricardo Ney; Andrade, Vania Sousa; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Postgrad Program Parasite Biol, BR-59072970 Natal, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, BR-59607360 Mossoro, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte Stat, Postgrad Program Hlth & Soc, Mossoro, RN, Brazil.
   [Oliveira Cobucci, Ricardo Ney] Univ Potiguar, Dept Gynecol & Obstet, BR-5905600 Natal, RN, Brazil.
   [Ferreira Lanza, Daniel Carlos] Univ Fed Rio Grande do Norte, Dept Biochemisty, BR-59072970 Natal, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Postgrad Program Parasite Biol, BR-59072970 Natal, RN, Brazil.; Fernandes, TAAD (corresponding author), Univ Rio Grande Norte State, Dept Biomed Sci, BR-59607360 Mossoro, RN, Brazil.; Fernandes, TAAD (corresponding author), Univ Rio Grande Norte Stat, Postgrad Program Hlth & Soc, Mossoro, RN, Brazil.
EM thalesallyrio@yahoo.com.br; veris@cb.ufrn.br
RI Cobucci, Ricardo N/J-8134-2017; Andrade, Vania Sousa/AAR-3922-2020;
   Araujo, Joselio M G/B-5502-2013; Fernandes, Thales/F-4813-2010; Cobucci,
   Ricardo Ney Oliveira/E-2907-2015
OI Cobucci, Ricardo N/0000-0002-0184-2061; Araujo, Joselio M
   G/0000-0003-3548-2786; Fernandes, Thales/0000-0003-4559-8918; Cobucci,
   Ricardo Ney Oliveira/0000-0002-0184-2061; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
CR Arisawa T, 2008, ONCOL REP, V19, P223
   Babu SN, 2012, ASIAN PAC J CANCER P, V13, P1737, DOI 10.7314/APJCP.2012.13.5.1737
   Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x
   Benigni F, 2000, J CLIN INVEST, V106, P1291, DOI 10.1172/JCI9900
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Bifulco C, 2008, CURR PHARM DESIGN, V14, P3790, DOI 10.2174/138161208786898608
   Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   Patrick KBA, 2008, J REPROD IMMUNOL, V77, P142, DOI 10.1016/j.jri.2007.07.004
   Bucala R, 1996, FASEB J, V10, P1607
   Cheng RJ, 2011, INT J GYNECOL CANCER, V21, P1004, DOI 10.1097/IGC.0b013e31821c45b7
   Cohen NA, 2012, CHEM BIOL, V19, P1175, DOI 10.1016/j.chembiol.2012.07.018
   Conroy H, 2010, QJM-INT J MED, V103, P831, DOI 10.1093/qjmed/hcq148
   Cooke G, 2009, BIOFACTORS, V35, P165, DOI 10.1002/biof.27
   Dambacher J, 2007, INFLAMM BOWEL DIS, V13, P71, DOI 10.1002/ibd.20008
   Rosado JD, 2011, INT J BIOL SCI, V7, P1239
   Dietlin TA, 2007, J LEUKOCYTE BIOL, V81, P1205, DOI 10.1189/jlb.1006640
   El-Turk F, 2008, BIOCHEMISTRY-US, V47, P10740, DOI 10.1021/bi800603x
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Fernandes JV, 2015, PATHOL ONCOL RES, V21, P527, DOI 10.1007/s12253-015-9913-z
   Fernandes JV, 2015, ONCOL LETT, V9, P1015, DOI 10.3892/ol.2015.2884
   Fingerle-Rowson G, 2003, AM J PATHOL, V162, P47, DOI 10.1016/S0002-9440(10)63797-2
   Fingerle-Rowson GR, 2001, IMMUNOL CELL BIOL, V79, P368, DOI 10.1046/j.1440-1711.2001.01024.x
   Funamizu N, 2013, INT J CANCER, V132, P785, DOI 10.1002/ijc.27736
   Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0
   Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884
   Gordon-Weeks AN, 2015, CYTOKINE GROWTH F R, V26, P451, DOI 10.1016/j.cytogfr.2015.03.002
   Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200
   Gregory JL, 2004, ARTHRITIS RHEUM-US, V50, P3023, DOI 10.1002/art.20470
   Grieb G, 2010, DRUG NEWS PERSPECT, V23, P257, DOI 10.1358/dnp.2010.23.4.1453629
   Guo CQ, 2013, VASC CELL, V5, DOI 10.1186/2045-824X-5-20
   Guo Yong-Shun, 2011, Zhonghua Zhong Liu Za Zhi, V33, P28
   Hagemann T, 2007, MOL CANCER THER, V6, P1993, DOI 10.1158/1535-7163.MCT-07-0118
   Hanel W, 2012, J CELL BIOCHEM, V113, P433, DOI 10.1002/jcb.23400
   Hoi Alberta Y., 2007, Inflammation & Allergy Drug Targets, V6, P183, DOI 10.2174/187152807781696455
   Ichihara E, 2011, ACTA MED OKAYAMA, V65, P353
   Jung HY, 2008, J BIOL CHEM, V283, P20383, DOI 10.1074/jbc.M800050200
   Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864
   Krockenberger M, 2008, J IMMUNOL, V180, P7338, DOI 10.4049/jimmunol.180.11.7338
   Krockenberger M, 2010, J CANCER RES CLIN, V136, P651, DOI 10.1007/s00432-009-0702-5
   Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185
   Lehmann LE, 2008, BIOFACTORS, V33, P281, DOI 10.1002/biof.5520330404
   Lerch JK, 2014, SEMIN IMMUNOL, V26, P409, DOI 10.1016/j.smim.2014.03.004
   Lolis E, 2003, EXPERT OPIN THER TAR, V7, P153, DOI 10.1517/eott.7.2.153.23778
   Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318
   Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5
   Massirer KB, 2011, WIRES SYST BIOL MED, V3, P107, DOI 10.1002/wsbm.100
   Matsunaga J, 1999, CELL MOL BIOL, V45, P1035
   Mawhinney L, 2014, MOL MED, V20, P729, DOI 10.2119/molmed.2014.00136
   McClelland M, 2009, AM J PATHOL, V174, P638, DOI 10.2353/ajpath.2009.080463
   Meyer-Siegler KL, 2007, GENES IMMUN, V8, P646, DOI 10.1038/sj.gene.6364427
   Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002
   Mittelbronn M, 2011, ACTA NEUROPATHOL, V122, P353, DOI 10.1007/s00401-011-0858-3
   Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226
   Nakaya K, 2012, ASIAN PAC J CANCER P, V13, P607, DOI 10.7314/APJCP.2012.13.2.607
   NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892
   Oda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002215
   Onodera S, 2004, ARTHRITIS RHEUM-US, V50, P1437, DOI 10.1002/art.20190
   Pende D, 2002, CANCER RES, V62, P6178
   Ren Y, 2006, ONCOGENE, V25, P3501, DOI 10.1038/sj.onc.1209395
   Ren Y, 2005, ANN SURG, V242, P55, DOI 10.1097/01.sla.0000168555.97710.bb
   Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287
   Rendon BE, 2009, EXP MOL PATHOL, V86, P180, DOI 10.1016/j.yexmp.2009.01.001
   Richard V, 2015, INT J ONCOL, V47, P1627, DOI 10.3892/ijo.2015.3185
   Richard V, 2014, ONCOL REP, V32, P523, DOI 10.3892/or.2014.3272
   Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210
   Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1
   Santos LL, 2006, WIEN MED WOCHENSCHR, V156, P11, DOI 10.1007/s10354-005-0243-8
   Shen YC, 2012, DEV BIOL, V363, P84, DOI 10.1016/j.ydbio.2011.12.023
   Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020
   Siegler KLM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-73
   Simpson KD, 2012, J IMMUNOL, V189, P5533, DOI 10.4049/jimmunol.1201161
   Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174
   SUZUKI M, 1994, J MOL BIOL, V235, P1141, DOI 10.1006/jmbi.1994.1063
   Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765
   Tanese K, 2015, J INVEST DERMATOL, V135, P2901, DOI 10.1038/jid.2015.259
   Tang Wei-min, 2011, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V27, P97
   Tarnowski M, 2010, MOL CANCER RES, V8, P1328, DOI 10.1158/1541-7786.MCR-10-0288
   Tillmann S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00115
   Tong X, 2015, INT J CLIN EXP MED, V8, P15949
   Veillat V, 2010, J CLIN ENDOCR METAB, V95, pE403, DOI 10.1210/jc.2010-0417
   Verjans E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-230
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   White ES, 2003, CLIN CANCER RES, V9, P853
   Wu SP, 2006, ARTHRITIS RHEUM-US, V54, P3661, DOI 10.1002/art.22179
   Wu SH, 2011, ONCOL LETT, V2, P1261, DOI 10.3892/ol.2011.409
   Yaddanapudi K, 2016, CANCER IMMUNOL RES, V4, P101, DOI 10.1158/2326-6066.CIR-15-0070-T
   Yaddanapudi K, 2013, J IMMUNOL, V190, P2984, DOI 10.4049/jimmunol.1201650
   Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791
   Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505
   Zhang XJ, 2013, INT J BIOL SCI, V9, P1108, DOI 10.7150/ijbs.7232
NR 93
TC 47
Z9 51
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD APR
PY 2017
VL 23
IS 2
BP 235
EP 244
DI 10.1007/s12253-016-0138-6
PG 10
WC Oncology; Pathology
SC Oncology; Pathology
GA ER7NQ
UT WOS:000399000200002
PM 27771887
DA 2020-10-30
ER

PT J
AU Branco, MSD
   Sousa, DMC
   Sousa, DMC
   Monteiro, JD
   Costa, DMP
   Almeida, RF
   Lima, TLC
   Farias, KJS
   Medeiros, RC
   Queiroz, MGL
   Gil, LHVG
   Fernandes, JV
   Nogueira, RMR
   Araujo, JMG
AF Branco, Mario S. D.
   Sousa, Denise M. C.
   Sousa, Daise M. C.
   Monteiro, Joelma D.
   Costa, Diego M. P.
   Almeida Junior, Renato F.
   Lima, Tabata L. C.
   Farias, Kleber J. S.
   Medeiros, Ralfo C.
   Queiroz, Maria Goretti L.
   Gil, Laura H. V. G.
   Fernandes, Jose V.
   Nogueira, Rita M. R.
   Araujo, Joselio M. G.
TI Dengue in the State of Rio Grande do Norte, Brazil, 2010-2012
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Dengue; Rio Grande do Norte; Epidemiology; Virological Surveillance
AB ObjectiveTo present results of virological surveillance and epidemiological aspects of dengue in the State of Rio Grande do Norte, Brazil.
   MethodsA total of 1581 cases, reported from 2010 to 2012 at various health centres in the state, were analysed by viral isolation and/or RT-PCR for viral detection and typing. To identify whether different genotypes were circulating in the state during this period, sequencing of the complete E gene for DENV (1485 bp in length) was performed directly from patient serum samples.
   ResultsAll four serotypes of dengue virus circulated in Rio Grande do Norte, with the introduction of DENV-4 in the state in 2011. In 2012, DENV-4 represented 100% of positive confirmed cases. 53.97% of cases occurred in Natal. Case numbers peaked in April (21%) and May (23%). Genetic characterisation of circulating strains confirmed the circulation of genotypes V, south-east Asian/American and II, respectively, for DENV-1, DENV-2 and DENV-4.
   ConclusionsThis work furthers a better understanding of dengue viruses in the State of Rio Grande do Norte. Strengthening control efforts in the region is important considering the impact of dengue.
C1 [Branco, Mario S. D.; Sousa, Denise M. C.; Sousa, Daise M. C.; Monteiro, Joelma D.; Costa, Diego M. P.; Almeida Junior, Renato F.; Lima, Tabata L. C.; Farias, Kleber J. S.; Fernandes, Jose V.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, BR-59072910 Natal, RN, Brazil.
   [Branco, Mario S. D.; Nogueira, Rita M. R.] Inst Oswaldo Cruz, Lab Flavivirus, BR-20001 Rio De Janeiro, Brazil.
   [Medeiros, Ralfo C.; Queiroz, Maria Goretti L.] Lab Cent Doutor Almino Fernandes, Natal, RN, Brazil.
   [Gil, Laura H. V. G.] Aggeu Magalhaes Res Ctr, Dept Virol & Expt Therapy, Recife, PE, Brazil.
RP Araujo, JMG (corresponding author), Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, Campus Univ, BR-59072910 Natal, RN, Brazil.
EM joselio@cb.ufrn.br
RI Araujo, Joselio M G/B-5502-2013; FARIAS, KLEBER/AAC-9815-2019
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX We gratefully acknowledge the Laboratorio Central Doutor Almino
   Fernandes for providing clinical samples. This investigation received
   financial support from the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq.
CR Araujo JMG, 2009, VIRUS DENGUE TIPO 3, P111
   Barbosa IR, 2012, EPIDEMIOL SERV SAUDE, V21, P149, DOI 10.5123/S1679-49742012000100015
   Cunha RV, 1999, T ROY SOC TROP MED H, V93, P247, DOI 10.1016/S0035-9203(99)90008-1
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101, DOI DOI 10.1016/0038-092X(88)90131-4
   Rodenhuis-Zybert IA, 2010, CELL MOL LIFE SCI, V67, P2773, DOI 10.1007/s00018-010-0357-z
   Ross TM, 2010, CLIN LAB MED, V30, P149, DOI 10.1016/j.cll.2009.10.007
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
NR 13
TC 3
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD DEC
PY 2015
VL 20
IS 12
BP 1707
EP 1710
DI 10.1111/tmi.12612
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CZ8JA
UT WOS:000367344800011
PM 26426773
OA Bronze
DA 2020-10-30
ER

PT J
AU Fernandes, JV
   Cobucci, RNO
   Jatoba, CAN
   Fernandes, TAAD
   de Azevedo, JWV
   de Araujo, JMG
AF Fernandes, Jose Verissimo
   Oliveira Cobucci, Ricardo Ney
   Jatoba, Carlos Andre Nunes
   Araujo de Medeiros Fernandes, Thales Allyrio
   Verissimo de Azevedo, Judson Welber
   Galvao de Araujo, Joselio Maria
TI The Role of the Mediators of Inflammation in Cancer Development
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Review
DE Inflammation and cancer; Inflammation mediators; Mechanisms of
   tumorigenesis
ID NF-KAPPA-B; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY;
   GENE-EXPRESSION; IFN-GAMMA; MICRORNA; MECHANISMS; INTERLEUKIN-10;
   RECRUITMENT; INHIBITION
AB Epigenetic disorders such as point mutations in cellular tumor suppressor genes, DNA methylation and post-translational modifications are needed to transformation of normal cells into cancer cells. These events result in alterations in critical pathways responsible for maintaining the normal cellular homeostasis, triggering to an inflammatory response which can lead the development of cancer. The inflammatory response is a universal defense mechanism activated in response to an injury tissue, of any nature, that involves both innate and adaptive immune responses, through the collective action of a variety of soluble mediators. Many inflammatory signaling pathways are activated in several types of cancer, linking chronic inflammation to tumorigenesis process. Thus, Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, growth, invasion, and metastasis, affecting also the immune surveillance. Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the molecular events that mediate this dialog have been revealed. A range of inflammation mediators, including cytokines, chemokines, free radicals, prostaglandins, growth and transcription factors, microRNAs, and enzymes as, cyclooxygenase and matrix metalloproteinase, collectively acts to create a favorable microenvironment for the development of tumors. In this review are presented the main mediators of the inflammatory response and discussed the likely mechanisms through which, they interact with each other to create a condition favorable to development of cancer.
C1 [Fernandes, Jose Verissimo; Galvao de Araujo, Joselio Maria] Univ Fed Rio Grande do Norte, Postgrad Program Biol Sci, BR-59072910 Natal, RN, Brazil.
   [Fernandes, Jose Verissimo; Galvao de Araujo, Joselio Maria] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072910 Natal, RN, Brazil.
   [Oliveira Cobucci, Ricardo Ney] Univ Fed Rio Grande do Norte, Maternidade Escola Januario Cicco, BR-59072910 Natal, RN, Brazil.
   [Jatoba, Carlos Andre Nunes] Univ Fed Rio Grande do Norte, Dept Pathol, BR-59072910 Natal, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, Mossoro, RN, Brazil.
   [Verissimo de Azevedo, Judson Welber] Univ Fed Triangulo Mineiro, Univ Hosp, Belo Horizonte, MG, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Campus Univ, BR-59072910 Natal, RN, Brazil.
EM joseverissimo1951@gmail.com
RI Fernandes, Thales/F-4813-2010; Araujo, Joselio M G/B-5502-2013; Cobucci,
   Ricardo N/J-8134-2017; Cobucci, Ricardo Ney Oliveira/E-2907-2015
OI Fernandes, Thales/0000-0003-4559-8918; Araujo, Joselio M
   G/0000-0003-3548-2786; Cobucci, Ricardo N/0000-0002-0184-2061; Cobucci,
   Ricardo Ney Oliveira/0000-0002-0184-2061; Cobucci,
   Ricardo/0000-0002-8958-1344; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
CR Adefuye A, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/548150
   Ahmad J, 2013, INDIAN J MED RES, V137, P680
   Allavena P, 2011, EXP CELL RES, V317, P664, DOI 10.1016/j.yexcr.2010.11.013
   Ashley NT, 2012, ANNU REV ECOL EVOL S, V43, P385, DOI 10.1146/annurev-ecolsys-040212-092530
   Asting AG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-238
   Bermejo-Martin JF, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/456256
   Butler GS, 2013, PERIODONTOL 2000, V63, P123, DOI 10.1111/prd.12035
   Campbell LM, 2013, PHARMACEUTICALS, V6, P929, DOI 10.3390/ph6080929
   Cathcart MC, 2012, BBA-REV CANCER, V1825, P49, DOI 10.1016/j.bbcan.2011.09.004
   Chen WJ, 2010, J MOL CELL BIOL, V2, P30, DOI 10.1093/jmcb/mjp004
   Chen WC, 2013, HISTOPATHOLOGY, V63, P225, DOI 10.1111/his.12156
   Chen ZF, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-61
   Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009
   Cope A, 2011, TRENDS IMMUNOL, V32, P278, DOI 10.1016/j.it.2011.03.010
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x
   Eiro N, 2012, WORLD J GASTRO SURG, V4, P62, DOI 10.4240/wjgs.v4.i3.62
   Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047
   Fan YH, 2013, PROTEIN CELL, V4, P176, DOI 10.1007/s13238-013-2084-3
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173
   Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046
   Iliopoulos D, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005053
   Josse C, 2014, AM J PHYSIOL-GASTR L, V306, pG229, DOI 10.1152/ajpgi.00484.2012
   Kaushal N, 2013, POSTDOC J, V1, P89
   Kleiner G, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/928315, 10.1155/2013/434010]
   Liang Y, 2004, CELL MOL IMMUNOL, V1, P343
   Loffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510
   Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Miossec P, 2009, MICROBES INFECT, V11, P625, DOI 10.1016/j.micinf.2009.04.003
   Mocellin S, 2005, J LEUKOCYTE BIOL, V78, P1043, DOI 10.1189/jlb.0705358
   Neel J.-C., 2012, ISRN MOL BIOL, V2012, P28, DOI [10.5402/2012/381428, DOI 10.5402/2012/381428]
   Ngiow SF, 2013, TRENDS IMMUNOL, V34, P548, DOI 10.1016/j.it.2013.07.004
   O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013
   Ostermann E, 2013, CURR TRENDS IMMUNOL, V14, P35
   Palma G, 2013, BBA-REV CANCER, V1836, P296, DOI 10.1016/j.bbcan.2013.09.001
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Pattison MJ, 2012, J IMMUNOL, V189, P2784, DOI 10.4049/jimmunol.1200310
   Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013
   Said AH, 2014, CANCERS, V6, P366, DOI 10.3390/cancers6010366
   Sales KJ, 2002, CANCER RES, V62, P424
   Sato T, 2011, IMMUNOL RES, V51, P170, DOI 10.1007/s12026-011-8262-6
   Schauer IG, 2013, NEOPLASIA, V15, P409, DOI 10.1593/neo.121228
   Schetter AJ, 2012, CANCER J, V18, P244, DOI 10.1097/PPO.0b013e318258b78f
   Sharkey DJ, 2012, J IMMUNOL, V188, P2445, DOI 10.4049/jimmunol.1102736
   Shigehara K, 2001, J IMMUNOL, V166, P642, DOI 10.4049/jimmunol.166.1.642
   Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015
   Srivastava S, 2010, CURR MED CHEM, V17, P3353, DOI 10.2174/092986710793176348
   Stewart CA, 2013, J CLIN INVEST, V123, P4859, DOI 10.1172/JCI65180
   Tang T, 2013, GYNECOL ONCOL, V129, P199, DOI 10.1016/j.ygyno.2012.12.043
   Tili E, 2013, IMMUNOL REV, V253, P167, DOI 10.1111/imr.12050
   Vicari AP, 2004, IMMUNOL REV, V202, P223, DOI 10.1111/j.0105-2896.2004.00216.x
   Visperas A, 2014, MUCOSAL IMMUNOL, V7, P625, DOI 10.1038/mi.2013.82
   Walter L, 2013, IMMUNOGASTROENTEROLO, V2, P22
   Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421
   Waters JP, 2013, J PATHOL, V230, P241, DOI 10.1002/path.4188
   Wong JL, 2013, CANCER RES, V73, P4653, DOI 10.1158/0008-5472.CAN-12-4366
   Wu LJ, 2014, INT J CLIN EXP PATHO, V7, P1140
   Gomis-Ruth FX, 2009, J BIOL CHEM, V284, P15353, DOI 10.1074/jbc.R800069200
   Xiang T, 2015, ONCOGENE, V34, P165, DOI 10.1038/onc.2013.537
   Yeung ML, 2011, PHARM RES-DORDR, V28, P3043, DOI 10.1007/s11095-011-0526-2
   Zha S, 2004, CANCER LETT, V215, P1, DOI 10.1016/j.canlet.2004.06.014
   Zhou QH, 2015, ANN RHEUM DIS, V74, P1265, DOI 10.1136/annrheumdis-2013-204377
   zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046
   Zyada MM, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-26
NR 67
TC 92
Z9 99
U1 0
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2015
VL 21
IS 3
BP 527
EP 534
DI 10.1007/s12253-015-9913-z
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA CJ6SU
UT WOS:000355624700003
PM 25740073
DA 2020-10-30
ER

PT J
AU Magalhaes, PAF
   Miranda, CAN
   Lima, EG
   Moizeis, RNC
   de Lima, DBS
   Cobucci, RNO
   Fernandes, TAAD
   de Azevedo, JCV
   de Azevedo, PRM
   de Araujo, JMG
   Fernandes, JV
AF Freire Magalhaes, Paulo Andre
   Nunes Miranda, Cleine Aglacy
   Lima, Erika Galvao
   Cunha Moizeis, Raiza Nara
   Soares de Lima, Diego Breno
   Oliveira Cobucci, Ricardo Ney
   Araujo de Medeiros Fernandes, Thales Allyrio
   Verissimo de Azevedo, Jenner Chrystian
   Medeiros de Azevedo, Paulo Roberto
   Galvao de Araujo, Joselio Maria
   Fernandes, Jose Verissimo
TI Genital tract infection with Chlamydia trachomatis in women attended at
   a cervical cancer screening program in Northeastern from Brazil
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Chlamydia trachomatis; Human papillomavirus; Risk factors; Genital tract
   infection
ID HUMAN-PAPILLOMAVIRUS; YOUNG-WOMEN; POPULATION; AMPLIFICATION;
   ADOLESCENTS; PREVALENCE; SEQUENCES; NEOPLASIA; PCR
AB This cross-sectional study aimed to estimate the prevalence of Chlamydia trachomatis (CT) infection alone and in combination with human papillomavirus (HPV). Furthermore, the study investigates whether the CT infection increases the risk of contracting HPV and whether the presence of both pathogens is associated with a higher prevalence of cervical lesions.
   Cervical samples of 1,134 asymptomatic women enrolled in a screening program for cervical cancer were analyzed. Two cervical specimens were collected from each patient, one for cytologic examination and the other for detection of CT by polymerase chain reaction (PCR), using a primer pair which amplifies a specific sequence of the DNA plasmid.
   The overall prevalence rate infection was 10.9 %, being 10 % in the women with normal cytology, 13.8 % in those with atypical squamous cells of undetermined significance (ASC-US), and 25 % with low-grade squamous intraepithelial lesion (LSIL). The infection by CT did not increase the risk of acquiring HPV infection. The higher prevalence of LSIL in women co-infected with HPV and CT is possibly due to HPV.
   CT infection was more prevalent in younger women aged up to 32 years, who had an early onset of reproductive activity and a history of having had multiple sexual partners lifelong may be at a greater risk of acquiring infection of the genital tract by C. trachomatis.
C1 [Freire Magalhaes, Paulo Andre; Nunes Miranda, Cleine Aglacy; Lima, Erika Galvao; Galvao de Araujo, Joselio Maria; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Postgrad Program Biol Sci, BR-59072910 Natal, RN, Brazil.
   [Cunha Moizeis, Raiza Nara; Soares de Lima, Diego Breno; Galvao de Araujo, Joselio Maria; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072910 Natal, RN, Brazil.
   [Oliveira Cobucci, Ricardo Ney] Univ Fed Rio Grande do Norte, Postgrad Program Hlth Sci, BR-59072910 Natal, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, Mossoro, RN, Brazil.
   [Verissimo de Azevedo, Jenner Chrystian] Univ Fed Rio Grande do Norte, Onofre Lopes Hosp, BR-59072910 Natal, RN, Brazil.
   [Medeiros de Azevedo, Paulo Roberto] Univ Fed Rio Grande do Norte, Dept Stat, BR-59072910 Natal, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Campus Univ, BR-59072910 Natal, RN, Brazil.
EM joseverissimo1951@gmail.com
RI Araujo, Joselio M G/B-5502-2013; Fernandes, Thales/F-4813-2010; Cobucci,
   Ricardo N/J-8134-2017; Cobucci, Ricardo Ney Oliveira/E-2907-2015
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes,
   Thales/0000-0003-4559-8918; Cobucci, Ricardo N/0000-0002-0184-2061;
   Cobucci, Ricardo Ney Oliveira/0000-0002-0184-2061; Magalhaes,
   Paulo/0000-0002-2224-9291; Fernandes, Jose
   Verissimo/0000-0002-5169-6496; Cobucci, Ricardo/0000-0002-8958-1344
FU Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do estado do Rio
   Grande do Norte, FAPERN (grant PPSUS-III)
FX The research described in this publication was made possible by support
   from the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPq and Fundacao de Amparo a Pesquisa do estado do Rio
   Grande do Norte, FAPERN (grant PPSUS-III).
CR Arráiz Nailet, 2008, Rev. salud pública, V10, P615, DOI 10.1590/S0124-00642008000400011
   BEbEar C, 2009, CLIN MICROBIOL INFEC, V15, P4, DOI 10.1111/j.1469-0691.2008.02647.x
   Bhatla N, 2013, INDIAN J MED RES, V137, P533
   Bias MM, 2007, SEX TRANSM INFECT, V83, DOI 10.1136/sti.2006.022665
   Cai T, 2011, J SEX MED, V8, P1131, DOI 10.1111/j.1743-6109.2010.02194.x
   de Paula FDF, 2007, DIAGN CYTOPATHOL, V35, P198, DOI 10.1002/dc.20629
   Ginocchio CC, 2012, J CLIN MICROBIOL, V50, P2601, DOI 10.1128/JCM.00748-12
   Guimaraes MO, 2001, CAD SAUDE PUBLICA, V7, P385
   HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057
   Igansi CN, 2012, CAD SAUDE COLET, V20, P287
   Johnson KA, 2009, CELL MICROBIOL, V11, P1064, DOI 10.1111/j.1462-5822.2009.01307.x
   Knowlton AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054022
   Knowlton AE, 2011, TRAFFIC, V12, P854, DOI 10.1111/j.1600-0854.2011.01204.x
   Leon SR, 2009, REV PANAM SALUD PUBL, V26, P39, DOI 10.1590/S1020-49892009000700006
   Tavares MCM, 2014, MOL BIOL REP, V41, P865, DOI 10.1007/s11033-013-2927-2
   Martins J, 2011, AN PEDIATR, V74, P298, DOI 10.1016/j.anpedi.2010.10.022
   Miranda AE, 2004, SEX TRANSM DIS, V31, P542, DOI 10.1097/01.olq.0000137899.25542.75
   Paavonen J, 2012, ANN MED, V44, P18, DOI 10.3109/07853890.2010.546365
   Poiares LA, 2008, REV BRAS ANAL CLIN, V40, P229
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Sambrook J, 2001, MOL CLONING LAB MANU
   Sánchez Ruth Mélida, 2006, Rev Colomb Obstet Ginecol, V57, P171
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Santos Cristina, 2003, Braz J Infect Dis, V7, P91, DOI 10.1590/S1413-86702003000200001
   Scott ME, 2006, J CLIN IMMUNOL, V26, P222, DOI 10.1007/s10875-006-9010-x
   Silins I, 2005, INT J CANCER, V116, P110, DOI 10.1002/ijc.20970
   Silva J, 2013, ARCH GYNECOL OBSTET, V288, P627, DOI 10.1007/s00404-013-2771-6
   Smith JS, 2002, J INFECT DIS, V185, P324, DOI 10.1086/338569
   Verteramo R, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-16
NR 29
TC 10
Z9 13
U1 0
U2 30
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAY
PY 2015
VL 291
IS 5
BP 1095
EP 1102
DI 10.1007/s00404-014-3514-z
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CE0BN
UT WOS:000351467600022
PM 25326872
DA 2020-10-30
ER

PT J
AU Fernandes, JV
   Fernandes, TAAD
   De Azevedo, JCV
   Cobucci, RNO
   De Carvalho, MGF
   Andrade, VS
   De Araujo, JMG
AF Fernandes, Jose Verissimo
   Araujo De Medeiros Fernandes, Thales Allyrio
   Verissimo De Azevedo, Jenner Chrystian
   Oliveira Cobucci, Ricardo Ney
   Freire De Carvalho, Maria Goretti
   Andrade, Vania Sousa
   De Araujo, Joselio Maria Galvao
TI Link between chronic inflammation and human papillomavirus-induced
   carcinogenesis
SO ONCOLOGY LETTERS
LA English
DT Review
DE inflammation; carcinogenesis; human papillomavirus; cervical cancer
ID NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; CERVICAL-CANCER;
   CHLAMYDIA-TRACHOMATIS; PATHOGEN RECOGNITION; INTERFERON-GAMMA; INNATE
   IMMUNITY; HPV INFECTION; FACTOR-ALPHA
AB Inflammation is a defense strategy against invading agents and harmful molecules that is activated immediately following a stimulus, and involves the release of cytokines and chemokines, which activate the innate immune response. These mediators act together to increase blood flow and vascular permeability, facilitating recruitment of effector cells to the site of injury. Following resolution of the injury and removal of the stimulus, inflammation is disabled, but if the stimulus persists, inflammation becomes chronic and is strongly associated with cancer. This is likely to be due to the fact that the inflammation leads to a wound that does not heal, requiring a constant:renewal of cells, which increases the risk of neoplastic transformation. Debris from phagocytosis, including the reactive species of oxygen and nitrogen that cause damage to DNA already damaged by the leukotrienes and prostaglandins, has an impact on inflammation and various carcinogenic routes. There is an association between chronic inflammation, persistent infection and cancer, where oncogenic action is mediated by autocrine and paracrine signals, causing changes in somatic cells under the influence of the microbial genome or of epigenetic factors. Among the infectious agents associated with cancer, certain genotypes of human papillomavirus (HPV) stand out. HPV is responsible for virtually all cases of cervical cancer and a lower proportion of cancers of the vagina, vulva, anus, penis and a number of extragenital cancers. In the present review, recent advances in the mechanisms involved in the inflammatory response are presented with their participation in the process of carcinogenesis, emphasizing the role of chronic inflammation in the development of HPV-induced cervical cancer.
C1 [Fernandes, Jose Verissimo; Andrade, Vania Sousa; De Araujo, Joselio Maria Galvao] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitoloy, BR-59072970 Natal, RN, Brazil.
   [Araujo De Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, BR-59607360 Mossoro, Brazil.
   [Verissimo De Azevedo, Jenner Chrystian] Univ Hosp Onofre Lopes, Dept Pediat, Petropolis, Brazil.
   [Oliveira Cobucci, Ricardo Ney] Univ Fed Rio Grande do Norte, Januario Cicco Matern Sch, BR-59072970 Natal, RN, Brazil.
   [Freire De Carvalho, Maria Goretti] Univ Potiguar, Dept Pathol, BR-59020500 Natal, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitoloy, Ave Salgado Filho,Campus Univ, BR-59072970 Natal, RN, Brazil.
EM veris@cb.ufrn.br
RI Cobucci, Ricardo Ney Oliveira/E-2907-2015; Cobucci, Ricardo
   N/J-8134-2017; Fernandes, Thales/F-4813-2010; Andrade, Vania
   Sousa/AAR-3922-2020; Araujo, Joselio M G/B-5502-2013
OI Cobucci, Ricardo Ney Oliveira/0000-0002-0184-2061; Cobucci, Ricardo
   N/0000-0002-0184-2061; Fernandes, Thales/0000-0003-4559-8918; Araujo,
   Joselio M G/0000-0003-3548-2786; Fernandes, Jose
   Verissimo/0000-0002-5169-6496; Cobucci, Ricardo/0000-0002-8958-1344
CR Adefuye A, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/548150
   Afsar U.AHMED, 2011, [Frontiers in Biology, 生物学前沿], V6, P274
   Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006
   Anthony MN, 2007, AIDS CARE, V19, P195, DOI 10.1080/09540120600966182
   Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199
   Ashley NT, 2012, ANNU REV ECOL EVOL S, V43, P385, DOI 10.1146/annurev-ecolsys-040212-092530
   Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X
   Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013
   Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723
   Biet F, 2002, J MOL MED-JMM, V80, P147, DOI 10.1007/s00109-001-0307-1
   Boccardo E, 2010, CARCINOGENESIS, V31, P1905, DOI 10.1093/carcin/bgq176
   Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002
   Castle PE, 2001, CANCER EPIDEM BIOMAR, V10, P1021
   Chen WJ, 2010, J MOL CELL BIOL, V2, P30, DOI 10.1093/jmcb/mjp004
   Chen ZF, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-61
   Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   de Abreu ALP, 2012, AM J TROP MED HYG, V87, P1149, DOI 10.4269/ajtmh.2012.12-0287
   de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Fernandes JV, 2013, OPEN ACCESS J CLIN T, V5, P1, DOI 10.2147/OAJCT.S37741
   Fernandes JV, 2013, HDB HUMAN PAPILLOMAV, P181
   Friedman R, 2002, IMMUNOGENETICS, V53, P964, DOI 10.1007/s00251-001-0399-3
   Gonzalez-Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133
   Graham AL, 2002, Q REV BIOL, V77, P409, DOI 10.1086/344414
   Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x
   Graham CS, 2005, AIDS, V19, P767, DOI 10.1097/01.aids.0000168970.80551.3d
   Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006
   Hammes LS, 2007, GYNECOL ONCOL, V105, P157, DOI 10.1016/j.ygyno.2006.11.023
   Hao JS, 2006, CANCER IMMUNOL IMMUN, V55, P1426, DOI 10.1007/s00262-006-0171-5
   Hawes SE, 2002, J NATL CANCER I, V94, P1592
   Hernadi Z, 2006, EUR J OBSTET GYN R B, V125, P114, DOI 10.1016/j.ejogrb.2005.08.005
   Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046
   Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8
   Jabbour HN, 2009, REPRODUCTION, V138, P903, DOI 10.1530/REP-09-0247
   James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Jenkins BJ, 2007, BLOOD, V109, P2380, DOI 10.1182/blood-2006-08-040352
   Karim R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003384
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kaul R, 2010, J LEUKOCYTE BIOL, V88, P427, DOI 10.1189/jlb.0410230
   Kemp TJ, 2010, CANCER EPIDEM BIOMAR, V19, P1954, DOI 10.1158/1055-9965.EPI-10-0184
   Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kovacic MB, 2008, HUM PATHOL, V39, P1088, DOI 10.1016/j.humpath.2007.12.002
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69
   Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012
   Luo Lihui, 2005, Eye Contact Lens, V31, P186, DOI 10.1097/01.ICL.0000162759.79740.46
   Maeda K, 2005, HEARING RES, V202, P154, DOI 10.1016/j.heares.2004.08.022
   Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Mazibrada J, 2008, GYNECOL ONCOL, V108, P112, DOI 10.1016/j.ygyno.2007.08.095
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mocellin S, 2005, J LEUKOCYTE BIOL, V78, P1043, DOI 10.1189/jlb.0705358
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
   Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Nakanishi Kenji, 2002, Kekkaku, V77, P87
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Niebler M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003536
   Niwa R, 2007, CURR OPIN GENET DEV, V17, P145, DOI 10.1016/j.gde.2007.02.004
   Oh JM, 2009, CARCINOGENESIS, V30, P141, DOI 10.1093/carcin/bgn236
   Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004
   Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Peghini BC, 2012, HUM IMMUNOL, V73, P920, DOI 10.1016/j.humimm.2012.06.003
   Proell M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002119
   Reddy P, 2003, J LAB CLIN MED, V141, P365, DOI 10.1016/S0022-2143(03)00028-3
   Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102
   Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017
   Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Sakurai F, 2008, MOL THER, V16, P726, DOI 10.1038/mt.2008.19
   Sales KJ, 2002, CANCER RES, V62, P424
   Sales KJ, 2003, PROSTAG OTH LIPID M, V71, P97, DOI 10.1016/S1098-8823(03)00050-9
   Santin AD, 2005, VIROLOGY, V331, P269, DOI 10.1016/j.virol.2004.09.045
   Schetter AJ, 2012, CANCER J, V18, P244, DOI 10.1097/PPO.0b013e318258b78f
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Schottenfeld D, 2005, ANNU REV PUBL HEALTH, V26, P37, DOI 10.1146/annurev.publhealth.26.021304.144402
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Schwebke JR, 1997, GENITOURIN MED, V73, P383
   Scott M, 1999, CLIN DIAGN LAB IMMUN, V6, P751, DOI 10.1128/CDLI.6.5.751-755.1999
   Scott ME, 2013, INT J CANCER, V133, P1187, DOI 10.1002/ijc.28119
   Senba M, 2012, ONCOL REV, V6, P135, DOI 10.4081/oncol.2012.e17
   Senba M, 2011, ONCOL LETT, V2, P65, DOI 10.3892/ol.2010.207
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Sharkey DJ, 2012, J IMMUNOL, V188, P2445, DOI 10.4049/jimmunol.1102736
   Shukla S, 2009, INDIAN J MED RES, V130, P222
   Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422
   Sieve AN, 2010, EUR J IMMUNOL, V40, P2236, DOI 10.1002/eji.200939759
   Silva J, 2014, ARCH GYNECOL OBSTET, V289, P715, DOI 10.1007/s00404-013-3122-3
   Smith JS, 2002, J INFECT DIS, V185, P324, DOI 10.1086/338569
   Smith JS, 2002, JNCI-J NATL CANCER I, V94, P1604, DOI 10.1093/jnci/94.21.1604
   Stanley M, 2006, VACCINE, V24, P16, DOI 10.1016/j.vaccine.2005.09.002
   Stanley MA, 2007, BIOCHEM SOC T, V35, P1456, DOI 10.1042/BST0351456
   Stanley M, 2010, GYNECOL ONCOL, V117, pS5, DOI [10.1016/j.ygyno.2010.01.024, 10.1016/j.ygyno.2010.04.002]
   Suvas S, 2004, J IMMUNOL, V172, P4123, DOI 10.4049/jimmunol.172.7.4123
   Tang T, 2013, GYNECOL ONCOL, V129, P199, DOI 10.1016/j.ygyno.2012.12.043
   Tili E, 2013, IMMUNOL REV, V253, P167, DOI 10.1111/imr.12050
   Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700
   Trinchieri Giorgio, 2011, F1000 Med Rep, V3, P11, DOI 10.3410/M3-11
   Trotta R, 2012, BLOOD, V119, P3478, DOI 10.1182/blood-2011-12-398099
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Viau M, 2005, CLIN IMMUNOL, V114, P17, DOI 10.1016/j.clim.2004.08.019
   Vicari AP, 2004, IMMUNOL REV, V202, P223, DOI 10.1111/j.0105-2896.2004.00216.x
   Viviani B, 2003, J NEUROSCI, V23, P8692
   Welsh RM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002352
   Yang Y C, 2001, Chang Gung Med J, V24, P615
   Zhang Y, 2011, CLIN CHIM ACTA, V412, P894, DOI 10.1016/j.cca.2011.01.015
   zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046
NR 118
TC 59
Z9 64
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2015
VL 9
IS 3
BP 1015
EP 1026
DI 10.3892/ol.2015.2884
PG 12
WC Oncology
SC Oncology
GA CD2OE
UT WOS:000350918100001
PM 25663851
OA Other Gold, Green Published
DA 2020-10-30
ER

PT J
AU Cobucci, RNO
   Lima, PH
   de Souza, PC
   Costa, VV
   Cornetta, MDD
   Fernandes, JV
   Goncalves, AK
AF Oliveira Cobucci, Ricardo Ney
   Lima, Paulo Henrique
   de Souza, Pollyana Carvalho
   Costa, Vanessa Viana
   de Mesquita Cornetta, Maria da Conceicao
   Fernandes, Jose Verssimo
   Goncalves, Ana Katherine
TI Assessing the impact of HAART on the incidence of defining and
   non-defining AIDS cancers among patients with HIV/AIDS: A systematic
   review
SO JOURNAL OF INFECTION AND PUBLIC HEALTH
LA English
DT Review
DE Acquired immunodeficiency syndrome; Highly active antiretroviral
   therapy; Carcinoma; Incidence
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; SWISS HIV
   COHORT; NON-HODGKIN-LYMPHOMA; INFECTED PATIENTS; UNITED-STATES; ANAL
   CANCER; HUMAN-PAPILLOMAVIRUS; ERA; RISK
AB After highly active antiretroviral therapy (HAART) became widespread, several studies demonstrated changes in the incidence of defining and non-defining AIDS cancers among HIV/AIDS patients. We conducted a systematic review of observational studies evaluating the incidence of malignancies before and after the introduction of HAART in people with HIV/AIDS. Eligible studies were searched up to December 2012 in the following databases: Pubmed, Embase, Scielo, Cancerlit and Google Scholar. In this study, we determined the cancer risk ratio by comparing the pre- and post-HAART eras. Twenty-one relevant articles were found, involving more than 600,000 people with HIV/AIDS and 10,891 new cases of cancers. The risk for the development of an AIDS-defining cancer decreased after the introduction of HAART: Kaposi's sarcoma (RR = 0.30, 95% CI: 0.28-0.33) and non-Hodgkin's lymphoma (RR = 0.52, 95% CI: 0.48-0.56), in contrast to invasive cervical cancer (RR = 1.46, 95% CI: 1.09-1.94). Among the non-AIDS-defining cancers, the overall risk increased after the introduction of HAART (RR = 2.00, 95% CI: 1.79-2.23). The incidence of AIDS-defining cancers decreased and the incidence of non-AIDS-defining cancers increased after the early use of HAART, probably due to better control of viral replication, increased immunity and increased survival provided by new drugs. (C) 2014 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Limited. All rights reserved.
C1 [Oliveira Cobucci, Ricardo Ney; Lima, Paulo Henrique] Univ Fed Rio Grande do Norte, Ctr Hlth Sci, BR-59072970 Natal, RN, Brazil.
   [Oliveira Cobucci, Ricardo Ney; de Souza, Pollyana Carvalho; Costa, Vanessa Viana] Univ Potiguar, Dept Gynecol & Obstet, Natal, RN, Brazil.
   [Fernandes, Jose Verssimo] Univ Fed Rio Grande do Norte, Dept Biosci, BR-59072970 Natal, RN, Brazil.
   [de Mesquita Cornetta, Maria da Conceicao; Goncalves, Ana Katherine] Univ Fed Rio Grande do Norte, Dept Gynecol & Obstet, BR-59072970 Natal, RN, Brazil.
RP Cobucci, RNO (corresponding author), Ave Abel Cabral 2035 Casa 105, Parnamirim, Rio Grande Do N, Brazil.
EM rncobucci@hotmail.com
RI Goncalves, Ana/AAO-4019-2020; GONCALVES, ANA KATHERINE/K-2300-2017;
   Cobucci, Ricardo Ney Oliveira/E-2907-2015; Cobucci, Ricardo
   N/J-8134-2017; Cornetta, Maria/P-5480-2017
OI Goncalves, Ana/0000-0002-8351-5119; GONCALVES, ANA
   KATHERINE/0000-0002-8351-5119; Cobucci, Ricardo Ney
   Oliveira/0000-0002-0184-2061; Cobucci, Ricardo N/0000-0002-0184-2061;
   Cobucci, Ricardo/0000-0002-8958-1344; Cornetta,
   Maria/0000-0002-6107-1983; Lima, Paulo/0000-0003-3892-1289; Fernandes,
   Jose Verissimo/0000-0002-5169-6496
CR Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823
   Besson C, 2001, BLOOD, V98, P2339, DOI 10.1182/blood.V98.8.2339
   Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109
   Bonnet F, 2004, CANCER-AM CANCER SOC, V101, P317, DOI 10.1002/cncr.20354
   Bower M, 2004, JAIDS-J ACQ IMM DEF, V37, P1563, DOI 10.1097/00126334-200412150-00004
   Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13
   Bower M, 2003, AIDS, V17, P371, DOI 10.1097/00002030-200302140-00011
   Buchacz K, 2010, AIDS, V24, P1549, DOI 10.1097/QAD.0b013e32833a3967
   Clifford GM, 2009, BLOOD, V113, P5737, DOI 10.1182/blood-2009-02-204172
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d
   Crum-Cianflone Nancy F, 2010, Infect Dis Clin Pract (Baltim Md), V18, P283
   D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe
   Dal Maso L, 2009, BRIT J CANCER, V100, P840, DOI 10.1038/sj.bjc.6604923
   Dorrucci M, 2001, J ACQ IMMUN DEF SYND, V26, P377, DOI 10.1097/00126334-200104010-00016
   Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487
   Franceschi S, 2008, BRIT J CANCER, V99, P800, DOI 10.1038/sj.bjc.6604520
   Franceschi S, 2010, BRIT J CANCER, V103, P416, DOI 10.1038/sj.bjc.6605756
   Franzetti M, 2013, JAIDS-J ACQ IMM DEF, V62, P414, DOI 10.1097/QAI.0b013e318282a189
   Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500
   Gingues S, 2006, HIV MED, V7, P369, DOI 10.1111/j.1468-1293.2006.00395.x
   Grulich AE, 2009, CURR OPIN HIV AIDS, V4, P183, DOI 10.1097/COH.0b013e328329c5b2
   Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096
   Hessol NA, 2004, JAIDS-J ACQ IMM DEF, V36, P978, DOI 10.1097/00126334-200408010-00013
   Kirk O, 2001, BLOOD, V98, P3406, DOI 10.1182/blood.V98.12.3406
   Legarth R, 2013, SCAND J INFECT DIS, V45, P453, DOI 10.3109/00365548.2012.737476
   Lo CKL, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-45
   Cobucci RNO, 2012, CANCER EPIDEMIOL, V36, pE69, DOI 10.1016/j.canep.2011.12.002
   Olivero OA, 2007, ENVIRON MOL MUTAGEN, V48, P215, DOI 10.1002/em.20195
   Palefsky JM, 2012, SEX TRANSM DIS, V39, P501, DOI 10.1097/OLQ.0b013e31825f7921
   Pantanowitz L, 2008, BJU INT, V101, P1519, DOI 10.1111/j.1464-410X.2008.07474.x
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Pinzone MR, 2012, EUR REV MED PHARMACO, V16, P1377
   Polesel J, 2008, AIDS, V22, P301, DOI 10.1097/QAD.0b013e3282f2705d
   Polesel J, 2010, INT J CANCER, V127, P1437, DOI 10.1002/ijc.25153
   Powles T, 2009, J CLIN ONCOL, V27, P884, DOI 10.1200/JCO.2008.19.6626
   Sahasrabuddhe VV, 2012, CANCER-AM CANCER SOC, V118, P6226, DOI 10.1002/cncr.27694
   Seaberg EC, 2010, CANCER-AM CANCER SOC, V116, P5507, DOI 10.1002/cncr.25530
   Silberstein J, 2009, PROSTATE CANCER P D, V12, P6, DOI 10.1038/pcan.2008.44
   Silverberg MJ, 2007, CURR OPIN ONCOL, V19, P446
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   van der Snoek EM, 2012, SEX TRANSM DIS, V39, P495, DOI 10.1097/OLQ.0b013e31825aa764
   van Leeuwen MT, 2009, AIDS, V23, P2183, DOI 10.1097/QAD.0b013e328331d384
NR 43
TC 71
Z9 76
U1 0
U2 6
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1876-0341
EI 1876-035X
J9 J INFECT PUBLIC HEAL
JI J. Infect. Public Health
PD JAN-FEB
PY 2015
VL 8
IS 1
BP 1
EP 10
DI 10.1016/j.jiph.2014.08.003
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CI7SH
UT WOS:000354964400001
PM 25294086
OA Bronze
DA 2020-10-30
ER

PT J
AU de Albuquerque, CLF
   Costa, MD
   Nunes, FM
   de Freitas, RWF
   de Azevedo, PRM
   Fernandes, JV
   Rego, JV
   Barreto, HM
AF Ferreira de Albuquerque, Carla Lorenna
   Costa, Marla da Paschoa
   Nunes, Felipe Moreira
   Junior Freire de Freitas, Roberto Wagner
   Medeiros de Azevedo, Paulo Roberto
   Fernandes, Jose Verissimo
   Rego, Juciane Vaz
   Barreto, Humberto Medeiros
TI Knowledge, attitudes and practices regarding the Pap test among women in
   northeastern Brazil
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE Papillomavirus infections; Uterine cervical neoplasms; Vaginal smears;
   Women's health; Socioeconomic factors
ID HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; SMEAR; GENOTYPES; VACCINES; SOUTH
AB CONTEXT AND OBJECTIVE: The Papanicolaou (Pap) test has been shown to be effective in preventing cervical cancer. However, both the national and international literature shows that Pap testing has not reached the level of coverage desired. The objective of this study was to assess women's knowledge, attitudes and practices regarding the Pap test and to investigate whether there are any associations between these three factors and the women's sociodemographic characteristics.
   DESIGN AND SETTING: Cross-sectional descriptive study conducted in Floriano, Piaui.
   METHODS: The study was conducted among 493 women between November 2009 and December 2010. A questionnaire with precoded questions was used, and the responses were analyzed in terms of appropriateness in relation to the Pap test.
   RESULTS: The degrees of adequacy of knowledge, attitudes and practices regarding the Pap test were 36.7%, 67.2% and 69.6%, respectively. Among the main barriers against testing, absence of symptoms and a sense of embarrassment were the most notable.
   CONCLUSIONS: Women who visit doctors periodically had the most appropriate practices regarding the Pap test, but their knowledge of the procedure was poor. This suggests that these women were not receiving adequate information about the benefits of periodic testing.
C1 [Ferreira de Albuquerque, Carla Lorenna; Costa, Marla da Paschoa; Nunes, Felipe Moreira; Junior Freire de Freitas, Roberto Wagner; Medeiros de Azevedo, Paulo Roberto; Fernandes, Jose Verissimo; Rego, Juciane Vaz; Barreto, Humberto Medeiros] Univ Fed Piaui UFPI, Teresina, Piaui, Brazil.
RP Barreto, HM (corresponding author), BR 343,KM 3,5, BR-64800000 Floriano, PI, Brazil.
EM hmbarreto@ufpi.edu.br
RI Freitas, Roberto/AAQ-7055-2020; Barreto, Humberto Medeiros/E-5699-2013;
   Barreto, Humberto Medeiros/AAZ-6031-2020
OI Barreto, Humberto Medeiros/0000-0001-5054-7555; Barreto, Humberto
   Medeiros/0000-0001-5054-7555; Freitas, Roberto/0000-0001-9295-1177;
   Fernandes, Jose Verissimo/0000-0002-5169-6496
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Piaui (FAPEPI) [PPSUS
   EFP-2329/2009]; Universidade Federal do Piau (UFPI)
FX Financial support was provided by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq, Fundacao de Amparo a Pesquisa do Estado
   do Piaui (FAPEPI; Projeto PPSUS EFP-2329/2009) and Universidade Federal
   do Piau (UFPI)
CR Amorim Vivian Mae Schmidt Lima, 2006, Cad. Saúde Pública, V22, P2329, DOI 10.1590/S0102-311X2006001100007
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   da Silva Jose Alencar Gomes, 2011, EST 2012 INC CANC BR
   de Quadros CAT, 2004, REV PANAM SALUD PUBL, V16, P223, DOI 10.1590/S1020-49892004001000001
   Entiauspe LG, 2010, REV SOC BRAS MED TRO, V43, P260, DOI 10.1590/S0037-86822010000300009
   Fernandes JV, 2009, REV SAUDE PUBL, V43, P851, DOI 10.1590/s0034-89102009005000055
   Gamarra CJ, 2005, REV SAUDE PUBL, V39, P270, DOI [10.1590/S0034-89102005000200019, 10.1590/s0034-89102005000200019]
   Greenwood Suzana de Azevedo, 2006, Rev. Latino-Am. Enfermagem, V14, P503, DOI 10.1590/S0104-11692006000400006
   Hackenhaar Arnildo A., 2006, Rev. bras. epidemiol., V9, P103, DOI 10.1590/S1415-790X2006000100013
   Lartey M, 2003, INT J GYNECOL OBSTET, V83, P315, DOI 10.1016/S0020-7292(03)00295-9
   Martins LFL, 2005, REV BRAS GINECOL OBS, V27, P485, DOI 10.1590/S0100-72032005000800009
   Muller DK, 2008, CAD SAUDE PUBLICA, V24, P2511, DOI 10.1590/S0102-311X2008001100006
   Munoz M, 2006, VACCINE S3, V24, pS3/1
   Oliveira Márcia Maria Hiluy Nicolau de, 2006, Rev. bras. epidemiol., V9, P325, DOI 10.1590/S1415-790X2006000300007
   Pinho Adriana de Araujo, 2003, Rev. Bras. Saude Mater. Infant., V3, P95, DOI 10.1590/S1519-38292003000100012
   Racho D, 2007, REV BRAS ANAL CLIN, V39, P259
   Ramos Aline da Silveira, 2006, Rev. Latino-Am. Enfermagem, V14, P170, DOI 10.1590/S0104-11692006000200004
   Oliveira LHS, 2010, REV SOC BRAS MED TRO, V43, P4, DOI 10.1590/S0037-86822010000100002
   Steenbergen RDM, 2005, J CLIN VIROL, V32, pS25, DOI 10.1016/j.jcv.2004.11.019
   Szwarcwald CL, 2004, RADIS, V23, P14
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Villa LL, 2006, VACCINE, V24, P23, DOI 10.1016/j.vaccine.2005.09.001
   Villa LL, 2003, SALUD PUBLICA MEXICO, V45, pS443
   Von Zuben MV, 2007, SAO PAULO MED J, V125, P42, DOI 10.1590/S1516-31802007000100008
NR 24
TC 3
Z9 3
U1 0
U2 7
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PY 2014
VL 132
IS 1
BP 3
EP 9
DI 10.1590/1516-3180.2014.1321551
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA1JV
UT WOS:000330853400002
PM 24474073
OA DOAJ Gold, Green Published
DA 2020-10-30
ER

PT J
AU Pereira, VSS
   Moizeis, RNC
   Fernandes, TAAM
   Araujo, JMG
   Meissner, RV
   Fernandes, JV
AF Pereira, Valeska S. S.
   Moizeis, Raiza N. C.
   Fernandes, Thales A. A. M.
   Araujo, Joselio M. G.
   Meissner, Rosely V.
   Fernandes, Jose V.
TI Herpes simplex virus type 1 is the main cause of genital herpes in women
   of Natal, Brazil
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Herpes simplex virus; Genital herpes; Sexually transmitted diseases
ID ANOGENITAL HERPES; EPIDEMIOLOGY; HSV-1
AB Objectives: The purpose of this study was to assess the prevalence of HSV-1 and HSV-2 in sexually active women who participated in the cervical cancer screening program in Natal, Brazil.
   Study design: The study included 261 sexually active women resident in the metropolitan area of Natal, Brazil and attending a public clinic for cervical screening. From each participant, a sample of exfoliated uterine cervical cells was collected, using a cytobrush which was conditioned in a tube containing a preserving solution (PBS + vancomycin + nystatin) and sent to a laboratory where it was processed for DNA extraction. The samples were analyzed for the presence of HSV-1 and HSV-2 DNA in separate reactions by PCRs using specific primers.
   Results: HSV-1 in genital infection is four times more prevalent than HSV-2 in the population analyzed. The highest prevalence rates for both viruses were found in women aged 31-39 years. We did not observe any association between the presence of both virus serotypes and socio-demographic characteristics in the population studied, nor with some classical risk factors for sexually transmitted diseases.
   Conclusions: HSV-1 was the major cause of genital infection by Herpes simplex virus in the women included in this study. No association was found between HSV infection and the socio-demographic characteristics or some classical risk factors for sexually transmitted diseases. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Fernandes, Jose V.] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, BR-59072970 Natal, RN, Brazil.
   [Pereira, Valeska S. S.; Araujo, Joselio M. G.; Fernandes, Jose V.] Univ Fed Rio Grande do Norte, Postgrad Program Biol Sci, BR-59072970 Natal, RN, Brazil.
   [Fernandes, Thales A. A. M.] Univ Rio Grande Norte State, Dept Biomed Sci, Mossoro, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, Av Sen Salgado Filho S-N,Campus Univ, BR-59072970 Natal, RN, Brazil.
EM veris@cb.ufrn.br
RI Araujo, Joselio M G/B-5502-2013; Fernandes, Thales/F-4813-2010
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes,
   Thales/0000-0003-4559-8918; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
CR Beydoun HA, 2010, INT J INFECT DIS, V14, pE154, DOI 10.1016/j.ijid.2009.12.007
   Buxbaum S, 2003, MED MICROBIOL IMMUN, V192, P177, DOI 10.1007/s00430-003-0183-0
   Clemens SAC, 2010, REV SAUDE PUBL, V44, P726, DOI 10.1590/s0034-89102010000400017
   Cowan FM, 2003, SEX TRANSM INFECT, V79, P286, DOI 10.1136/sti.79.4.286
   DaRosaSantos OL, 1996, INT J DERMATOL, V35, P794
   Forward Kevin R, 2003, Can J Infect Dis, V14, P94
   Gonzalez-Villasenor LI, 1999, MOL CELL PROBE, V13, P309, DOI 10.1006/mcpr.1999.0253
   Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284
   Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4
   Haddow LJ, 2006, SEX TRANSM INFECT, V82, P255, DOI 10.1136/sti.2005.018176
   Halioua B, 1999, EUR J DERMATOL, V9, P177
   Lafetty WE, 2000, J INFECT DIS, V181, P1454
   LUCOTTE G, 1995, MOL CELL PROBE, V9, P287, DOI 10.1016/S0890-8508(95)91508-7
   Manavi K, 2004, SEX TRANSM DIS, V31, P322, DOI 10.1097/01.OLQ.0000123652.88904.9B
   Mertz GJ, 2003, SEX TRANSM DIS, V30, P801, DOI 10.1097/01.OLQ.0000093080.55201.D1
   Nieuwenhuis RF, 2006, ACTA DERM-VENEREOL, V86, P129, DOI 10.2340/00015555-0029
   Passos MRL, 2002, J BRAS DOENCAS SEX T, V14, P3
   Pena KC, 2010, J CLIN MICROBIOL, V48, P150, DOI 10.1128/JCM.01336-09
   Penello AM, 2010, J BRAS DOENCAS SEX T, V22, P64
   Roberts CM, 2003, SEX TRANSM DIS, V30, P797, DOI 10.1097/01.OLQ.0000092387.58746.C7
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Sambrook J, 2001, MOL CLONING LAB MANU
   Samra Z, 2003, SEX TRANSM DIS, V30, P794, DOI 10.1097/01.OLQ.0000079517.04451.79
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Tideman RL, 2001, SEX TRANSM INFECT, V77, P413, DOI 10.1136/sti.77.6.413
   Turner CF, 2009, INT J EPIDEMIOL, V38, P1118, DOI 10.1093/ije/dyp210
   Wald A, 2003, J INFECT DIS, V188, P1345, DOI 10.1086/379043
NR 27
TC 25
Z9 27
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD APR
PY 2012
VL 161
IS 2
BP 190
EP 193
DI 10.1016/j.ejogrb.2011.12.006
PG 4
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 925MN
UT WOS:000302765400014
PM 22424592
DA 2020-10-30
ER

PT J
AU Fernandes, JV
   Meissner, RD
   Carvalho, MGF
   Fernandes, TAAD
   Azevedo, PRM
   De Azevedo, JWV
   De Araujo, JMG
AF Fernandes, Jose Verissimo
   Meissner, Rosely De Vasconcellos
   Freire Carvalho, Maria Goretti
   Araujo De Medeiros Fernandes, Thales Allyrio
   Medeiros Azevedo, Paulo Roberto
   Verissimo De Azevedo, Judson Weber
   Galvao De Araujo, Joselio Maria
TI Human papillomavirus prevalence in women with normal cytology and with
   cervical cancer in Natal, Brazil
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE human papillomavirus; uterine cervical cancer; risk factors
ID NATURAL-HISTORY; RISK-FACTORS; HPV; INFECTION; NEOPLASIA; AGE;
   EPIDEMIOLOGY; VACCINES; BIOLOGY
AB This study analyzed the prevalence of human papillomavirus (HPV) in cervical specimens obtained from women with normal cytology and with cervical cancer, in order to evaluate their correlation with health status and demographic characteristics, as well as sexual and reproductive activity in women treated at a cancer reference hospital in Natal, Northeast Brazil. A total of 158 women were divided into 2 groups according to their health status: group I comprised 110 women with normal cytology, and group II comprised 48 women with cervical cancer. Cervical smears were analyzed by cytological or histopathological examination for the detection of cytological alterations, and by PCR for HPV DNA detection using MY09/11 primers, followed by HPV genotyping by dot blot hybridization. Results showed overall HPV prevalence to be 24.5% in group I, with 19.1% of patients having single infection and 5.4% double infection. The HPV prevalence in group II was 85.4%, with 79.2% of patients having single and 6.2% double infection. We identified 10 different HPV genotypes, roost with high oncogenic potential. HPV 16 was the most prevalent genotype in the two studied groups, followed by HPV 58 and HPV 18. High-risk HPV genital infection, chronological age, ethnicity, early onset of sexual and reproductive activities, multiple sexual partners and smoking increased the risk for cervical cancer.
C1 [Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Freire Carvalho, Maria Goretti] Univ Fed Rio Grande do Norte, Dept Pathol, BR-59072970 Natal, RN, Brazil.
   [Araujo De Medeiros Fernandes, Thales Allyrio] Univ Rio Grande Norte State, Dept Biomed Sci, Mossoro, Brazil.
   [Medeiros Azevedo, Paulo Roberto] Univ Fed Rio Grande do Norte, Dept Stat, BR-59072970 Natal, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Microbiol & Parasitol, Av Sen Selgado Filho S-N,Campus Univ, BR-59072970 Natal, RN, Brazil.
EM veris@cb.ufrn.br
RI Fernandes, Thales/F-4813-2010; Araujo, Joselio M G/B-5502-2013
OI Fernandes, Thales/0000-0003-4559-8918; Araujo, Joselio M
   G/0000-0003-3548-2786; Fernandes, Jose Verissimo/0000-0002-5169-6496
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES
FX The authors would like to thank CNPq and CAPES for their financial
   support and the Ludwig Institute for Cancer Research Sao Paulo Branch,
   for its technical support.
CR Almonte M, 2008, VACCINE, V26, pL16, DOI 10.1016/j.vaccine.2008.06.008
   Ault KA, 2007, GYNECOL ONCOL, V107, pS31, DOI 10.1016/j.ygyno.2007.08.059
   BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   *CDC DEP HLTH HUM, PREV GEN HUM PAP INF
   Chan PKS, 2010, INT J CANCER, V126, P297, DOI 10.1002/ijc.24731
   Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Herrero R, 2005, J INFECT DIS, V191, P1796, DOI 10.1086/428850
   JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Louie KS, 2009, BRIT J CANCER, V100, P1191, DOI 10.1038/sj.bjc.6604974
   MANOS MM, 1989, CANCER CEL, V7, P209
   Moscicki AB, 2008, J ADOLESCENT HEALTH, V43, pS1, DOI 10.1016/j.jadohealth.2008.07.008
   Moscicki AB, 2006, VACCINE, V24, P42, DOI 10.1016/j.vaccine.2006.06.018
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Nonnenmacher B, 2002, REV SAUDE PUBL, V36, P95, DOI [10.1590/S0034-89102002000100015, 10.1590/s0034-89102002000100015]
   Noronha V, 1999, Rev Soc Bras Med Trop, V32, P235, DOI 10.1590/S0037-86821999000300003
   Rabelo-Santos SH, 2003, MEM I OSWALDO CRUZ, V98, P181, DOI 10.1590/S0074-02762003000200003
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Sambrook J, 2001, MOL CLONING LAB MANU
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C
   SHERMAN ME, 1992, ARCH PATHOL LAB MED, V116, P1155
   Sichero L, 2007, INT J CANCER, V120, P1763, DOI 10.1002/ijc.22481
   Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Villa LL, 2003, SALUD PUBLICA MEXICO, V45, pS443
   Weaver BA, 2006, J AM OSTEOPATH ASSOC, V106, pS2
NR 29
TC 9
Z9 10
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV-DEC
PY 2011
VL 4
IS 6
BP 1321
EP 1326
DI 10.3892/mmr.2011.579
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 826XR
UT WOS:000295389400045
PM 21887467
OA Bronze
DA 2020-10-30
ER

PT J
AU Fernandes, JV
   Rodrigues, SHL
   da Costa, YGAS
   da Silva, LCM
   de Brito, AML
   de Azevedo, JWV
   do Nascimento, ED
   de Azevedo, PRM
   Fernandes, TAAD
AF Fernandes, Jose Verissimo
   Lacerda Rodrigues, Silvia Helena
   Alexandre Silva da Costa, Yuri Guilherme
   Moura da Silva, Luiz Claudio
   Lima de Brito, Alipio Maciel
   Verissimo de Azevedo, Judson Welber
   do Nascimento, Ermeton Duarte
   Medeiros de Azevedo, Paulo Roberto
   Araujo de Medeiros Fernandes, Thales Allyrio
TI Knowledge, attitudes, and practices related to Pap test by women,
   Northeastern Brazil
SO REVISTA DE SAUDE PUBLICA
LA Portuguese
DT Article
DE Cervix Neoplasms Prevention; Vaginal Smears; Health Knowledge,
   Attitudes, Practice; Socioeconomic Factors; Women's Health;
   Cross-Sectional Studies
ID CERVICAL-CANCER; HUMAN-PAPILLOMAVIRUS; SMEAR
AB OBJECTIVE: To assess the knowledge, attitudes and practices of women related to the Pap test and the association between these behaviors and sociodemographic characteristics.
   METHODS: A household survey with quantitative approach was conducted. A total of 267 women aged 15 to 69 years, randomly selected in a stratified manner, living in the city of Sao Jose de Mipibu, Northeastern Brazil, were interviewed in 2007. A questionnaire consisting of pre-coded open questions was administered and answers were described and analyzed, as for adequacy of knowledge, attitudes, and practices of women regarding the Pap test. Tests of association were carried out between sociodemographic characteristics and behaviors studied at a 5% significance level.
   RESULTS: Although 46.1% of the women interviewed showed adequate knowledge about the Pap test, a significantly higher proportion of adequacy was seen regarding attitudes and practices, 63.3% and 64.4%, respectively. Higher schooling was associated with adequacy of knowledge, attitudes, and practices. The main barriers to the Pap test were negligence, non-requesting by their physicians, and shame.
   CONCLUSIONS: The physician is the main source of information about the Pap test. However, women who more often attend medical visits, despite their good practice, show low adequacy of knowledge and attitudes related to the Pap test, which indicates that they are not receiving appropriate information on the test's purpose, advantages and benefits to women's health.
C1 [Fernandes, Jose Verissimo; Lacerda Rodrigues, Silvia Helena; Alexandre Silva da Costa, Yuri Guilherme; Moura da Silva, Luiz Claudio; Lima de Brito, Alipio Maciel; Verissimo de Azevedo, Judson Welber; do Nascimento, Ermeton Duarte] Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Medeiros de Azevedo, Paulo Roberto] Univ Fed Rio Grande do Norte, Ctr Ciencias Exatas & Terra, Dept Estatist, BR-59072970 Natal, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Estado Rio Grande do Norte, Fac Ciencias Saude, Dept Ciencias Biomed, Mossoro, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Microbiol & Parasitol, Av Sen Salgado Filho S-N, BR-59072970 Natal, RN, Brazil.
EM veris@cb.ufrn.br
RI Fernandes, Thales/F-4813-2010
OI Fernandes, Thales/0000-0003-4559-8918; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
CR Amorim Vivian Mae Schmidt Lima, 2006, Cad. Saúde Pública, V22, P2329, DOI 10.1590/S0102-311X2006001100007
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Brenna S M, 2001, Cad Saude Publica, V17, P909, DOI 10.1590/S0102-311X2001000400024
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Gamarra CJ, 2005, REV SAUDE PUBL, V39, P270, DOI [10.1590/S0034-89102005000200019, 10.1590/s0034-89102005000200019]
   Greenwood Suzana de Azevedo, 2006, Rev. Latino-Am. Enfermagem, V14, P503, DOI 10.1590/S0104-11692006000400006
   Hackenhaar Arnildo A., 2006, Rev. bras. epidemiol., V9, P103, DOI 10.1590/S1415-790X2006000100013
   HERRERO R, 1992, INT J EPIDEMIOL, V21, P1050, DOI 10.1093/ije/21.6.1050
   Kahn JA, 2000, OBSTET GYNECOL, V96, P625, DOI 10.1016/S0029-7844(00)00987-X
   Lartey M, 2003, INT J GYNECOL OBSTET, V83, P315, DOI 10.1016/S0020-7292(03)00295-9
   Martins LFL, 2005, REV BRAS GINECOL OBS, V27, P485, DOI 10.1590/S0100-72032005000800009
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Oliveira Márcia Maria Hiluy Nicolau de, 2006, Rev. bras. epidemiol., V9, P325, DOI 10.1590/S1415-790X2006000300007
   Pinho Adriana de Araujo, 2003, Rev. Bras. Saude Mater. Infant., V3, P95, DOI 10.1590/S1519-38292003000100012
   RACHO D, 2007, REV BRAS ANAL CLIN, V39, P59
   Ramos Aline da Silveira, 2006, Rev. Latino-Am. Enfermagem, V14, P170, DOI 10.1590/S0104-11692006000200004
   Steenbergen RDM, 2005, J CLIN VIROL, V32, pS25, DOI 10.1016/j.jcv.2004.11.019
   Szwarcwald CL, 2004, RADIS, V23, P14
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Villa LL, 2006, VACCINE, V24, P23, DOI 10.1016/j.vaccine.2005.09.001
   Villechaise-Dupont A, 2003, SOCIOL TRAV, V45, P443, DOI 10.1016/S0038-0296(03)00042-6
   *WHO, 1988, CYT SCREEN CONTR CER
NR 22
TC 21
Z9 26
U1 0
U2 2
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD OCT
PY 2009
VL 43
IS 5
BP 851
EP 858
DI 10.1590/S0034-89102009005000055
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 510TC
UT WOS:000271113900015
PM 19768236
OA DOAJ Gold
DA 2020-10-30
ER

PT J
AU Fernandes, JV
   Meissner, RD
   de Carvalho, MGF
   Fernandes, TAAD
   de Azevedo, PRM
   Villa, LL
AF Fernandes, Jose Verissimo
   Meissner, Rosely de Vasconcellos
   Freire de Carvalho, Maria Goretti
   Araujo de Medeiros Fernandes, Thales Allyrio
   Medeiros de Azevedo, Paulo Roberto
   Villa, Luisa Lina
TI Prevalence of HPV infection by cervical cytologic status in Brazil
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Cervical lesions; Human papillomavirus; Polymerase chain reaction; Risk
   factors
ID HUMAN-PAPILLOMAVIRUS INFECTION; HISTOLOGICAL ABNORMALITIES; GENOTYPE
   DISTRIBUTION; RISK-FACTORS; YOUNG-WOMEN; CANCER; NEOPLASIA; PERSISTENCE;
   SEQUENCES; LESIONS
AB Objectives: To assess the prevalence Of human papillomavirus (HPV) infection according to cervical cytologic status in northeastern Brazil: identify other risk factors for low- and high-grade squamous intraepithelial lesions (LSILs and HSILs); and identify the most prevalent HPV genotypes associated with the lesions. Method: Two cervical smears were collected from 250 women referred for cancer screening, one for cytologic examination and the other to test for the presence of HPV by PCR with genotyping by clot blot hybridization. Result: There were 110 healthy cervices, 82 LSILs, and 58 HSILs. The overall HPV prevalence was 48%, with higher rates for HSILs, and HPV-16 was the most prevalent type. Age. multiple sexual partners, type of HPV present, smoking, and early onset Of Sexual activity were risk factors for cervical lesions. Conclusion: Age, multiple sexual partners, and infection with HPV-16 increased the risk of having LSILs or HSILs. Early onset of sexual activity and smoking only increased the risk of having HSILs. (C) 2008 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, BR-59072970 Natal, RN, Brazil.
   [Freire de Carvalho, Maria Goretti] Univ Fed Rio Grande do Norte, Dept Pathol, BR-59072970 Natal, RN, Brazil.
   [Araujo de Medeiros Fernandes, Thales Allyrio] Univ Estado Rio Grande do Norte, Dept Biomed Sci, Mossoro, RN, Brazil.
   [Medeiros de Azevedo, Paulo Roberto] Univ Fed Rio Grande do Norte, Dept Stat, BR-59072970 Natal, RN, Brazil.
   [Villa, Luisa Lina] Hosp Alemao Oswaldo Cruz, Ludwig Inst Canc Res, Sao Paulo, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, Av Sen Salgado Filho S-N,Campus Univ, BR-59072970 Natal, RN, Brazil.
EM veris@cb.ufrn.br
RI Fernandes, Thales/F-4813-2010; VILLA, LUISA/AAH-4761-2019
OI Fernandes, Thales/0000-0003-4559-8918; VILLA, LUISA/0000-0003-4074-2335;
   Fernandes, Jose Verissimo/0000-0002-5169-6496
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (National
   Council of Scientific and Technological Development [CNPq])National
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (Coordination of
   Improvement of Higher Education [CAPES])CAPES
FX This Study was supported by funds from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (National Council of Scientific
   and Technological Development [CNPq]) and the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (Coordination of
   Improvement of Higher Education [CAPES]).
CR Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
   Camara GNL, 2003, MEM I OSWALDO CRUZ, V98, P879, DOI 10.1590/S0074-02762003000700003
   CASTELLSAGUE X, 2003, J NATL CANC I MONOGR, P29
   Castle PE, 2005, J INFECT DIS, V191, P1808, DOI 10.1086/428779
   Clifford GM, 2005, CANCER EPIDEM BIOMAR, V14, P1157, DOI 10.1158/1055-9965.EPI-04-0812
   Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   De Villiers EM, 2004, INT J CANCER, V109, P253, DOI 10.1002/ijc.11685
   Derchain SF, 2008, J MED SCREEN, V15, P97, DOI 10.1258/jms.2008.007061
   Doorbar J, 2005, J CLIN VIROL, V32, pS7, DOI 10.1016/j.jcv.2004.12.006
   Frega A, 2003, CANCER LETT, V196, P127, DOI 10.1016/S0304-3835(03)00218-0
   Gontijo RC, 2007, EUR J OBSTET GYN R B, V133, P239, DOI 10.1016/j.ejogrb.2006.05.012
   JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Manhart LE, 2006, SEX TRANSM DIS, V33, P502, DOI 10.1097/01.olq.0000204545.89516.0a
   MANOS MM, 1989, CANCER CEL, V7, P209
   Nonnenmacher B, 2002, REV SAUDE PUBL, V36, P95, DOI [10.1590/S0034-89102002000100015, 10.1590/s0034-89102002000100015]
   Rama C, 2008, REV SAUDE PUBL, V42, P411, DOI 10.1590/S0034-89102008000300004
   Revzina NV, 2005, INT J STD AIDS, V16, P528, DOI 10.1258/0956462054679214
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   SAMBROOK J, 2001, MOL CLONING, V6, P28
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Trottier H, 2006, CANCER EPIDEM BIOMAR, V15, P1274, DOI 10.1158/1055-9965.EPI-06-0129
   Villechaise-Dupont A, 2003, SOCIOL TRAV, V45, P443, DOI 10.1016/S0038-0296(03)00042-6
NR 25
TC 26
Z9 29
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD APR
PY 2009
VL 105
IS 1
BP 21
EP 24
DI 10.1016/j.ijgo.2008.12.004
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 434XR
UT WOS:000265308100007
PM 19150057
DA 2020-10-30
ER

PT J
AU Fernandes, TAADM
   Meissner, RD
   Bezerra, LF
   de Azevedo, PRM
   Fernandes, JV
AF de Medeiros Fernandes, Thales Allyrio Araujo
   Meissner, Rosely de Vasconcellos
   Bezerra, Laelson Freire
   Medeiros de Azevedo, Paulo Roberto
   Fernandes, Jose Verissimo
TI HUMAN PAPILLOMAVIRUS INFECTION IN WOMEN ATTENDED AT A CERVICAL CANCER
   SCREENING SERVICE IN NATAL, BRAZIL
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Human papillomavirus; Cervical cancer; Epidemiology; Prevalence; Risk
   factors
ID INTRAEPITHELIAL NEOPLASIA; YOUNG-WOMEN; PREVALENCE; RISK; AGE;
   PERSISTENCE; LESIONS
AB We analyzed cervical specimens of 202 women, aged 15 to 64 years, attended at Luis Antonio Hospital, Natal, Brazil, to determine the prevalence of HPV and identify the more frequent genotypes and risk factors for HPV infection in women attended at a cervical cancer screening service. Two specimens were collected from each patient: one for cytological examination and the other to detect HPV DNA by PCR, and typing by dot blot hybridization. A total of 54.5% of the sample had normal cytology and 45.5% had cytological alterations. HPV was detected in 24.5% of the cytologically normal women and in 59.8% of those with altered cytology. Both single and double HPV infection increased the likelihood of cytological alterations. Thirteen types of HPV were identified, most of which were high risk. HPV 16 was the most prevalent single-type infection, followed by HPV 58. The most frequent double infection was the association between HPV 56 and 57. The prevalence of HPV in cytologically normal women was greater than that reported for countries on all the continents except Africa. The inverse was observed in women with cytological alterations. The distribution of HPV types was similar to that described for the Americas, with some differences. Multiple sexual partners was the only risk factor showing an association with the presence of HPV infection.
C1 [Meissner, Rosely de Vasconcellos; Fernandes, Jose Verissimo] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, BR-59072970 Natal, RN, Brazil.
   [de Medeiros Fernandes, Thales Allyrio Araujo] Univ Estado Rio Grande do Norte, Dept Ciencias Biomed, Mossoro, RN, Brazil.
   [Bezerra, Laelson Freire] Hosp Luiz Antonio, Natal, RN, Brazil.
   [Medeiros de Azevedo, Paulo Roberto] Univ Fed Rio Grande do Norte, Dept Estat, BR-59072970 Natal, RN, Brazil.
RP Fernandes, JV (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, Campus Univ, BR-59072970 Natal, RN, Brazil.
RI Fernandes, Thales/F-4813-2010
OI Fernandes, Thales/0000-0003-4559-8918; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
FU CNPqNational Council for Scientific and Technological Development (CNPq)
FX To Dr. Luisa Lima Villa and her team at Sao Paulo Branch of the Ludwig
   Institute for Cancer Research, Brazil, for the technical-scientific
   assistance provided and for performing viral typing, and to CNPq for the
   financial support.
CR Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008
   Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Camara GNL, 2003, MEM I OSWALDO CRUZ, V98, P879, DOI 10.1590/S0074-02762003000700003
   Castle PE, 2005, J INFECT DIS, V191, P1808, DOI 10.1086/428779
   Clifford GM, 2005, CANCER EPIDEM BIOMAR, V14, P1157, DOI 10.1158/1055-9965.EPI-04-0812
   Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9
   CLIFFORD GM, 2003, VACCINE S3, V24, pS26
   da Silva TT, 2006, REV BRAS GINECOL OBS, V28, P285, DOI 10.1590/S0100-72032006000500004
   Ferreccio C, 2004, CANCER EPIDEM BIOMAR, V13, P2271
   Frega A, 2003, CANCER LETT, V196, P127, DOI 10.1016/S0304-3835(03)00218-0
   GAHLINGER PM, 1995, COMPUTER PROGRAMS EP
   Herrero R, 2000, JNCI-J NATL CANCER I, V92, P464, DOI 10.1093/jnci/92.6.464
   JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995
   Kjaer SK, 2000, SEX TRANSM DIS, V27, P438, DOI 10.1097/00007435-200009000-00003
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   MANOS MM, 1989, CANCER CEL, V7, P209
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Naud P, 2006, EUR J OBSTET GYN R B, V124, P110, DOI 10.1016/j.ejogrb.2005.02.001
   Rabelo-Santos SH, 2003, MEM I OSWALDO CRUZ, V98, P181, DOI 10.1590/S0074-02762003000200003
   Ronco G, 2005, EUR J CANCER, V41, P297, DOI 10.1016/j.ejca.2004.07.005
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Sambrook J, 2001, MOL CLONING LAB MANU
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Trottier H, 2006, CANCER EPIDEM BIOMAR, V15, P1274, DOI 10.1158/1055-9965.EPI-06-0129
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
NR 26
TC 18
Z9 18
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD JUL-SEP
PY 2008
VL 39
IS 3
BP 573
EP 578
DI 10.1590/S1517-83822008000300031
PG 6
WC Microbiology
SC Microbiology
GA 359IY
UT WOS:000259981200031
PM 24031268
OA DOAJ Gold, Green Published
DA 2020-10-30
ER

PT J
AU Fernandes, TAAM
   Lima, GLF
   De Souza, FCG
   Fernandes, JV
   Meissner, RV
AF Fernandes, T. A. A. M.
   Lima, G. L. F.
   De Souza, F. C. G.
   Fernandes, J. V.
   Meissner, R. V.
TI EVALUATION OF THE POLYMORPHISMS IN THE EXONS 2 TO 4 OF THE TP53 IN
   CERVICAL CARCINOMA PATIENTS FROM A BRAZILIAN POPULATION
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE cervical cancer; TP53 gene; polymorphisms
ID HUMAN-PAPILLOMAVIRUS; CODON 72; P53 POLYMORPHISM; CANCER; HAPLOTYPES;
   VARIANTS; NEOPLASIA; INFECTION; GENOTYPES; RISK
AB The majority of TP53 polymorphisms and cervical cancer association studies have only analyzed codon 72 polymorphism. Eight polymorphisms were reported in the region encompassing exon 2 to 4 of TP53 that codify the aminoterminal p53 region containing domains involved in the transcription transactivation and apoptosis induction. We investigated if the polymorphisms present in this region were associated with cervical cancer risk. A total of 140 samples (83 from Brazilian patients with cervical carcinoma and 57 from Brazilian healthy women) were analyzed by PCR and DNA sequencing. Only three from the eight TP53 polymorphisms described in the analyzed region were polymorphic within our samples: the 11827 base from intron 2, the 16bp duplication in the intron3 and the codon 72 (Arg>Pro) from exon 4. No statistically significant association was observed between polymorphisms from intron 2 and the 16bp duplication from intron 3 with cervical cancer. No statistically significant difference in the frequency of homozygotes for Arg in relation to other genotypes was found when comparing patient and healthy groups (OR-0.70; 95% CI=0.31-1.56 p=0.222). However, Arg/Pro heterozygotes were more frequent within HPV positive cancer patients than in healthy women (p=0.023; OR (Arg/Pro:Pro/Pro)=5.82; 95% CI: 1.22-30.78; p=0.024).
C1 [Fernandes, J. V.; Meissner, R. V.] Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Fernandes, T. A. A. M.; Lima, G. L. F.; De Souza, F. C. G.; Meissner, R. V.] Univ Fed Rio Grande do Norte, Ctr Biociencias, Programa Posgrad Genet & Biol Mol, BR-59072970 Natal, RN, Brazil.
RP Meissner, RV (corresponding author), Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Microbiol & Parasitol, Av Salgado Filho S-N,Campus Univ, BR-59072970 Natal, RN, Brazil.
EM vmrosely@yahoo.com.br
CR Abramson Joseph H, 2004, Epidemiol Perspect Innov, V1, P6, DOI 10.1186/1742-5573-1-6
   BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Calhoun ES, 2002, CLIN CHEM, V48, P1218
   Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093
   FELIX CA, 1994, ONCOGENE, V9, P327
   FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752
   Gaspar PA, 2001, ANN HUM BIOL, V28, P184
   Ge H, 1996, INT J CANCER, V69, P120, DOI 10.1002/(SICI)1097-0215(19960422)69:2<120::AID-IJC9>3.0.CO;2-2
   HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0
   IARC, 1995, IARC MON EV CARC RIS
   Josefsson AM, 1998, NATURE, V396, P531, DOI 10.1038/25037
   Kim JW, 2000, CANCER-AM CANCER SOC, V88, P2082, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2082::AID-CNCR14>3.0.CO;2-D
   Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009
   Koushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11, DOI 10.1158/1055-9965.EPI-083-3
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   LAZAR V, 1993, ONCOGENE, V8, P1703
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Makni H, 2000, INT J CANCER, V87, P528, DOI 10.1002/1097-0215(20000815)87:4&lt;528::AID-IJC11&gt;3.0.CO;2-O
   Malcolm EK, 2000, MODERN PATHOL, V13, P373, DOI 10.1038/modpathol.3880061
   MANOS MM, 1989, CANCER CEL, V7, P209
   Mitra S, 2005, J CLIN PATHOL, V58, P26, DOI 10.1136/jcp.2004.019315
   Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263
   Sambrook J, 2001, MOL CLONING LAB MANU
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Shamsher M, 1996, GENE, V176, P259, DOI 10.1016/0378-1119(96)00000-5
   Sjalander A, 1996, HUM HERED, V46, P41, DOI 10.1159/000154324
   Storey A, 1998, NATURE, V393, P229
   Thomas M, 1999, MOL CELL BIOL, V19, P1092
   UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x
   van Duin M, 2000, J GEN VIROL, V81, P317, DOI 10.1099/0022-1317-81-2-317
   Vos M, 2003, CANCER GENET CYTOGEN, V140, P23, DOI 10.1016/S0165-4608(02)00638-6
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 37
TC 4
Z9 4
U1 0
U2 0
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2008
VL 54
SU S
BP 1025
EP 1031
DI 10.1170/116
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 460PN
UT WOS:000267199700001
DA 2020-10-30
ER

PT J
AU Meissner, RD
   Barbosa, RNF
   Fernandes, JV
   Galvao, TM
   Galvao, AFO
   Oliveira, GHD
AF Meissner, Rosely de Vasconcellos
   Ferreira Barbosa, Rodrigo Niskier
   Fernandes, Jose Verissimo
   Galvao, Tatiana Medeiros
   Oliveira Galvao, Ana Flavia
   de Medeiros Oliveira, Gustavo Henrique
TI No association between SNP309 promoter polymorphism in the MDM2 and
   cervical cancer in a study from northeastern Brazil
SO CANCER DETECTION AND PREVENTION
LA English
DT Article
DE cervical cancer; MDM2 promoter polymorphism; SNP309; cancer risk factor;
   primer-introduced restriction analysis (PIRA) PCR; HPV; DNA
   polymorphism; cervix carcinoma; MDM2 gene; Brazilian population
ID HUMAN-PAPILLOMAVIRUS; RISK; DEGRADATION; BREAST
AB Background: A functional variant in the MDM2 promoter (a T/G substitution, SNP309) was found to be associated with increased expression of MDM2 gene products and at significantly earlier age onset of tumors in both hereditary Li-Fraumeni individuals and sporadic cancer patients. We tested the hypothesis that this functional variant was associated with either risk or early age diagnosis of cervical cancer in a Brazilian population. Methods: A primer-introduced restriction analysis PCR assay was used to genotype the MDM2 SNP309 of 72 cervical carcinoma patients and 100 healthy women. Results: No statistically significant association was observed between SNP309 and cervical cancer. We did not find allele or genotype frequency differences between the group of patients with cancer diagnosis at an early age (younger than 40 years old) and the group of older patients. Conclusions: Our findings suggest that SNP309 MDM2 may not be a risk factor for cervical cancer. (c) 2007 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
C1 [Meissner, Rosely de Vasconcellos; Fernandes, Jose Verissimo; Galvao, Tatiana Medeiros; Oliveira Galvao, Ana Flavia; de Medeiros Oliveira, Gustavo Henrique] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, BR-59072970 Natal, RN, Brazil.
   [Meissner, Rosely de Vasconcellos; Ferreira Barbosa, Rodrigo Niskier] Univ Fed Rio Grande do Norte, Programa Posgrad Genet & Biol Mol, BR-59072970 Natal, RN, Brazil.
RP Meissner, RD (corresponding author), Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Ctr Biociencias, Av Salgado Filho S-N,Campus Univ, BR-59072970 Natal, RN, Brazil.
EM vmrosely@yahoo.com.br
CR Abramson Joseph H, 2004, Epidemiol Perspect Innov, V1, P6, DOI 10.1186/1742-5573-1-6
   Alhopuro P, 2005, J MED GENET, V42, P694, DOI 10.1136/jmg.2005.031260
   BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P23
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Bougeard G, 2006, J MED GENET, V43, P531, DOI 10.1136/jmg.2005.037952
   Campbell IG, 2006, CANCER LETT, V240, P195, DOI 10.1016/j.canlet.2005.09.003
   Harris SL, 2005, P NATL ACAD SCI USA, V102, P16297, DOI 10.1073/pnas.0508390102
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Hu ZB, 2006, INT J CANCER, V118, P1275, DOI 10.1002/ijc.21463
   Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Ma HX, 2006, CANCER LETT, V240, P261, DOI 10.1016/j.canlet.2005.09.019
   MANOS MM, 1989, CANCER CEL, V7, P209
   SAMBROOK J, 1992, MOL CLONING LAB MANU
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
NR 19
TC 17
Z9 18
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0361-090X
J9 CANCER DETECT PREV
JI Cancer Detect. Prev.
PY 2007
VL 31
IS 5
BP 371
EP 374
DI 10.1016/j.cdp.2007.09.001
PG 4
WC Oncology
SC Oncology
GA 249CH
UT WOS:000252203900005
PM 18023538
DA 2020-10-30
ER

EF